

Priority Health Medicare Part B
Medical Drug List



Priority Health Medical Drug List

Medicare

Table of Contents

* Miscellaneous Medical Drugs	2
Antidote Therapeutics	4
Antihistamine Drugs	6
Anti-Infective Agents	8
Antineoplastic Agents	31
Antitoxins, Immune Glob, Toxoids, Vaccines	60
Autonomic Drugs	71
Blood Derivatives	84
Blood Formation, Coagulation, Thrombosis	85
Cardiovascular Drugs	109
Cellular And Gene Therapy	119
Central Nervous System Agents	125
Devices	139
Diagnostic Agents	142
Electrolytic, Caloric, And Water Balance	144
Enzymes	150
Eye, Ear, Nose And Throat (Eent) Preps	152
Gastrointestinal Drugs	168
Heavy Metal Antagonists	175
Hormones And Synthetic Substitutes	175
Immunomodulatory Agents (90:00)	190
Local Anesthetics	219
Miscellaneous Therapeutic Agents	221
Oxytocics	225
Radioactive Agents	225
Respiratory Tract Agents	226
Skin And Mucous Membrane Agents	235
Vitamins	242

Medicare

CURRENT AS OF 8/1/2026

lowercase italics = Generic drugs

UPPERCASE = Brand name drugs

Coverage Level

Notes & Restrictions

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
* Miscellaneous Medical Drugs				
* <i>Miscellaneous Medical Drugs</i>				
B4189	N/A	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 10 to 51 grams of protein - premix	Part B Drug	Drug Name: TROPHAMINE
B4199	N/A	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, over 100 grams of protein - premix	Part B Drug	Drug Name: TROPHAMINE
G0138	N/A	Intravenous infusion of cipaglusosidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglusosidase alfa-atga	Part B Drug	PA; Drug Name: OPFOLDA

PA-Prior Authorization; **ST applies**-Step Therapy applies;

B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
G2082	N/A	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation	Part B Drug	PA; Drug Name: SPRAVATO
G2083	N/A	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation	Part B Drug	PA; Drug Name: SPRAVATO
J1736	N/A	Injection, meloxicam (delova), 1 mg	Part B Drug	PA; Drug Name: QAMZOVA
J9003	N/A	Leuprolide injectable (camcevi etm), 1 mg	Part B Drug	PA; Drug Name: CAMCEVI ETM
Q5150	N/A	Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg	Part B Drug	PA; Drug Name: Ahzantive (aflibercept-mrbb)
Q5171	N/A	Injection, denosumab-mobz (boncresa), biosimilar, 1 mg	Part B Drug	PA; Drug Name: Boncresa

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Antidote Therapeutics				
<i>Acetaminophen Antidote</i>				
J7608	<i>acetylcysteine</i>	Acetylcysteine, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per gram	Part B Drug	B vs D (PA applies)
Antidote Therapeutics				
J0600	<i>edetate calcium disodium</i>	Injection, edetate calcium disodium, up to 1000 mg	Part B Drug	PA; No PA required for ICD 10 codes R78.79, T56.0x1A, T56.2xA-T56.2xD, T56.2x2A-T56.2x2D, T56.2x3A-T56.2x3D, T56.2x4A-T56.2x4D, T56.5x1A-T56.5x1D, T56.5x2A-T56.5x2D, T56.5x3A-T56.5x3D, T56.5x4A-T56.5x4D, T56.891A-T56.891D, T57.2x1A-T57.2x1D, T57.2x2A-T57.2x2D, T57.2x3A-T57.2x3D, T57.2x4A-T57.2x4D, Z77.012.
J0618	<i>calcium chloride</i>	Injection, calcium chloride, 2 mg	Part B Drug	
J0716	ANASCORP	Injection, centrurides immune f(ab)2, up to 120 milligrams (Code Price is per 1 vial) (For billing prior to 1/1/13 use C9288 or J3590)	Not Covered	
J0841	ANAVIP	Injection, crotalidae immune f(ab')2 (equine), 120 mg	Part B Drug	
J0895	<i>deferoxamine</i>	Injection, deferoxamine mesylate, 500 mg	Part B Drug	PA; No PA required for ICD 10 codes D56.0-D56.9, D57.00-D57.819, E83.10-E83.119, T56.0x1A-T56.0x4S, T80.92xA-T80.92xS.
J0895	DESFERAL	Injection, deferoxamine mesylate, 500 mg	Part B Drug	PA; No PA required for ICD 10 codes D56.0-D56.9, D57.00-D57.819, E83.10-E83.119, T56.0x1A-T56.0x4S, T80.92xA-T80.92xS.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1610	GLUCAGON EMERGENCY KIT (HUMAN)	Injection, glucagon hydrochloride, per 1 mg	Part B Drug	
J1611	GLUCAGON (HCL) EMERGENCY KIT	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon 1 mg vial</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J2312	LIFEMS NALOXONE	Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg	Part B Drug	
J2312	<i>naloxone injection</i>	Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg	Part B Drug	
J2313	ZIMHI	Injection, naloxone hydrochloride (zimhi), 0.01 mg	Part B Drug	
Chemotherapy Antidotes/Protectants				
C9310	VYKOURA	Injection, leucovorin calcium (avyxa), 1 mg	Part B Drug	
J0207	ETHYOL	Injection, amifostine, 500mg	Part B Drug	
J0640	<i>leucovorin calcium injection</i>	Injection, leucovorin calcium, per 50 mg	Part B Drug	
J0641	<i>levoleucovorin calcium</i>	Injection, levoleucovorin, not otherwise specified, 0.5 mg	Part B Drug	
J0642	KHAPZORY	Injection, levoleucovorin (khapsory), 0.5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1190	<i>dexrazoxane hcl</i>	Injection, dexrazoxane hydrochloride, per 250 mg	Part B Drug	
J1448	COSELA	Injection, trilaciclib, 1mg	Part B Drug	PA
J9209	<i>mesna intravenous</i>	Injection, mesna, 200 mg	Part B Drug	
J9209	MESNEX INTRAVENOUS	Injection, mesna, 200 mg	Part B Drug	
Antihistamine Drugs				
Ethanolamine Derivatives				
J1200	<i>diphenhydramine hcl injection</i>	Injection, diphenhydramine HCl, up to 50 mg	Part B Drug	
First Generation Antihistamines				
J1200	<i>diphenhydramine hcl injection</i>	Injection, diphenhydramine HCl, up to 50 mg	Part B Drug	
Other Antihistamines				
J1308	<i>famotidine (pf)-nacl (iso-os)</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial 25's, sdv, p/f, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial inner, p/f, suv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial inner, suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial outer, p/f, suv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial outer, suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1308	<i>famotidine 20 mg/2 ml vial p/f, inner, sdv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, outer, sdv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, suv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, suv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial sdv,p/f,inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial 10's,mdv,outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial mdv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial mdv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial muv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial muv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial mdv,inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial mdv,outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1308	<i>famotidine 40 mg/4 ml vial muv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial muv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
Phenothiazine Derivatives				
J2550	PHENERGAN	Injection, promethazine HCl, up to 50 mg	Part B Drug	
J2550	<i>promethazine injection</i>	Injection, promethazine HCl, up to 50 mg	Part B Drug	
Second Generation Antihistamines				
J1201	QUZYTTR	Injection, cetirizine hydrochloride, 0.5 mg	Part B Drug	PA; ST applies
Anti-Infective Agents				
1st Generation Cephalosporin Antibiotics				
J0687	<i>cefazolin 2 gm vial inner, suv</i>	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0687	<i>cefazolin 2 gm vial outer, suv</i>	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0687	<i>cefazolin 3 gm vial inner, suv, plf</i>	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0687	<i>cefazolin 3 gm vial outer, suv, plf</i>	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0688	<i>cefazolin 2 gm vial inner, suv</i>	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0688	<i>cefazolin 2 gm vial outer, suv</i>	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0688	<i>cefazolin 3 gm vial inner, suv</i>	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0688	<i>cefazolin 3 gm vial outer, suv</i>	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0689	<i>cefazolin in dextrose (iso-os)</i>	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	Part B Drug	
J0690	<i>cefazolin 1 gm add-van vial suv, plf, inner</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 1 gm add-van vial suv, plf, outer</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial inner, mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial inner, muv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial inner, plf, mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial inner,muv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0690	<i>cefazolin 10 gm vial mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial outer, mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial outer, muv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial outer, muv, plf</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial outer, plf, mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial outer, muv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin 10 gm vial plf, mdv</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin in dextrose (iso-os)</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J0690	<i>cefazolin injection</i>	Injection, cefazolin sodium, 500 mg	Part B Drug	
J3490	<i>cefazolin injection</i>	Unclassified drugs	Part B Drug	
J7999	<i>cefazolin in dextrose 5 %</i>	Compounded drug, not otherwise classified (NDCs listed are for final compounded products only)	Part B Drug	
2Nd Generation Cephalosporin Antibiotics				
J0525	CEFOTAN	Injection, cefotetan disodium, 10 mg	Part B Drug	
J0525	<i>cefotetan</i>	Injection, cefotetan disodium, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
3Rd Generation Cephalosporin Antibiotics				
J0696	<i>ceftriaxone 1 gm vial inner, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial inner, suv, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial outer, 10's, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial outer, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial outer, suv, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial p/f, sdv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial sdv, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial sdv, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial suv, 25's</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial suv, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial suv, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 1 gm vial suv, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0696	<i>ceftriaxone 1 gm vial suv,outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 10 gm vial mdv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 10 gm vial muv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 10 gm vial muv, plf</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial 10's,20ml sdv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial inner, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial inner, suv, plf</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial inner,suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial outer, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial outer, suv, plf</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial outer,suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial plf, sdv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial sdv, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial sdv, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0696	<i>ceftriaxone 2 gm vial suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv , inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv , outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, 25's</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, plf</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, plf, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv, plf, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 2 gm vial suv,outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial 10's,suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial inner, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial inner, suv, plf</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial outer, suv</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0696	<i>ceftriaxone 250 mg vial outer, sub, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial sdv, p/f, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial sdv, p/f, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial sub</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial sub, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 250 mg vial sub, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial 10's, outer, sub</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial inner, sub</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial inner, sub, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial outer, sub</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial outer, sub, p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial sub</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial sub, inner</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial sub, outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0696	<i>ceftriaxone 500 mg vial suv,outer</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone 500 mg vial suv,p/f</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone in dextrose,iso-os</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0696	<i>ceftriaxone intravenous</i>	Injection, ceftriaxone sodium, per 250 mg	Part B Drug	
J0714	AVYCAZ	Injection, ceftazidime and avibactam, 0.5 g/0.125 g (For billing prior to 1/1/16 use C9399 or J3490)	Part B Drug	
4Th Generation Cephalosporin Antibiotics				
J0692	<i>cefepime</i>	Injection, cefepime HCl, 500 mg	Part B Drug	
J3490	<i>cefepime</i>	Unclassified drugs	Part B Drug	
5Th Generation Cephalosporin Antibiotics				
J0681	ZEVTERA	Injection, ceftobiprole medocaril sodium, 3 mg	Part B Drug	PA; ST applies
J0695	ZERBAXA	Injection, ceftolozane 50 mg and tazobactam 25 mg (Code re-used by CMS effective 1/1/16) (For billing prior to 1/1/16 use C9452 or J3490)	Part B Drug	
J0712	<i>ceftaroline fosamil</i>	Injection, ceftaroline fosamil, 10 mg (For billing prior to 1/1/12 use J3490 or C9282)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0712	TEFLARO	Injection, ceftaroline fosamil, 10 mg (For billing prior to 1/1/12 use J3490 or C9282)	Part B Drug	
Amebicides				
J1836	METRO I.V.	Injection, metronidazole, 10 mg	Part B Drug	
J1836	<i>metronidazole in nacl (iso-os)</i>	Injection, metronidazole, 10 mg	Part B Drug	
Aminoglycoside Antibiotics				
J0278	<i>amikacin</i>	Injection, amikacin sulfate, 100 mg	Part B Drug	
J0291	ZEMDRI	Injection, plazomicin, 5 mg	Part B Drug	
J3535	TOBI PODHALER	Drug administered through a metered dose inhaler	Part D Drug	
J7682	BETHKIS	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)
J7682	KITABIS PAK	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)
J7682	TOBI	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7682	<i>tobramycin in 0.225 % nacl</i>	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)
J7682	<i>tobramycin inhalation</i>	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)
J7682	<i>tobramycin with nebulizer</i>	Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, per 300 milligrams	Part B Drug	B vs D (PA applies)
Aminomethylcyclines				
J0121	NUZYRA INTRAVENOUS	Injection, omadacycline, 1 mg	Part B Drug	PA; ST applies
Antimalarials				
J1271	DOXY-100	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1271	<i>doxycycline hyclate 100 mg vial plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, sub, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, sub, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
Antiprotozoals, <i>P. jirovecii</i> Pneumonia				
J2545	NEBUPENT	Pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg	Part B Drug	
J2545	<i>pentamidine inhalation</i>	Pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg	Part B Drug	
Antituberculosis Agents				
J1834	<i>isoniazid injection</i>	Injection, isoniazid, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Azole Antifungals				
J1833	CRESEMBA INTRAVENOUS	Injection, isavuconazonium sulfate, 1 mg (For billing prior to 1/1/16 use C9456 or J3490)	Part B Drug	
J3465	VFEND IV	Injection, voriconazole, 10 mg	Part B Drug	
J3465	<i>voriconazole intravenous</i>	Injection, voriconazole, 10 mg	Part B Drug	
J3465	<i>voriconazole-hpbc</i>	Injection, voriconazole, 10 mg	Part B Drug	
Carbapenem Antibiotics				
J0742	RECARBRIO	Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg	Part B Drug	PA
J1335	<i>ertapenem</i>	Injection, ertapenem sodium, 500 mg	Part B Drug	
J2183	<i>meropenem</i>	Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg	Part B Drug	
J2184	<i>meropenem-0.9% sodium chloride</i>	Injection, meropenem (b. braun), not therapeutically equivalent to j2185, 100 mg	Part B Drug	
J2185	<i>meropenem</i>	Injection, meropenem, 100 mg	Part B Drug	
J2186	VABOMERE	Injection, meropenem and vaborbactam, 10mg/10mg, (20mg)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Cmv Antivirals				
C9399	PREVYMIS INTRAVENOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
J3490	PREVYMIS INTRAVENOUS	Unclassified drugs	Part B Drug	PA
Cyclic Lipopeptide Antibiotics				
J0872	<i>daptomycin</i>	Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg	Part B Drug	
J0873	<i>daptomycin</i>	Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg	Part B Drug	
J0874	<i>daptomycin in 0.9 % sod chlor</i>	Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg	Part B Drug	
J0877	<i>daptomycin</i>	Injection, daptomycin (hospira), not therapeutically equivalent to j0878, 1 mg	Part B Drug	
J0878	<i>daptomycin</i>	Injection, daptomycin, 1 mg	Part B Drug	
J3490	<i>daptomycin</i>	Unclassified drugs	Part B Drug	
Echinocandin Antifungals				
J0349	REZZAYO	Injection, rezafungin, 1 mg	Part B Drug	PA
J0637	<i>caspofungin</i>	Injection, caspofungin acetate, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2246	<i>micafungin in 0.9 % sodium chl</i>	Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg	Part B Drug	
J2247	<i>micafungin</i>	Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg	Part B Drug	
J2248	<i>micafungin</i>	Injection, micafungin sodium, 1 mg	Part B Drug	
Extended-Spectrum Penicillins				
C9399	<i>piperacillin-tazo 3.375 g dplx</i>	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	
C9399	<i>piperacillin-tazo 4.5 g duplex</i>	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	
J2543	<i>piperacillin-tazobactam intravenous recon soln</i>	Injection, piperacillin sodium/tazobactam sodium, 1 g/0.125 g (1.125 g)	Part B Drug	
J2543	ZOSYN IN DEXTROSE (ISO-OSM)	Injection, piperacillin sodium/tazobactam sodium, 1 g/0.125 g (1.125 g)	Part B Drug	
J3490	<i>piperacillin-tazo 3.375 g dplx</i>	Unclassified drugs	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	<i>piperacillin-tazo 4.5 g duplex</i>	Unclassified drugs	Part B Drug	
Fluorocyclines				
J0122	XERAVA	Injection, eravacycline, 1 mg	Part B Drug	
Glycopeptide Antibiotics				
J0875	<i>dalbavancin</i>	Injection, dalbavancin, 5 mg (For billing prior to 1/1/16 use C9443 or J3490)	Part B Drug	
J0875	DALVANCE	Injection, dalbavancin, 5 mg (For billing prior to 1/1/16 use C9443 or J3490)	Part B Drug	
J2406	KIMYRSA	Injection, oritavancin (kimyrsa), 10 mg	Part B Drug	PA; ST applies
J2407	ORBACTIV	Injection, oritavancin (orbactiv), 10 mg (For billing prior to 1/1/16 use C9444 or J3490)	Part B Drug	PA; ST applies
J3095	VIBATIV	Injection, telavancin, 10 mg (For billing prior to 1/1/11 use J3490 or C9258)	Part B Drug	PA; ST applies
J3373	<i>vancomycin in 0.9 % sodium chl intravenous piggyback</i>	Injection, vancomycin hydrochloride, 10 mg	Part B Drug	
J3373	<i>vancomycin in dextrose 5 % intravenous piggyback</i>	Injection, vancomycin hydrochloride, 10 mg	Part B Drug	
J3373	<i>vancomycin intravenous</i>	Injection, vancomycin hydrochloride, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3374	vancomycin intravenous	Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg	Part B Drug	
J3375	TYZAVAN	Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg	Part B Drug	
J3375	vancomycin-diluent combo no.1	Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg	Part B Drug	
Hiv Capsid Inhibitors				
J0738	YEZTUGO	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)	Part B Drug	
J0752	YEZTUGO	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)	Part B Drug	
J1961	SUNLENCA SUBCUTANEOUS	Injection, lenacapavir (only for use as hiv treatment), 1 mg	Part B Drug	PA
J8499	SUNLENCA ORAL	Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Hiv Entry And Fusion Inhibitors				
J1746	TROGARZO	Injection, ibalizumab-uiyk, 10 mg	Part B Drug	PA
Hiv Integrase Inhibitor Antiretrovirals				
J0739	APRETUDE	Injection, cabotegravir, 1 mg	Part B Drug	
J0741	CABENUVA	Injection, cabotegravir and rilpivirine, 2mg/3mg	Part B Drug	PA
Hiv Nucleoside, Nucleotide Rt Inhibitors				
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200-300 mg tab</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200-300 mg tab inner</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200-300 mg tab outer</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0750	TRUVADA 200 MG-300 MG TABLET	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	TRUVADA 200 MG-300 MG TABLET F/C	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0751	DESCOVY 200-25 MG TABLET	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	
Interferon Antivirals				
J9215	ALFERON N	Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 IU (All NDCs inactive as of 5/8/2024)	Medicare Chemo	
Lincomycin Antibiotics				
J0736	CLEOCIN INJECTION	Injection, clindamycin phosphate, 300 mg	Part B Drug	
J0736	<i>clindamycin in 5 % dextrose</i>	Injection, clindamycin phosphate, 300 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0736	<i>clindamycin phosphate injection</i>	Injection, clindamycin phosphate, 300 mg	Part B Drug	
J0737	<i>clindamycin in 0.9 % sod chlor</i>	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg	Part B Drug	
Monobactam Antibiotics				
J0457	AZACTAM 1 GM VIAL SUV	Injection, aztreonam, 100 mg	Part B Drug	
J0457	AZACTAM 2 GM VIAL SUV	Injection, aztreonam, 100 mg	Part B Drug	
J0457	<i>aztreonam</i>	Injection, aztreonam, 100 mg	Part B Drug	
J0458	EMBLAVEO	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)	Part B Drug	PA; ST applies
Monoclonal Antibodies (08:18)				
90378	SYNAGIS 100 MG/ML VIAL	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each (All NDCs Inactive as 12/31/2025)	Part B Drug	PA
90378	SYNAGIS 50 MG/0.5 ML VIAL	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each (All NDCs Inactive as 12/31/2025)	Part B Drug	PA
90380	BEYFORTUS	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
90381	BEYFORTUS	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	Part B Drug	PA
90382	ENFLONISIA	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use	Part B Drug	PA
J0638	ILARIS (PF)	Injection, canakinumab, 1 mg (For billing prior to 1/1/11 use J3590 or C9399)	Part B Drug	PA; ST applies
Q0224	PEMGARDA (EUA)	Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known SARS-CoV-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to COVID-19 vaccination, 4500 mg	Part B Drug	
Nitroimidazole Derivatives, Misc				
J1836	METRO I.V.	Injection, metronidazole, 10 mg	Part B Drug	
J1836	<i>metronidazole in nacl (iso-os)</i>	Injection, metronidazole, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
Nucleoside And Nucleotide Antivirals				
J0133	<i>acyclovir sodium</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0248	VEKLURY	Injection, remdesivir, 1 mg	Part B Drug	
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200- 300 mg tab</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200- 300 mg tab inner</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	<i>emtricitabine-tenofovir disoproxil fumarate 200- 300 mg tab outer</i>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0750	TRUVADA 200 MG-300 MG TABLET	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0750	TRUVADA 200 MG-300 MG TABLET F/C	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	B vs D (PA applies)
J0751	DESCOVY 200-25 MG TABLET	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)	Part B Drug	
J1570	<i>ganciclovir sodium</i>	Injection, ganciclovir sodium, 500 mg	Part B Drug	
Other Misc. Antibacterial Agents				
J0911	DEFENCATH	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	Not Separately Payable	
Oxazolidinone Antibiotics				
J2020	<i>linezolid in dextrose 5%</i>	Injection, linezolid, 200 mg	Part B Drug	
J2020	ZYVOX INTRAVENOUS	Injection, linezolid, 200 mg	Part B Drug	PA
J2021	<i>linezolid-0.9% sodium chloride</i>	Injection, linezolid (hospira), not therapeutically equivalent to j2020, 200 mg	Part B Drug	
J3090	SIVEXTRO INTRAVENOUS	Injection, tedizolid phosphate, 1 mg (For billing prior to 1/1/16 use C9446 or J3490)	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Penicillinase-Resistant Penicillins				
J2291	<i>nafcillin in dextrose iso-osm</i>	Injection, nafcillin sodium (baxter), 20 mg	Part B Drug	
Polyene Antifungals				
J0285	<i>amphotericin b</i>	Injection, amphotericin B, 50mg	Part B Drug	B vs D (PA applies)
J0287	ABELCET 100 MG/20 ML VIAL	Injection, amphotericin B lipid complex, 10 mg (NDC inactive as of 9/17/2025)	Part B Drug	
J0289	<i>amphotericin b liposome</i>	Injection, amphotericin B liposome, 10 mg	Part B Drug	
Quinolone Antibiotics				
C9462	BAXDELA INTRAVENOUS	Injection, delafloxacin, 1 mg	Part B Drug	PA
J2280	<i>moxifloxacin-sod.chloride(iso)</i>	Injection, moxifloxacin, 100 mg	Part B Drug	
Siderophore Cephalosporins				
J0699	FETROJA	Injection, cefiderocol, 10 mg	Part B Drug	
Tetracycline Antibiotics				
J1271	DOXY-100	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1271	<i>doxycycline hyclate 100 mg vial outer, sub, p/f</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial p/f, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial p/f, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial p/f, sub, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial p/f, sub, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, p/f, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, p/f, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
Urinary Anti-Infectives				
J0528	CONTEPO	Injection, fosfomycin disodium, 20 mg	Part B Drug	
Antineoplastic Agents				
Antineoplastic Agents				
A9513	LUTATHERA	Lutetium lu 177, dotatate, therapeutic, 1 millicurie	Medicare Chemo	PA
A9543	ZEVALIN (Y-90)	Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries (Code Price is per dose)	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
A9590	AZEDRA DOSIMETRIC VIAL	Iodine i-131, iobenguane, 1 millicurie (All NDCs Inactive as of April 2024)	Medicare Chemo	PA
A9590	AZEDRA THERAPEUTIC VIAL	Iodine i-131, iobenguane, 1 millicurie (All NDCs Inactive as of April 2024)	Medicare Chemo	PA
A9607	PLUVICTO	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	Medicare Chemo	PA
C9257	AVASTIN 100 MG/4 ML VIAL P/F,SUV	Injection, bevacizumab, 0.25 mg	Part B Drug	PA; No PA required for ICD-10 codes B39.4, B39.5, B39.9, E08.311, E08.3211 - E08.3213, E08.3311 - E08.3313, E08.3411 - E08.3413, E08.3511 - E08.3513, E08.3591 - E08.3593, E09.311, E09.3211 - E09.3213, E09.3311 - E09.3313, E09.3411 - E09.3413, E09.3511 - E09.3513, E09.3591 - E09.3593, E10.311, E10.3211 - E10.3213, E10.3311 - E10.3313, E10.3411 - E10.3413, E10.3511 - E10.3513, E10.3591-E10.3593, E11.3100-E11.3199, E11.3211-E11.3213, E11.3311-E11.3313, E11.3411 - E11.3413, E11.3511-E11.3513, E11.3591-E11.3593, E13.311, E13.3211 - E13.3213, E13.3311 - E13.3313, E13.3411-E13.3413, E13.3511, E13.3513, E13.3591 - E13.3593, H21.1x1-H21.1x3, H32, H34.8110-H34.8132, H34.8310-H34.8332, H35.051-H35.059, H35.3210 - H35.3233, H35.351 - H35.353, H35.81, H40.89, H44.2a1-H44.2E3.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9257	AVASTIN 400 MG/16 ML VIAL P/F,SUV	Injection, bevacizumab, 0.25 mg	Part B Drug	PA; No PA required for ICD-10 codes B39.4, B39.5, B39.9, E08.311, E08.3211 - E08.3213, E08.3311 - E08.3313, E08.3411 - E08.3413, E08.3511 - E08.3513, E08.3591 - E08.3593, E09.311, E09.3211 - E09.3213, E09.3311 - E09.3313, E09.3411 - E09.3413, E09.3511 - E09.3513, E09.3591 - E09.3593, E10.311, E10.3211 - E10.3213, E10.3311 - E10.3313, E10.3411 - E10.3413, E10.3511 - E10.3513, E10.3591-E10.3593, E11.3100-E11.3199, E11.3211-E11.3213, E11.3311-E11.3313, E11.3411 - E11.3413, E11.3511-E11.3513, E11.3591-E11.3593, E13.311, E13.3211- E13.3213, E13.3311 - E13.3313, E13.3411-E13.3413, E13.3511, E13.3513, E13.3591- E13.3593, H21.1x1-H21.1x3, H32, H34.8110-H34.8132, H34.8310-H34.8332, H35.051-H35.059, H35.3210 - H35.3233, H35.351 - H35.353, H35.81, H40.89, H44.2a1- H44.2E3.
C9399	AMTAGVI	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
C9399	AVOPEF	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	BESREMI	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	FAVLYXA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	
C9399	UNITUXIN	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Medicare Chemo	PA
J0614	GRAFAPEX	Injection, treosulfan, 50 mg	Medicare Chemo	PA; No PA required for ICD-10 codes C92.00, C92.02, C92.A0, C92.A2, D46.Z, D46.9.
J0870	RYTELO	Injection, imetelstat, 1 mg	Medicare Chemo	PA
J0893	<i>decitabine</i>	Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg	Part B Drug	
J0894	<i>decitabine</i>	Injection, decitabine, 1 mg	Part B Drug	
J1323	ELREXFIO	Injection, elranatamab-bcmm, 1 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1326	VYLOY	Injection, zolbetuximab-clzb, 2 mg	Medicare Chemo	PA
J1950	LUPRON DEPOT 11.25 MG 3MO KIT 3 MONTH, SUV	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT 3.75 MG KIT P/F, SUV	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT-PED	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT-PED (3 MONTH)	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1951	FENSOLVI	Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg	Part B Drug	PA
J1952	CAMCEVI (6 MONTH)	Leuprolide injectable, camcevi, 1 mg	Medicare Chemo	
J1954	LUTRATE DEPOT (3 MONTH)	Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg	Medicare Chemo	
J2860	SYLVANT	Injection, siltuximab, 10 mg (Code re-used by CMS effective 1/1/16) (For billing prior to 1/1/16 use C9455 or J3590)	Part B Drug	
J3055	TALVEY	Injection, talquetamab-tgvs, 0.25 mg	Medicare Chemo	PA
J3263	LOQTORZI	Injection, toripalimab-tpzi, 1 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3315	TRELSTAR	Injection, triptorelin pamoate, 3.75 mg	Part B Drug	B vs D (PA applies)
J3316	TRIPTODUR	Injection, triptorelin, extended-release, 3.75 mg	Part B Drug	
J7527	<i>everolimus 0.25 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.25 mg tablet inner</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.25 mg tablet outer</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.5 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	<i>everolimus 0.5 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.5 mg tablet inner</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.5 mg tablet outer</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.75 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.75 mg tablet inner</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 0.75 mg tablet outer</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 1 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	<i>everolimus 1 mg tablet</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 1 mg tablet inner</i>	Everolimus, oral, 0.25 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7527	<i>everolimus 1 mg tablet inner</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	<i>everolimus 1 mg tablet outer</i>	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	<i>everolimus 1 mg tablet outer</i>	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	ZORTRESS	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J8522	<i>capecitabine</i>	Capecitabine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J8522	XELODA 150 MG TABLET	Capecitabine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J8522	XELODA 500 MG TABLET	Capecitabine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J8522	XELODA 500 MG TABLET F/C	Capecitabine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J8530	<i>cyclophosphamide oral</i>	Cyclophosphamide, oral, 25 mg	Part B Drug	B vs D (PA applies)
J8610	<i>methotrexate sodium oral</i>	Methotrexate, oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8610	TREXALL	Methotrexate, oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8611	JYLAMVO	Methotrexate (jylamvo), oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8612	XATMEP	Methotrexate (xatmep), oral, 2.5 mg	Part B Drug	B vs D (PA applies)
J9000	ADRIAMYCIN	Injection, doxorubicin hydrochloride, 10 mg	Medicare Chemo	
J9000	<i>doxorubicin</i>	Injection, doxorubicin hydrochloride, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9011	DATROWAY	Injection, datopotamab deruxtecan-dlnk, 1 mg	Medicare Chemo	PA
J9015	PROLEUKIN	Injection, aldesleukin, per single-use vial	Part B Drug	
J9021	RYLAZE	Injection, asparaginase, recombinant, (rylaze), 0.1 mg	Medicare Chemo	PA
J9022	TECENTRIQ	Injection, atezolizumab, 10 mg (For billing prior to 1/1/18 use J9999 or C9483 for OPSP billing)	Medicare Chemo	PA
J9023	BAVENCIO	Injection, avelumab, 10 mg (For billing prior to 1/1/18 use J9999 or C9491 for OPSP billing)	Medicare Chemo	PA
J9024	TECENTRIQ HYBREZA	Injection, atezolizumab, 5 mg and hyaluronidase-tqjs	Medicare Chemo	PA
J9025	<i>azacitidine</i>	Injection, azacitidine, 1 mg	Part B Drug	
J9025	VIDAZA	Injection, azacitidine, 1 mg	Part B Drug	
J9026	IMDELLTRA	Injection, tarlatamab-dlle, 1 mg	Medicare Chemo	PA
J9028	ANKTIVA	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram	Medicare Chemo	PA
J9029	ADSTILADRIN	Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9030	TICE BCG	BCG live intravesical instillation, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9032	BELEODAQ	Injection, belinostat, 10 mg (For billing prior to 1/1/16 use C9442 or J9999)	Medicare Chemo	
J9033	<i>bendamustine</i>	Injection, bendamustine hydrochloride, 1 mg	Medicare Chemo	
J9033	TREANDA	Injection, bendamustine hydrochloride, 1 mg	Medicare Chemo	
J9034	BENDEKA	Injection, bendamustine HCl (Bendeka), 1 mg	Medicare Chemo	
J9035	AVASTIN 100 MG/4 ML VIAL P/F,SUV	Injection, bevacizumab, 10 mg	Medicare Chemo	PA; ST applies
J9035	AVASTIN 400 MG/16 ML VIAL P/F,SUV	Injection, bevacizumab, 10 mg	Medicare Chemo	PA; ST applies
J9036	BELRAPZO	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Medicare Chemo	
J9036	<i>bendamustine</i>	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Medicare Chemo	
J9039	BLINCYTO	Injection, blinatumomab, 1 microgram (For billing prior to 1/1/16 use C9449 or J9999)	Medicare Chemo	PA
J9040	<i>bleomycin</i>	Injection, bleomycin sulfate, 15 units	Part B Drug	
J9041	<i>bortezomib injection</i>	Injection, bortezomib, 0.1 mg	Medicare Chemo	
J9041	VELCADE	Injection, bortezomib, 0.1 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9042	ADCETRIS	Injection, brentuximab vedotin, 1 mg (For billing prior to 1/1/13 use C9287 or J9999)	Medicare Chemo	PA
J9043	JEVTANA	Injection, cabazitaxel, 1 mg (For billing prior to 1/1/12 use J9999 or C9276)	Medicare Chemo	PA
J9045	<i>carboplatin</i>	Injection, carboplatin, 50 mg	Part B Drug	
J9045	PARAPLATIN 1,000 MG/100 ML VL MUV, P/F	Injection, carboplatin, 50 mg	Part B Drug	
J9045	PARAPLATIN 50 MG/5 ML VIAL MUV, P/F	Injection, carboplatin, 50 mg	Part B Drug	
J9047	KYPROLIS	Injection, carfilzomib, 1 mg (For billing prior to 1/1/14 use C9295 or J9999)	Medicare Chemo	
J9048	<i>bortezomib 3.5 mg iv vial sdv</i>	Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg (All NDCs inactive as of 4/3/2024)	Medicare Chemo	
J9049	<i>bortezomib injection</i>	Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg	Medicare Chemo	
J9050	<i>carmustine</i>	Injection, carmustine, 100 mg	Part B Drug	
J9052	<i>carmustine</i>	Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg (All NDCs inactive as of 5/6/2026)	Part B Drug	
J9053	BLNREP	Injection, belantamab mafodotin-blmf, 0.1 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9054	BORUZU	Injection, bortezomib (boruzu), 0.1 mg	Part B Drug	PA; ST applies
J9055	ERBITUX	Injection, cetuximab, 10 mg	Medicare Chemo	PA
J9056	VIVIMUSTA	Injection, bendamustine hydrochloride (vivimusta), 1 mg	Medicare Chemo	PA; ST applies
J9057	ALIQOPA 60 MG VIAL	Injection, copanlisib, 1 mg (All NDCs inactive as of 10/16/2024)	Medicare Chemo	PA
J9060	<i>cisplatin</i>	Injection, cisplatin, powder or solution, per 10 mg	Part B Drug	
J9061	RYBREVANT	Injection, amivantamab-vmjw, 2 mg	Medicare Chemo	PA
J9062	RYBREVANT FASPRO	Injection, amivantamab 5 mg and hyaluronidase-lpuj	Medicare Chemo	PA
J9063	ELAHERE	Injection, mirvetuximab soravtansine-gynx, 1 mg	Medicare Chemo	PA
J9065	<i>cladribine</i>	Injection, cladribine, per 1 mg	Part B Drug	
J9071	<i>cyclophosphamide 1 gm/5 ml vl muv, p/f</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	<i>cyclophosphamide 1 gm/5 ml vl suv</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	<i>cyclophosphamide 2 gm/10 ml vl muv, p/f</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	<i>cyclophosphamide 500 mg/2.5 ml muv, p/f</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	<i>cyclophosphamide 500 mg/2.5 ml suv</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9072	<i>cyclophosphamide 1 gm/2 ml vial</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	<i>cyclophosphamide 2 gm/4 ml vial</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	<i>cyclophosphamide 500 mg/ml vial</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	FRINDOVYX	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9073	<i>cyclophosphamide 1 gm/5 ml vial inner, multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 1 gm/5 ml vial multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 1 gm/5 ml vial outer, multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 2 gm/10 ml vial multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 500 mg/2.5 ml inner, multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 500 mg/2.5 ml multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 500 mg/2.5 ml outer, multivial, push/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9074	<i>cyclophosphamide 1 gm/10 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 1 gm/10 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 2 gm/20 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 2 gm/20 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 500 mg/5 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 500 mg/5 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9075	<i>cyclophosphamide intravenous recon soln</i>	Injection, cyclophosphamide, not otherwise specified, 5mg	Medicare Chemo	
J9076	<i>cyclophosphamide 1 gm/5 ml vial muv, p/f</i>	Injection, cyclophosphamide (baxter), 5 mg	Medicare Chemo	
J9076	<i>cyclophosphamide 500 mg/2.5 ml muv, p/f</i>	Injection, cyclophosphamide (baxter), 5 mg	Medicare Chemo	
J9118	ASPARLAS	Injection, calaspargase pegol-mknl, 10 units	Medicare Chemo	PA; No PA required for ICD-10 codes C91.00 - C91.02, C83.50 - C83.59.
J9119	LIBTAYO	Injection, cemiplimab-rwlc, 1 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9120	COSMEGEN 500 MCG VIAL	Injection, dactinomycin, 0.5 mg	Part B Drug	
J9120	<i>dactinomycin</i>	Injection, dactinomycin, 0.5 mg	Part B Drug	
J9130	<i>dacarbazine</i>	Dacarbazine, 100 mg	Part B Drug	
J9144	DARZALEX FASPRO	Injection, daratumumab, 10 mg and hyaluronidase-fihj	Medicare Chemo	PA; No PA required when billed with the following ICD-10 codes: C90.00-C90.32 (multiple myeloma) or E85.81.
J9145	DARZALEX	Injection, daratumumab, 10 mg (For billing prior to 1/1/17 use J9999 or C9476 for OPPS billing)	Medicare Chemo	PA; No PA required when billed with the following ICD-10 codes: C90.00-C90.32 (multiple myeloma) or E85.81.
J9153	VYXEOS	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Medicare Chemo	PA
J9155	FIRMAGON	Injection, degarelix, 1 mg (For billing prior to 1/1/10 use J9999 or C9399)	Medicare Chemo	PA; No PA required for ICD-10 codes C61, C79.82 and D07.5.
J9155	FIRMAGON KIT W DILUENT SYRINGE	Injection, degarelix, 1 mg (For billing prior to 1/1/10 use J9999 or C9399)	Medicare Chemo	PA; No PA required for ICD-10 codes C61, C79.82 and D07.5.
J9161	LYMPHIR	Injection, denileukin diftitox-cxdl, 1 mcg	Medicare Chemo	PA
J9171	<i>docetaxel</i>	Injection, docetaxel, 1 mg	Medicare Chemo	
J9172	DOCIVYX	Injection, docetaxel (docivyx), 1 mg	Medicare Chemo	PA; ST applies
J9173	IMFINZI	Injection, durvalumab, 10 mg	Medicare Chemo	PA
J9174	BEIZRAY	Injection, docetaxel (beizray), 1 mg	Medicare Chemo	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9174	BEIZRAY-ALBUMIN	Injection, docetaxel (beizray), 1 mg	Medicare Chemo	PA; ST applies
J9176	EMPLICITI	Injection, elotuzumab, 1 mg (For billing prior to 1/1/17 use J9999 or C9477 for OPPS billing)	Part B Drug	
J9177	PADCEV	Injection, enfortumab vedotin-ejfv, 0.25 mg	Medicare Chemo	PA
J9178	ELLEENCE	Injection, epirubicin HCl, 2 mg	Part B Drug	
J9178	<i>epirubicin 200 mg/100 ml vial sub, p/f</i>	Injection, epirubicin HCl, 2 mg	Part B Drug	
J9179	<i>eribulin</i>	Injection, eribulin mesylate, 0.1 mg (For billing prior to 1/1/12 use J9999 or C9280)	Part B Drug	
J9179	HALAVEN	Injection, eribulin mesylate, 0.1 mg (For billing prior to 1/1/12 use J9999 or C9280)	Part B Drug	
J9181	ETOPOPHOS	Injection, etoposide, 10 mg	Part B Drug	
J9181	<i>etoposide intravenous</i>	Injection, etoposide, 10 mg	Part B Drug	
J9183	INLEXZO	Gemcitabine intravesical system, 225 mg	Medicare Chemo	PA
J9184	AVGEMSI	Injection, gemcitabine hydrochloride (avyxa), 200 mg	Part B Drug	PA; ST applies
J9190	ADRUCIL	Injection, fluorouracil, 500 mg	Medicare Chemo	
J9190	<i>fluorouracil intravenous</i>	Injection, fluorouracil, 500 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9196	<i>gemcitabine</i>	Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg	Medicare Chemo	
J9200	<i>floxuridine</i>	Injection, floxuridine, 500 mg	Part B Drug	
J9201	<i>gemcitabine</i>	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	Medicare Chemo	
J9202	ZOLADEX	Goserelin acetate implant, per 3.6 mg	Not Covered	
J9203	MYLOTARG	Injection, gemtuzumab ozogamicin, 0.1 mg (For billing prior to 1/1/18 use J9999 or C9399 for OPPS billing)	Medicare Chemo	PA
J9204	POTELIGEO	Injection, mogamulizumab-kpkc, 1 mg	Medicare Chemo	
J9205	ONIVYDE	Injection, irinotecan liposome, 1 mg (For billing prior to 1/1/17 use J9999 or C9474 for OPPS billing)	Medicare Chemo	PA
J9206	CAMPTOSAR	Injection, irinotecan, 20 mg	Part B Drug	
J9206	<i>irinotecan</i>	Injection, irinotecan, 20 mg	Part B Drug	
J9207	IXEMPRA	Injection, ixabepilone, 1 mg	Part B Drug	
J9208	IFEX	Injection, ifosfamide, 1 gram	Part B Drug	
J9208	<i>ifosfamide</i>	Injection, ifosfamide, 1 gram	Part B Drug	
J9211	IDAMYCIN PFS	Injection, idarubicin hydrochloride, 5 mg	Part B Drug	
J9211	<i>idarubicin</i>	Injection, idarubicin hydrochloride, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9215	ALFERON N	Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 IU (All NDCs inactive as of 5/8/2024)	Medicare Chemo	
J9217	ELIGARD	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (3 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (6 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT (6 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT 22.5 MG 3MO KIT SUV, P/F	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT 7.5 MG 1 MONTH KT SINGLE DOSE	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT 7.5 MG 1 MONTH KT SUV, P/F	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	VABRINTY (1 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	VABRINTY (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9218	<i>leuprolide</i>	Leuprolide acetate, per 1 mg	Part D Drug	
J9223	ZEPZELCA	Injection, lurbinectedin, 0.1 mg	Medicare Chemo	PA
J9226	SUPPRELIN LA	Histrelin implant (Supprelin LA), 50 mg	Part B Drug	PA; ST applies
J9227	SARCLISA	Injection, isatuximab-irfc, 10 mg	Medicare Chemo	PA
J9228	YERVOY	Injection, ipilimumab, 1 mg (For billing prior to 1/1/12 use J9999 or C9284)	Medicare Chemo	PA
J9229	BESPONSA	Injection, inotuzumab ozogamicin, 0.1 mg	Medicare Chemo	PA
J9232	<i>docetaxel</i>	Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg	Medicare Chemo	
J9245	<i>melphalan hcl</i>	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Medicare Chemo	
J9246	EVOMELA	Injection, melphalan (evomela), 1 mg	Medicare Chemo	PA
J9248	HEPZATO	Injection, melphalan (hepzato), 1 mg	Medicare Chemo	PA
J9248	HEPZATO (50 MM CATHETER)	Injection, melphalan (hepzato), 1 mg	Medicare Chemo	PA
J9248	HEPZATO (62 MM CATHETER)	Injection, melphalan (hepzato), 1 mg	Medicare Chemo	PA
J9249	IVRA	Injection, melphalan (apotex), 1 mg	Medicare Chemo	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9263	oxaliplatin	Injection, oxaliplatin, 0.5 mg	Medicare Chemo	
J9264	ABRAXANE	Injection, paclitaxel protein-bound particles, 1 mg	Medicare Chemo	
J9264	paclitaxel protein-bound	Injection, paclitaxel protein-bound particles, 1 mg	Medicare Chemo	
J9266	ONCASPAR	Injection, pegaspargase, per single dose vial	Medicare Chemo	PA; No PA required for ICD-10 codes C91.00 - C91.02, C83.50 - C83.59.
J9267	paclitaxel	Injection, paclitaxel, 1 mg	Medicare Chemo	
J9268	NIPENT	Injection, pentostatin, per 10 mg	Part B Drug	
J9269	ELZONRIS	Injection, tagraxofusp-erzs, 10 micrograms	Medicare Chemo	PA
J9271	KEYTRUDA	Injection, pembrolizumab, 1 mg (For billing prior to 1/1/16 use C9027 or J9999)	Medicare Chemo	PA
J9272	JEMPERLI	Injection, dostarlimab-gxly, 10 mg	Medicare Chemo	PA
J9273	TIVDAK	Injection, tisotumab vedotin-tftv, 1 mg	Medicare Chemo	PA
J9274	KIMMTRAK	Injection, tebentafusp-tebn, 1 microgram	Medicare Chemo	PA
J9275	UNLOXCYT	Injection, cosibelimab-ipdl, 2 mg	Medicare Chemo	PA
J9276	ZIIHERA	Injection, zanidatamab-hrii, 2 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9277	KEYTRUDA QLEX	Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph	Medicare Chemo	PA
J9278	KYXATA	Injection, carboplatin (avyxa), 1 mg	Medicare Chemo	PA
J9280	<i>mitomycin intravenous</i>	Injection, mitomycin, 5 mg	Part B Drug	
J9280	MUTAMYCIN	Injection, mitomycin, 5 mg	Part B Drug	
J9281	JELMYTO	Mitomycin pyelocalyceal instillation, 1 mg	Medicare Chemo	PA
J9282	ZUSDURI	Mitomycin, intravesical instillation, 1 mg	Part B Drug	PA
J9286	COLUMVI	Injection, glofitamab-gxbm, 2.5 mg	Medicare Chemo	PA
J9289	OPDIVO QVANTIG	Injection, nivolumab, 2 mg and hyaluronidase-nvhy	Medicare Chemo	PA
J9292	AXTLE	Injection, pemetrexed dipotassium, 10 mg	Medicare Chemo	PA
J9293	<i>mitoxantrone</i>	Injection, mitoxantrone hydrochloride, per 5 mg	Part B Drug	
J9294	<i>pemetrexed disodium</i>	Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg	Medicare Chemo	
J9295	PORTRAZZA 800 MG/50 ML VIAL	Injection, necitumumab, 1 mg (For billing prior to 1/1/17 use J9999 or C9475 for OPPS billing) (NDC inactive since 7/15/2025)	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9296	<i>pemetrexed disodium</i>	Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg (All NDCs inactive as of 5/5/2026)	Medicare Chemo	
J9297	<i>pemetrexed disodium</i>	Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg	Medicare Chemo	
J9298	OPDUALAG	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	Medicare Chemo	PA
J9299	OPDIVO	Injection, nivolumab, 1 mg (For billing prior to 1/1/16 use C9453 or J9999)	Medicare Chemo	PA
J9301	GAZYVA	Injection, obinutuzumab, 10 mg (For billing prior to 1/1/15 use C9021 or J9999)	Medicare Chemo	PA; No Prior Authorization required when billed with the following ICD-10 codes: C82.00 - C82.69, C82.80 - C82.99, C91.40, C91.42, C83.00 - C83.09, C91.10, C91.12. For all other indications, prior authorization is required.
J9302	ARZERRA	Injection, ofatumumab, 10 mg (All NDCs inactive as of 4/8/2026)	Medicare Chemo	PA
J9303	VECTIBIX	Injection, panitumumab, 10 mg	Medicare Chemo	PA; No PA required for ICD-10 codes C18.0 - C21.8, C17.0 - C17.8, C78.01 - C78.02, C78.6 - C78.7.
J9304	PEMFEXY	Injection, pemetrexed (pemfexy), 10 mg	Medicare Chemo	
J9305	ALIMTA 100 MG VIAL	Injection, pemetrexed, not otherwise specified, 10 mg	Medicare Chemo	
J9305	ALIMTA 500 MG VIAL	Injection, pemetrexed, not otherwise specified, 10 mg	Medicare Chemo	
J9305	<i>pemetrexed disodium</i>	Injection, pemetrexed, not otherwise specified, 10 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9306	PERJETA	Injection, pertuzumab, 1 mg (For billing prior to 1/1/14 use C9292 or J9999)	Medicare Chemo	
J9307	FOLOTYN	Injection, pralatrexate, 1 mg (For billing prior to 1/1/11 use J9999 or C9259)	Medicare Chemo	
J9307	<i>pralatrexate</i>	Injection, pralatrexate, 1 mg (For billing prior to 1/1/11 use J9999 or C9259)	Medicare Chemo	
J9308	CYRAMZA	Injection, ramucirumab, 5 mg (For billing prior to 1/1/16 use C9025 or J9999)	Medicare Chemo	PA
J9309	POLIVY	Injection, polatuzumab vedotin-piiq, 1 mg	Medicare Chemo	PA
J9311	RITUXAN HYCELA	Injection, rituximab 10 mg and hyaluronidase	Medicare Chemo	PA; ST applies
J9312	RITUXAN	Injection, rituximab, 10 mg	Medicare Chemo	PA; ST applies
J9314	<i>pemetrexed</i>	Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg	Medicare Chemo	
J9316	PHESGO	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg	Medicare Chemo	PA; No PA required for ICD-10 codes C50.000 - C50.999 and C50.A0 - C50.A9
J9317	TRODELVY	Injection, sacituzumab govitecan-hziy, 2.5 mg	Medicare Chemo	PA
J9318	<i>romidepsin</i>	Injection, romidepsin, non-lyophilized, 0.1 mg	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9319	ISTODAX	Injection, romidepsin, lyophilized, 0.1 mg	Medicare Chemo	PA
J9319	<i>romidepsin</i>	Injection, romidepsin, lyophilized, 0.1 mg	Medicare Chemo	PA
J9320	ZANOSAR	Injection, streptozocin, 1 gram	Part B Drug	
J9321	EPKINLY	Injection, epcoritamab-bysp, 0.16 mg	Medicare Chemo	PA
J9322	<i>pemetrexed disodium</i>	Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg	Medicare Chemo	
J9324	PEMRYDI RTU	Injection, pemetrexed (pemrydi rtu), 10 mg	Medicare Chemo	PA; ST applies
J9325	IMLYGIC	Injection, talimogene laherparepvec, per 1 million plaque forming units (For billing prior to 1/1/17 use J9999 or C9472 for OPSP billing)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9326	EMRELIS	Injection, telisotuzumab vedotin-tllv, 1 mg	Medicare Chemo	PA
J9329	TEVIMBRA	Injection, tislelizumab-jsgr, 1mg	Medicare Chemo	PA
J9331	FYARRO	Injection, sirolimus protein-bound particles, 1 mg	Medicare Chemo	PA
J9341	TEPYLUTE	Injection, thiotepa (tepylute), 1 mg	Medicare Chemo	
J9342	TEPADINA 200 MG BAG	Injection, thiotepa, not otherwise specified, 1 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9345	ZYNYZ	Injection, retifanlimab-dlwr, 1 mg	Medicare Chemo	PA
J9347	IMJUDO	Injection, tremelimumab-actl, 1 mg	Medicare Chemo	PA
J9348	DANYELZA	Injection, naxitamab-gqqk, 1 mg	Medicare Chemo	PA
J9349	MONJUVI	Injection, tafasitamab-cxix, 2 mg	Medicare Chemo	PA
J9350	LUNSUMIO	Injection, mosunetuzumab-axgb, 1 mg (Code reused effective 7/1/2023)	Medicare Chemo	PA
J9350	LUNSUMIO VELO	Injection, mosunetuzumab-axgb, 1 mg (Code reused effective 7/1/2023)	Medicare Chemo	PA
J9351	<i>topotecan</i>	Injection, topotecan, 0.1 mg	Part B Drug	
J9352	YONDELIS	Injection, trabectedin, 0.1 mg (For billing prior to 1/1/17 use J9999 or C9480 for OPPS billing)	Medicare Chemo	PA
J9353	MARGENZA	Injection, margetuximab-cmkb, 5 mg	Medicare Chemo	PA; ST applies
J9354	KADCYLA	Injection, ado-trastuzumab emtansine, 1 mg (For billing prior to 1/1/14 use C9131 or J9999)	Medicare Chemo	
J9355	HERCEPTIN	Injection, trastuzumab, excludes biosimilar, 10 mg	Medicare Chemo	PA; ST applies
J9356	HERCEPTIN HYLECTA	Injection, trastuzumab, 10 mg and Hyaluronidase-oysk	Medicare Chemo	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9357	<i>valrubicin</i>	Injection, valrubicin, intravesical, 200 mg	Medicare Chemo	
J9357	VALSTAR	Injection, valrubicin, intravesical, 200 mg	Medicare Chemo	
J9358	ENHERTU	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	Medicare Chemo	PA
J9359	ZYNLONTA	Injection, loncastuximab tesirine-lpyl, 0.075 mg	Medicare Chemo	PA
J9360	<i>vinblastine</i>	Injection, vinblastine sulfate, 1 mg	Part B Drug	
J9370	<i>vincristine</i>	Vincristine sulfate, 1 mg	Part B Drug	
J9380	TECVAYLI	Injection, teclistamab-cqyv, 0.5 mg (Code reused effective 7/1/2023)	Medicare Chemo	PA
J9382	BIZENGRI	Injection, zenocutuzumab-zbco, 1 mg	Medicare Chemo	PA
J9390	<i>vinorelbine</i>	Injection, vinorelbine tartrate, per 10 mg	Part B Drug	
J9394	<i>fulvestrant</i>	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg	Medicare Chemo	
J9395	FASLODEX	Injection, fulvestrant, 25 mg	Medicare Chemo	
J9395	<i>fulvestrant</i>	Injection, fulvestrant, 25 mg	Medicare Chemo	
J9400	ZALTRAP	Injection, ziv-aflibercept, 1 mg (For billing prior to 1/1/14 use C9296 or J9999)	Part B Drug	
J9600	PHOTOFRIN	Injection, porfimer sodium, 75 mg	Not Covered	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9601	LYNOZYFIC	Injection, linvoseltamab-gcpt, 1 mg	Medicare Chemo	PA
J9999	AMTAGVI	Not otherwise classified, antineoplastic drugs	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9999	AVOPEF	Not otherwise classified, antineoplastic drugs	Part B Drug	
J9999	BESREMI	Not otherwise classified, antineoplastic drugs	Part D Drug	
J9999	FAVLYXA	Not otherwise classified, antineoplastic drugs	Part B Drug	
J9999	UNITUXIN	Not otherwise classified, antineoplastic drugs	Medicare Chemo	PA
Q2041	YESCARTA	Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (For billing prior to 4/1/18 use J9999 or C9399 for OPSS billing) (Code Price is for drug ONLY) (Code re-used by CMS)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2042	KYMRIAH	Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code was reused by CMS 1/1/2019) (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2043	PROVENGE	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion (Code Price is per 250 mL)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2053	TECARTUS	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2054	BREYANZI	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2054	BREYANZI CD4 COMPONENT (2OF 2)	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2054	BREYANZI CD8 COMPONENT (1OF 2)	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2055	ABECMA	Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2056	CARVYKTI	Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2058	AUCATZYL	Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion (Split dose infusion; complete therapy=2 separate infusions 10 days apart)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q5107	MVASI	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	Medicare Chemo	
Q5112	ONTRUZANT	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Medicare Chemo	
Q5113	HERZUMA	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Medicare Chemo	PA; ST applies
Q5114	OGIVRI	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Medicare Chemo	
Q5115	TRUXIMA	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Medicare Chemo	
Q5116	TRAZIMERA	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	Medicare Chemo	PA; ST applies
Q5117	KANJINTI	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	Medicare Chemo	PA; ST applies
Q5118	ZIRABEV	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg	Medicare Chemo	
Q5119	RUXIENCE	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	Medicare Chemo	
Q5123	RIABNI	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5126	ALYMSYS	Injection, bevacizumab-maly, biosimilar, (alymysys), 10 mg	Medicare Chemo	PA; ST applies
Q5129	VEGZELMA	Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg	Medicare Chemo	PA; ST applies
Q5146	HERCESSI	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg	Medicare Chemo	PA; ST applies
Q5160	JOBEVNE	Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg	Medicare Chemo	PA; ST applies
Antitoxins, Immune Glob, Toxoids, Vaccines				
Allergenic Extracts (Therapeutic)				
C9399	PALFORZIA (LEVEL 1)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 2)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 3)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	PALFORZIA (LEVEL 4)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 5)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 6)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 7)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 8)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPSC/ CPT Code	Drug Name	HCPSC/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	PALFORZIA (LEVEL 9)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 10)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA (LEVEL 11 UP-DOSE)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA 1 MG (LEVEL 0)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA INITIAL (1-3 YRS)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	PALFORZIA INITIAL (4-17 YRS)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	PALFORZIA LEVEL 11 MAINTENANCE	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
J3590	PALFORZIA (LEVEL 1)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 2)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 3)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 4)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 5)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 6)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 7)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 8)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 9)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 10)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA (LEVEL 11 UP-DOSE)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA 1 MG (LEVEL 0)	Unclassified biologics	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3590	PALFORZIA INITIAL (1-3 YRS)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA INITIAL (4-17 YRS)	Unclassified biologics	Part B Drug	PA
J3590	PALFORZIA LEVEL 11 MAINTENANCE	Unclassified biologics	Part B Drug	PA
Antitoxins And Immune Globulins				
J0565	ZINPLAVA	Injection, bezlotoxumab, 10 mg (For billing prior to 1/1/18 use J3590 or C9490 for OPPS billing)	Part B Drug	PA
J0716	ANASCORP	Injection, centrurides immune f(ab)2, up to 120 milligrams (Code Price is per 1 vial) (For billing prior to 1/1/13 use C9288 or J3590)	Not Covered	
J0841	ANAVIP	Injection, crotalidae immune f(ab')2 (equine), 120 mg	Not Covered	
J1459	PRIVIGEN	Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1551	CUTAQUIG	Injection, immune globulin (cutaquit), 100 mg	Part B Drug	B vs D (PA applies)
J1552	ALYGLO	Injection, immune globulin (alyglo), 500 mg	Part B Drug	PA; B vs D (PA applies); ST applies
J1553	YIMMUGO	Injection, immune globulin (yimmugo), 100 mg	Part B Drug	PA; B vs D (PA applies)
J1554	ASCENIV	Injection, immune globulin (asceniv), 500 mg	Part B Drug	PA; B vs D (PA applies); ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1555	CUVITRU	Injection, immune globulin (Cuvitru), 100 mg (For billing prior to 1/1/18 use J3590 or C9399 for OPSP billing)	Part B Drug	B vs D (PA applies)
J1556	BIVIGAM	Injection, immune globulin (Bivigam), 500 mg (For billing prior to 1/1/14 see C9130 or J1599)	Part B Drug	PA; B vs D (PA applies); ST applies
J1557	GAMMAPLEX	Injection, immune globulin, (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg (For billing prior to 1/1/12 use 90283, J1599 or C9270)	Part B Drug	B vs D (PA applies)
J1557	GAMMAPLEX (WITH SORBITOL)	Injection, immune globulin, (Gammaplex), intravenous, non-lyophilized (e.g. liquid), 500 mg (For billing prior to 1/1/12 use 90283, J1599 or C9270)	Part B Drug	B vs D (PA applies)
J1558	XEMBIFY	Injection, immune globulin (xembify), 100 mg	Part B Drug	B vs D (PA applies)
J1559	HIZENTRA 1 GRAM/5 ML VIAL P/F. OUTER, SUV	Injection, immune globulin (Hizentra), 100 mg (For billing prior to 1/1/11 use J3590 or C9399) (see also 90284 for CPT billing requirements)	Part B Drug	B vs D (PA applies)
J1561	GAMUNEX-C 1 GRAM/10 ML VIAL SUV, OUTER	Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1566	GAMMAGARD S-D (IGA < 1 MCG/ML)	Injection, immune globulin, intravenous, lyophilized (e.g powder), not otherwise specified, 500 mg (Only Carimune NF, Panglobulin NF and Gammagard S/D should be billed using this code)	Part B Drug	PA
J1568	OCTAGAM	Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1569	GAMMAGARD LIQUID	Injection, immune globulin, (gammagard liquid/gammagard liquid etc), 500 mg	Part B Drug	B vs D (PA applies)
J1569	GAMMAGARD LIQUID ERC	Injection, immune globulin, (gammagard liquid/gammagard liquid etc), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 0.5 GM,INNER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 0.5 GM,OUTER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 10 GM,INNER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1572	FLEBOGAMMA DIF 5% VIAL 10 GM,OUTER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 20 GM,INNER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 20 GM,OUTER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 5 GM,INNER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1572	FLEBOGAMMA DIF 5% VIAL 5 GM,OUTER,P/F,SUV	Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg	Part B Drug	B vs D (PA applies)
J1573	HEPAGAM B	Injection, hepatitis B immune globulin (Hepagam B), intravenous, 0.5 mL (see J1571 for IM use)	Part B Drug	
J1575	HYQVIA	Injection, immune globulin/hyaluronidase, (Hyqvia), 100 mg immune globulin (For billing prior to 1/1/16 use C9399 or J3590)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1576	PANZYGA	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	Part B Drug	PA; B vs D (PA applies); ST applies
J1577	QIVIGY	Injection, immune globulin (qivigy), 100 mg	Part B Drug	PA
J2790	HYPERRHO 1,500 UNIT SYRINGE P/F,INNER,SDV	Injection, Rho d immune globulin, human, full dose, 300 micrograms (1500 I.U.) (see also 90384 for CPT billing requirements)	Part B Drug	
J2790	HYPERRHO 1,500 UNIT SYRINGE P/F,OUTER,SDV	Injection, Rho d immune globulin, human, full dose, 300 micrograms (1500 I.U.) (see also 90384 for CPT billing requirements)	Part B Drug	
J2790	RHOGAM ULTRA-FILTERED PLUS	Injection, Rho d immune globulin, human, full dose, 300 micrograms (1500 I.U.) (see also 90384 for CPT billing requirements)	Part B Drug	
J2791	RHOPHYLAC	Injection, Rho(D) immune globulin (human), (Rhophylac), intramuscular or intravenous, 100 IU (see also 90384 and 90386 for CPT billing requirements)	Part B Drug	
Vaccines				
90740	RECOMBIVAX HB (PF)	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3-dose schedule, for intramuscular use (Code price is per dose = 40mcg)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
90744	ENGERIX-B PEDIATRIC (PF)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3- dose schedule, for intramuscular use (Code price is per dose = 0.5 mL)	Part B Drug	B vs D (PA applies)
90744	RECOMBIVAX HB (PF)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3- dose schedule, for intramuscular use (Code price is per dose = 0.5 mL)	Part B Drug	B vs D (PA applies)
90746	ENGERIX-B (PF)	Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use (Code Price is per dose = 1 mL)	Part B Drug	B vs D (PA applies)
90746	RECOMBIVAX HB (PF)	Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use (Code Price is per dose = 1 mL)	Part B Drug	B vs D (PA applies)
90747	ENGERIX-B (PF)	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4-dose schedule, for intramuscular use (Code price is per 40mcg = 1 dose)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
91304	NUVAXOVID 2025-2026 (PF)	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use (All NDCs inactive effective 7/2026)	Part B Drug	
91319	COMIRNATY 2025-2026(5-11Y)(PF)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Part B Drug	
91320	COMIRNATY 2025-26 (12Y UP)(PF)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Part B Drug	
91321	SPIKEVAX 2025-26 (6M-11Y) (PF)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, 25 mcg/0.25 mL dosage, for intramuscular use	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
91322	SPIKEVAX 2025-2026(12Y UP)(PF)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	Part B Drug	
91323	MNEXSPIKE 2025-2026 (PF)	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use	Part B Drug	
Autonomic Drugs				
Alpha- And Beta-Adrenergic Agonists				
J0163	ADRENALIN IN 0.9 % SOD CHLOR	Injection, epinephrine in sodium chloride (endo), 0.1 mg	Part B Drug	
J0164	<i>epineph 16 mg/250 ml-0.9% nacl</i>	Injection, epinephrine in sodium chloride (baxter), 0.1 mg	Part B Drug	
J0165	ADRENALIN	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	ADYPHREN	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	<i>epinephrine injection solution</i>	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0166	<i>epinephrine hcl (pf)</i>	Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0166	<i>epinephrine injection solution</i>	Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0167	<i>epinephrine 1 mg/10 ml abbojct inner, sub</i>	Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg (All NDCs inactive as of 11/4/2025)	Part B Drug	
J0167	<i>epinephrine 1 mg/10 ml abbojct sub, outer</i>	Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg (All NDCs inactive as of 11/4/2025)	Part B Drug	
J0168	<i>epinephrine 1 mg/10 ml luerjet inner, sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0168	<i>epinephrine 1 mg/10 ml luerjet outer, sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0169	ADRENALIN	Injection, epinephrine (adrenalin), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J3490	AUVI-Q	Unclassified drugs	Part D Drug	
J3490	<i>epinephrine injection auto-injector</i>	Unclassified drugs	Part D Drug	
J3490	EPIPEN	Unclassified drugs	Part D Drug	
J3490	EPIPEN 2-PAK	Unclassified drugs	Part D Drug	
J3490	EPIPEN JR 2-PAK	Unclassified drugs	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	NEFFY	Unclassified drugs	Part D Drug	
J3490	REZIPRES	Unclassified drugs	Part B Drug	
Alpha-Adrenergic Agonists (12:12)				
J2371	<i>phenylephrine hcl injection</i>	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
J2371	VAZCULEP	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
J2372	BIORPHEN	Injection, phenylephrine hydrochloride (biorphen), 20 micrograms	Part B Drug	
J2373	IMMPHENTIV	Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms	Part B Drug	
Antimuscarinics/Antispasmodics				
J0462	<i>atropine injection solution</i>	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg	Part B Drug	
J0462	<i>atropine intravenous solution</i>	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg	Part B Drug	
J0463	<i>atropine injection solution</i>	Injection, atropine sulfate (fresenius and therapeutically equivalent), 0.01 mg	Part B Drug	
J7620	<i>ipratropium-albuterol</i>	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7644	<i>ipratropium bromide inhalation solution</i>	Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram	Part B Drug	B vs D (PA applies)
J7677	YUPELRI	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through DME, 1 microgram	Part B Drug	PA; ST applies
Antiparkinsonian Agents				
J0515	<i>benztropine injection</i>	Injection, benztropine mesylate, per 1mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
<i>Botulinum Toxins</i>				

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0585	BOTOX	Injection, onabotulinumtoxinA, 1 unit	Part B Drug	PA; No Prior Authorization Required when billed with a below ICD-10 code in addition to meeting all criteria outlined in the Local Coverage Determination (LCD) L39909 AND the Billing and Coding A59809 article, including all required documentation and step therapy: K22.0, K60.0-K60.2, K60.30, K60.311-K60.313, K60.319, K60.321-K60.323, K60.329, K60.40, K60.411-K60.413, K60.419, K60.421-K60.423, K60.429, K60.50, K60.511-K60.513, K60.519, K60.521-K60.523, K60.529, G24.8, G24.1-G24.5, M43.6, M47.812, M47.892, M54.2, Q68.0, G43.001-G43.819, G43.901-G43.A0, L74.510-L74.513, L74.519, L74.52, L74.8-L74.9, J38.01-J38.02, J38.5, R49.0, R49.8, N31.1-N31.2, N31.8-N31.9, N32.81, N39.41-N39.46, N39.490-N39.492, N39.498, N30.10-N30.11, R39.89, G51.2, G51.31-G51.33, G51.4, G51.8, H02.041-H02.045, H02.141-H02.145, H02.431-H02.433, H02.59, R25.8, K11.7, H49.01-H49.03, H49.11-H49.13, H49.21-H49.23, H49.31-H49.33, H49.41-H49.43, H49.881-H49.883, H49.9, H50.00, H50.011-H50.012, H50.021-H50.022, H50.031-H50.032, H50.041-H50.042, H50.05-H50.08, H50.10, H50.111-H50.112, H50.121-H50.122, H50.131-H50.132, H50.141-H50.142, H50.15-H50.18, H50.21-H50.22, H50.30, H50.311-H50.312, H50.32, H50.331-H50.332, H50.34, H50.40, H50.411-H50.412, H50.42-H50.43, H50.50-H50.55, H50.60, H50.611-H50.612, H50.621-H50.622, H50.631-H50.632, H50.641-H50.642, H50.651-H50.652, H50.661-H50.662, H50.671-H50.672, H50.681-H50.682, H50.69, H50.811-H50.812, H50.89, H50.9, H51.0, H51.11-H51.12, H51.21-H51.23, H51.8, G04.1, G11.4, G24.02, G24.09, G25.0-G25.2, G25.61, G25.69, G25.89, G35.A, G35.B0-G35.B2, G35.C0-G35.C2, G35.D, G80.0-G80.4, G80.8, G81.11-G81.14, G82.21-G82.22, G82.51-G82.54, G83.0, G83.11-G83.14, G83.21-G83.24, I69.031-I69.034, I69.041-I69.044, I69.051-I69.054, I69.131-I69.134, I69.141-I69.144, I69.151-I69.154, I69.231-I69.234, I69.241-I69.244, I69.251-I69.254, I69.331-I69.334, I69.341-I69.344, I69.351-I69.354, I69.831-I69.834, I69.841-I69.844, I69.851-I69.854, I69.931-I69.934, I69.941-I69.944, I69.951-I69.954 ; ST applies
PA-Prior Authorization; ST applies-Step Therapy applies; B vs D (PA applies)-Part B vs Part D Priority Health Medicare Plans <i>Last updated August 24, 2026</i>			76	

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0585	BOTOX COSMETIC	Injection, onabotulinumtoxinA, 1 unit	Not Covered	
J0586	DYSPO	Injection, abobotulinumtoxinA, 5 units (For billing prior to 1/1/10 use J3590 or C9399)	Part B Drug	PA; No Prior Authorization Required when billed with a below ICD-10 code in addition to meeting all criteria outlined in the Local Coverage Determination (LCD) L39909 AND the Billing and Coding A59809 article, including all required documentation and step therapy: G11.4, G24.02, G24.09, G24.1-G24.3, G24.5, G80.0-G80.3, G80.8-G80.9, G81.11-G81.14, G82.21-G82.22, G82.51-G82.54, G83.0, G83.11-G83.14, G83.21-G83.24, I69.031-I69.034, I69.041-I69.044, I69.051-I69.054, I69.131-I69.134, I69.141-I69.144, I69.151-I69.154, I69.231-I69.234, I69.241-I69.244, I69.251-I69.254, I69.331-I69.334, I69.341-I69.344, I69.351-I69.354, I69.831-I69.834, I69.841-I69.844, I69.851-I69.854, I69.931-I69.934, I69.941-I69.944, I69.951-I69.954, K11.7, K60.0-K60.2, L74.510-L74.513, L74.519, L74.52, M43.6, M47.812, M47.892, M54.2, Q68.0 ; ST applies
J0587	MYOBLOC	Injection, rimabotulinumtoxinB, 100 units	Part B Drug	PA; No Prior Authorization Required when billed with a below ICD-10 code in addition to meeting all criteria outlined in the Local Coverage Determination (LCD) L39909 AND the Billing and Coding A59809 article, including all required documentation and step therapy: G24.02, G24.09, G24.1-G24.3, G80.3, M43.6, M47.812, M47.892, M54.2, Q68.0, K11.7 ; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0588	XEOMIN	Injection, incobotulinumtoxinA, 1 unit	Part B Drug	PA; No Prior Authorization Required when billed with a below ICD-10 code in addition to meeting all criteria outlined in the Local Coverage Determination (LCD) L39909 AND the Billing and Coding A59809 article, including all required documentation and step therapy: G24.02, G24.09, G24.1-G24.3, G24.5, G80.0-G80.3, G81.11-G81.14, G82.53-G82.54, G83.0, G83.21-G83.24, I69.031-I69.034, I69.051-I69.054, I69.131-I69.134, I69.151-I69.154, I69.231-I69.234, I69.251-I69.254, I69.331-I69.334, I69.351-I69.354, I69.831-I69.834, I69.851-I69.854, I69.931-I69.934, I69.951-I69.954, K11.7, M43.6, M47.812, M47.892, M54.2, Q68.0 ; ST applies
J0589	DAXXIFY	Injection, daxibotulinumtoxinA-lanm, 1 unit	Part B Drug	PA; No Prior Authorization Required when billed with a below ICD-10 code in addition to meeting all criteria outlined in the Local Coverage Determination (LCD) L39909 AND the Billing and Coding A59809 article, including all required documentation and step therapy: G24.02, G24.09, G24.1 - G24.3, G80.3, M43.6, M47.812, M47.892, M54.2, Q68.0 ; ST applies
J3590	JEUVEAU	Unclassified biologics	Not Covered	
Gaba-Derivative Skeletal Muscle Relaxant				
J0475	<i>baclofen intrathecal</i>	Injection, baclofen, 10 mg	Part B Drug	
J0475	GABLOFEN	Injection, baclofen, 10 mg	Part B Drug	
J0475	LIORESAL	Injection, baclofen, 10 mg	Part B Drug	
J0476	<i>baclofen intrathecal</i>	Injection, baclofen, 50 mcg, for intrathecal trial	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0476	GABLOFEN	Injection, baclofen, 50 mcg, for intrathecal trial	Part B Drug	
J0476	LIORESAL	Injection, baclofen, 50 mcg, for intrathecal trial	Part B Drug	
Neuromuscular Blocking Agents				
J0330	<i>succinylcholine 100 mg/5 ml syringe sub, p/f, outer</i>	Injection, succinylcholine chloride, up to 20mg	Part B Drug	
J0330	<i>succinylcholine 200 mg/10 ml syr sub, p/f, outer</i>	Injection, succinylcholine chloride, up to 20mg	Part B Drug	
J0330	<i>succinylcholine chloride injection</i>	Injection, succinylcholine chloride, up to 20mg	Part B Drug	
Non-SEL. Beta-Adrenergic Blocking Agents				
J1920	<i>labetalol hcl 20 mg/4 ml crpjt sub, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt sub, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng sub, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng sub, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng inner, sub, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1921	<i>labetalol hcl 10 mg/2 ml syrng outer, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
Parasympathomimetic (Cholinergic Agents)				
J2710	BLOXIVERZ	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine 3 mg/3 ml syringe inner, suv</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine 3 mg/3 ml syringe outer, suv</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine methylsulfate intravenous solution</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2711	PREVDUO	Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg	Part B Drug	
Selective Alpha-1-Adrenergic Block.Agent				
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1920	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng inner, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng outer, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
Selective Beta-2-Adrenergic Agonists				
J3105	<i>terbutaline subcutaneous</i>	Injection, terbutaline sulfate, up to 1 mg	Part B Drug	
J3535	XOPENEX HFA	Drug administered through a metered dose inhaler	Part B Drug	
J7605	<i>arformoterol</i>	Arformoterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 15 micrograms	Part B Drug	B vs D (PA applies)
J7605	BROVANA	Arformoterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 15 micrograms	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7606	<i>formoterol fumarate</i>	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms	Part B Drug	B vs D (PA applies)
J7606	PERFOROMIST	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms	Part B Drug	B vs D (PA applies)
J7611	<i>albuterol sulfate inhalation solution for nebulization</i>	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7612	<i>levalbuterol hcl</i>	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7613	<i>albuterol sulfate inhalation solution for nebulization</i>	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7614	<i>levalbuterol hcl</i>	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7614	XOPENEX 1.25 MG/3 ML SOLUTION P/F, 24'S	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	
J7620	<i>ipratropium-albuterol</i>	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME	Part B Drug	B vs D (PA applies)
Selective Beta-Adrenergic Blocking Agent				
J0616	<i>metoprolol tartrate intravenous</i>	Injection, metoprolol tartrate, 1 mg	Part B Drug	
J1805	BREVIBLOC	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	BREVIBLOC IN NACL (ISO-OSM)	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol in nacl (iso-osm)</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol intravenous solution</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1806	<i>esmolol in sterile water</i>	Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg	Part B Drug	
Smoking Cessation Agents				
J2315	VIVITROL	Injection, naltrexone, depot form, 1 mg	Part B Drug	
Blood Derivatives				
Blood Derivatives				
J0256	ARALAST NP	Injection, alpha 1-proteinase inhibitor, human, 10 mg, not otherwise specified	Part B Drug	PA
J0256	PROLASTIN-C	Injection, alpha 1-proteinase inhibitor, human, 10 mg, not otherwise specified	Part B Drug	PA
J0256	ZEMAIRA	Injection, alpha 1-proteinase inhibitor, human, 10 mg, not otherwise specified	Part B Drug	PA
J0257	GLASSIA	Injection, alpha 1 proteinase inhibitor (human), (Glassia), 10 mg (For billing prior to 1/1/12 use J3590 or C9399)	Part B Drug	PA
J2998	RYPLAZIM	Injection, plasminogen, human-tvmh, 1 mg	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Blood Formation, Coagulation, Thrombosis				
<i>Antianemia Drugs</i>				
J0881	ARANESP 10 MCG/0.4 ML SYRINGE P/F, INNER, SUV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 10 MCG/0.4 ML SYRINGE P/F, OUTER, SUV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 100 MCG/0.5 ML SYRINGE P/F, SDV, INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 100 MCG/0.5 ML SYRINGE P/F, SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 100 MCG/ML VIAL P/F, 4'S, SDV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 100 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 150 MCG/0.3 ML SYRINGE P/F, SDV, INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 150 MCG/0.3 ML SYRINGE P/F, SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 200 MCG/0.4 ML SYRINGE P/F, SDV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0881	ARANESP 200 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 200 MCG/ML VIAL SUV, P/F	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 25 MCG/0.42 ML SYRING P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 25 MCG/0.42 ML SYRING P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 25 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 25 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 300 MCG/0.6 ML SYRINGE	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 40 MCG/0.4 ML SYRINGE P/F, INNER, SDV	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 40 MCG/0.4 ML SYRINGE P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 40 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 40 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 500 MCG/1 ML SYRINGE	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0881	ARANESP 60 MCG/0.3 ML SYRINGE P/F,SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 60 MCG/0.3 ML SYRINGE P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 60 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0881	ARANESP 60 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0882	ARANESP 10 MCG/0.4 ML SYRINGE P/F, INNER, SUV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 10 MCG/0.4 ML SYRINGE P/F, OUTER, SUV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 100 MCG/0.5 ML SYRINGE P/F, SDV, INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 100 MCG/0.5 ML SYRINGE P/F, SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 100 MCG/ML VIAL P/F, 4'S, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 100 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
J0882	ARANESP 150 MCG/0.3 ML SYRINGE P/F, SDV, INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 150 MCG/0.3 ML SYRINGE P/F, SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 200 MCG/0.4 ML SYRINGE P/F, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 200 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 200 MCG/ML VIAL SUV, P/F	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/0.42 ML SYRING P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/0.42 ML SYRING P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 300 MCG/0.6 ML SYRINGE	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 40 MCG/0.4 ML SYRINGE P/F, INNER, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0882	ARANESP 40 MCG/0.4 ML SYRINGE P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 40 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 40 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 500 MCG/1 ML SYRINGE	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/0.3 ML SYRINGE P/F,SDV, OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/0.3 ML SYRINGE P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0887	MIRCERA	Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0896	REBLOZYL	Injection, luspatercept-aamt, 0.25 mg	Part B Drug	PA
J0901	VAFSEO	Vadadustat, oral, 1 mg (for esrd on dialysis)	Not Separately Payable	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Anticoagulants, Miscellaneous				
J0911	DEFENCATH	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)	Not Separately Payable	
Blood Form.,Coag,Thrombosis Agents Misc.				
J0791	ADAKVEO	Injection, crizanlizumab-tmca, 5 mg	Part B Drug	PA; ST applies
Direct Thrombin Inhibitors				
J0582	<i>bivalirudin intravenous solution</i>	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg	Part B Drug	
Hematopoietic Agents				
C9399	FILKRI	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
J0881	ARANESP 200 MCG/ML VIAL SUV, P/F	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)	Part B Drug	
J0882	ARANESP (IN POLYSORBATE) INJECTION SYRINGE	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 100 MCG/ML VIAL P/F, 4'S, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0882	ARANESP 100 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 200 MCG/ML VIAL P/F, SDV	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 200 MCG/ML VIAL SUV, P/F	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 25 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 40 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 40 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/ML VIAL P/F,SDV,INNER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0882	ARANESP 60 MCG/ML VIAL P/F,SDV,OUTER	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0885	EPOGEN	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	PA; ST applies
J0885	PROCRIT 10,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 10,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0885	PROCRIT 2,000 UNITS/ML VIAL SDV, P/F, INNER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 2,000 UNITS/ML VIAL SDV,P/F, OUTER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 4,000 UNITS/ML VIAL SDV, P/F, INNER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 4,000 UNITS/ML VIAL SDV, P/F, OUTER	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 40,000 UNITS/ML VIAL INNER, P/F,SDV	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0885	PROCRIT 40,000 UNITS/ML VIAL OUTER, SDV,P/F	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Part B Drug	
J0887	MIRCERA	Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)	Part B Drug	B vs D (PA applies)
J0896	REBLOZYL	Injection, luspatercept-aamt, 0.25 mg	Part B Drug	PA
J0901	VAFSEO	Vadadustat, oral, 1 mg (for esrd on dialysis)	Not Separately Payable	
J1442	NEUPOGEN	Injection, filgrastim (G-CSF), excludes biosimilars, 1 microgram	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1447	GRANIX	Injection, tbo-filgrastim, 1 microgram	Part B Drug	PA; ST applies
J1449	ROLVEDON	Injection, eflapegrastim-xnst, 0.1 mg	Part B Drug	PA; ST applies
J2277	APHEXDA	Injection, motixafortide, 0.25 mg	Part B Drug	
J2506	NEULASTA	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Part B Drug	
J2506	NEULASTA ONPRO	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Part B Drug	
J2562	MOZOBIL	Injection, plerixafor, 1 mg (For billing prior to 1/1/10 use J3490 or C9252)	Part B Drug	
J2562	<i>plerixafor</i>	Injection, plerixafor, 1 mg (For billing prior to 1/1/10 use J3490 or C9252)	Part B Drug	
J2802	NPLATE	Injection, romiplostim, 1 microgram	Part B Drug	PA
J2820	LEUKINE	Injection, sargramostim (GM-CSF), 50 mcg	Part B Drug	
J3590	FILKRI	Unclassified biologics	Part B Drug	PA
J9361	RYZNEUTA	Injection, efbemalenograstim alfa-vuxw, 0.5 mg	Part B Drug	PA; ST applies
Q4081	EPOGEN	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	PA; ST applies
Q4081	PROCRIT 10,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q4081	PROCRIT 10,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 2,000 UNITS/ML VIAL SDV, P/F, INNER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 2,000 UNITS/ML VIAL SDV,P/F, OUTER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 4,000 UNITS/ML VIAL SDV, P/F, INNER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 4,000 UNITS/ML VIAL SDV, P/F, OUTER	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 40,000 UNITS/ML VIAL INNER, P/F,SDV	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q4081	PROCRIT 40,000 UNITS/ML VIAL OUTER, SDV,P/F	Injection, epoetin alfa, 100 units (for ESRD on dialysis) (for renal dialysis facilities and hospital use)	Part B Drug	
Q5101	ZARXIO	Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 microgram	Part B Drug	
Q5105	RETACRIT 10,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 10,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5105	RETACRIT 10,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 10,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 2,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 2,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 2,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 2,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/2 ML VIAL INNER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/2 ML VIAL MUV, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/2 ML VIAL MUV, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5105	RETACRIT 20,000 UNIT/2 ML VIAL OUTER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/ML VIAL INNER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/ML VIAL MUV, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/ML VIAL MUV, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 20,000 UNIT/ML VIAL OUTER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 3,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 3,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 3,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 3,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5105	RETACRIT 4,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 4,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 4,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 4,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 40,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5105	RETACRIT 40,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units	Part B Drug	B vs D (PA applies)
Q5106	RETACRIT 10,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 10,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 10,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5106	RETACRIT 10,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 2,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 2,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 2,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 2,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/2 ML VIAL INNER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/2 ML VIAL MUV, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/2 ML VIAL MUV, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/2 ML VIAL OUTER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5106	RETACRIT 20,000 UNIT/ML VIAL INNER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/ML VIAL MUV, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/ML VIAL MUV, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 20,000 UNIT/ML VIAL OUTER, MUV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 3,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 3,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 3,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 3,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 4,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5106	RETACRIT 4,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 4,000 UNIT/ML VIAL SUV, P/F, INNER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 4,000 UNIT/ML VIAL SUV, P/F, OUTER	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 40,000 UNIT/ML VIAL P/F, INNER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5106	RETACRIT 40,000 UNIT/ML VIAL P/F, OUTER, SDV	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	Part B Drug	
Q5108	FULPHILA	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	Part B Drug	
Q5110	NIVESTYM	Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 microgram	Part B Drug	
Q5111	UDENYCA	Injection, pegfilgrastim-cbqv (udenyc), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5111	UDENYCA AUTOINJECTOR	Injection, pegfilgrastim-cbqv (udenyc), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5111	UDENYCA ONBODY	Injection, pegfilgrastim-cbqv (udenyc), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5120	ZIEXTENZO	Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5122	NYVEPRIA	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5125	RELEUKO	Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram	Part B Drug	PA; ST applies
Q5127	STIMUFEND	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5130	FYLNETRA	Injection, pegfilgrastim-pbbk (flyneta), biosimilar, 0.5 mg	Part B Drug	PA; ST applies
Q5148	NYPOZI	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram	Part B Drug	PA; ST applies
Hemostatics				
J1411	HEMGENIX	Injection, etranacogene dezaparvovec-drlb, per therapeutic dose	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J1412	ROCTAVIAN	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2×10^{13} vector genomes (All NDCs inactive as of 6/10/2026)	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J2597	DDAVP INJECTION	Injection, desmopressin acetate, per 1 mcg	Part B Drug	
J2597	<i>desmopressin injection</i>	Injection, desmopressin acetate, per 1 mcg	Part B Drug	
J3290	CYKLOKAPRON	Injection, tranexamic acid, 5 mg	Part B Drug	
J3290	<i>tranexamic acid intravenous</i>	Injection, tranexamic acid, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7165	BALFAXAR	Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity	Part B Drug	
J7170	HEMLIBRA	Injection, emicizumab-kxwh, 0.5 mg	Part B Drug	
J7172	HYMPAVZI PEN	Injection, marstacimab-hncq, 0.5 mg	Part B Drug	PA; ST applies
J7173	ALHEMO PEN	Injection, concizumab-mtci, 0.5 mg	Part B Drug	PA; ST applies
J7174	QFITLIA	Injection, fitusiran, 0.04 mg	Part B Drug	PA; ST applies
J7174	QFITLIA PEN	Injection, fitusiran, 0.04 mg	Part B Drug	PA; ST applies
J7175	COAGADEX	Injection, factor X, (human), 1 IU (For billing prior to 1/1/17 use J3590 or C9399 for OPPS billing)	Part B Drug	
J7176	FESILTY	Injection, human fibrinogen - chmt (fesilty), 1 mg	Part B Drug	
J7177	FIBRYGA	Injection, human fibrinogen concentrate (fibryga), 1 mg (Price is per 1mg. Product contains approximately 1 gram (900-1300mg))	Part B Drug	
J7179	VONVENDI	Injection, Von Willebrand factor (recombinant), (Vonvendi), 1 IU VWF:RCo (For billing prior to 1/1/17 use J7199 or C9399 for OPPS billing)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7180	CORIFACT	Injection, factor XIII (antihemophilic factor, human), 1 IU (Code Price is per 1 IU - Corifact contains 1000-1600 Units) (For billing prior to 1/1/12 use J3590 or C9399)	Part B Drug	
J7181	TRETEN	Injection, factor XIII A-subunit, (recombinant), per IU For billing prior to 1/1/15 use C9134 or J3590)	Part B Drug	
J7182	NOVOEIGHT	Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU	Part B Drug	
J7183	WILATE	Injection, Von Willebrand factor complex (human), Wilate, 1 IU VWF:RCO	Part B Drug	
J7185	XYNTHA	Injection, factor VIII (antihemophilic factor, recombinant) (Xyntha), per IU	Part B Drug	
J7185	XYNTHA SOLOFUSE	Injection, factor VIII (antihemophilic factor, recombinant) (Xyntha), per IU	Part B Drug	
J7186	ALPHANATE	Injection, antihemophilic factor VIII/Von Willebrand factor complex (human), per factor VIII I.U.	Part B Drug	
J7187	HUMATE-P	Injection, Von Willebrand factor complex (Humate-P), per IU, VWF:RCO	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7188	OBIZUR	Injection, factor VIII (antihemophilic factor, recombinant), (Obizur), per IU (Code re-used by CMS effective 1/1/16) (For billing prior to 1/1/16 use C9399 or J7199)	Part B Drug	
J7189	NOVOSEVEN RT	Factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram	Part B Drug	
J7190	HEMOFIL M HIGH	Factor VIII (antihemophilic factor [human]) per IU	Part B Drug	
J7190	HEMOFIL M LOW	Factor VIII (antihemophilic factor [human]) per IU	Part B Drug	
J7190	HEMOFIL M MID	Factor VIII (antihemophilic factor [human]) per IU	Part B Drug	
J7190	HEMOFIL M SUPER HIGH	Factor VIII (antihemophilic factor [human]) per IU	Part B Drug	
J7190	KOATE	Factor VIII (antihemophilic factor [human]) per IU	Part B Drug	
J7192	ADVATE	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 1,000 UNIT VIAL INNER, SUV	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7192	KOGENATE FS 1,000 UNIT VIAL PRICE/UNIT,SUV OUTER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 2,000 UNIT VIAL PRICE/UNIT,SUV,INNER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 2,000 UNIT VIAL PRICE/UNIT,SUV,OUTER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 250 UNIT VIAL PRICE/UNIT,SUV,INNER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 250 UNIT VIAL PRICE/UNIT,SUV,OUTER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 3,000 UNIT VIAL PRICE/UNIT,SUV,OUTER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7192	KOGENATE FS 3,000 UNIT VIAL SUV, INNER	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	KOGENATE FS 500 UNIT VIAL PRICE/UNIT, SUV	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7192	RECOMBINATE	Factor VIII (antihemophilic factor, recombinant) per IU, not otherwise specified (Effective 9/1/18 Code Price is based on Median Pricing Methodology)	Part B Drug	
J7193	ALPHANINE SD	Factor IX (antihemophilic factor, purified, non-recombinant) per IU	Part B Drug	
J7194	PROFILNINE	Factor IX, complex, per IU	Part B Drug	
J7195	BENEFIX	Injection factor IX (antihemophilic factor, recombinant) per IU, not otherwise specified	Part B Drug	
J7198	FEIBA NF	Anti-inhibitor, per IU	Part B Drug	
J7200	RIXUBIS	Injection, factor IX, (antihemophilic factor, recombinant), Rixubis, per IU (For billing prior to 1/1/15 use C9133 or J7195)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7201	ALPROLIX	Injection, factor IX, Fc fusion protein, (recombinant), Alprolix, 1 IU	Part B Drug	
J7202	IDELVION	Injection, factor IX, albumin fusion protein, (recombinant), Idelvion, 1 IU (For billing prior to 1/1/17 use J7199 or C9139 for OPPS billing)	Part B Drug	
J7203	REBINYN	Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu	Part B Drug	
J7204	ESPEROCT	Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu	Part B Drug	
J7205	ELOCTATE	Injection, factor VIII, Fc fusion protein (recombinant), per IU	Part B Drug	
J7207	ADYNOVATE	Injection, factor VIII, (antihemophilic factor, recombinant), pegylated, 1 IU (For billing prior to 1/1/17 use J7199 or C9137 for OPPS billing)	Part B Drug	
J7208	JIVI	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.	Part B Drug	
J7209	NUWIQ	Injection, factor VIII, (antihemophilic factor, recombinant), (Nuwiq), 1 IU (For billing prior to 1/1/17 use J7199 or C9138 for OPPS billing)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7210	AFSTYLA	Injection, factor VIII, (antihemophilic factor, recombinant), (Afstyla), 1 IU (For billing prior to 1/1/18 use J7199 or C9140 for OPPS billing)	Part B Drug	
J7211	KOVALTRY	Injection, factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 IU (For billing prior to 1/1/18 use J7192)	Part B Drug	
J7212	SEVENFACT	Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram	Part B Drug	
J7213	IXINITY	Injection, coagulation factor ix (recombinant), ixinity, 1 i.u.	Part B Drug	
J7214	ALTUVIIIO	Injection, factor viii/von willebrand factor complex, recombinant (altuviio), per factor viii i.u.	Part B Drug	
Iron Preparations				
J1437	MONOFERRIC	Injection, ferric derisomaltose, 10 mg	Part B Drug	
J1439	<i>ferric carboxymaltose</i>	Injection, ferric carboxymaltose, 1 mg	Part B Drug	
J1439	INJECTAFER	Injection, ferric carboxymaltose, 1 mg	Part B Drug	
J1750	INFED	Injection, iron dextran, 50 mg (Code reinstated effective 1/1/09)	Part B Drug	
J1756	<i>iron sucrose 100 mg/5 ml vial sub, p/f</i>	Injection, iron sucrose, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1756	VENOFER	Injection, iron sucrose, 1 mg	Part B Drug	
J2916	FERRLECIT	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg	Part B Drug	
J2916	<i>sodium ferric gluconate-sucrose</i>	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg	Part B Drug	
Q0138	FERAHEME	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use) (For billing prior to 1/1/10 use J3490 or C9399)	Part B Drug	
Q0138	<i>ferumoxytol</i>	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use) (For billing prior to 1/1/10 use J3490 or C9399)	Part B Drug	
Von Willebrand Factor-Related Antithromb				
C9047	CABLIVI INJECTION KIT	Injection, caplacizumab-yhdp, 1 mg	Part B Drug	PA
Cardiovascular Drugs				
Alpha-Adrenergic Blocking Agents (24:16)				
J1920	<i>labetalol hcl 20 mg/4 ml crpjt sub, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt sub, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng sub, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1920	<i>labetalol hcl 20 mg/4 ml syring sub, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syring inner, sub, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syring outer, sub, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
Angptl3 Inhibitors (24:06)				
J1305	EVKEEZA	Injection, evinacumab-dgnb, 5mg	Part B Drug	PA; ST applies
Antilipemic Agents, Miscellaneous				
C9399	REDEMPLO	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J1306	LEQVIO	Injection, inclisiran, 1 mg	Part B Drug	PA; ST applies
J3490	REDEMPLO	Unclassified drugs	Part D Drug	
Beta-Adrenergic Blocking Agents (24:20)				
J0616	<i>metoprolol tartrate intravenous</i>	Injection, metoprolol tartrate, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1805	BREVIBLOC	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	BREVIBLOC IN NACL (ISO-OSM)	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol in nacl (iso-osm)</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol intravenous solution</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1806	<i>esmolol in sterile water</i>	Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng inner, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng outer, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1921	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
Bradykinin Receptors Antagonists				
J1744	FIRAZYR	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
J1744	<i>icatibant</i>	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
J1744	SAJAZIR	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
Calcium-Channel Blocking Agents				
J1164	<i>diltiazem 100 mg/100 ml-nacl bag inner, suv, p/f</i>	Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg	Part B Drug	
J1164	<i>diltiazem 100 mg/100 ml-nacl bag outer, suv, p/f</i>	Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg	Part B Drug	
Cardiotonic Agents				
J1160	<i>digoxin injection</i>	Injection, digoxin, up to 0.5 mg	Part B Drug	
J1160	LANOXIN INJECTION	Injection, digoxin, up to 0.5 mg	Part B Drug	
J1160	LANOXIN PEDIATRIC	Injection, digoxin, up to 0.5 mg	Part B Drug	
Class II Antiarrhythmics				
J0616	<i>metoprolol tartrate intravenous</i>	Injection, metoprolol tartrate, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1805	BREVIBLOC	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	BREVIBLOC IN NACL (ISO-OSM)	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol in nacl (iso-osm)</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1805	<i>esmolol intravenous solution</i>	Injection, esmolol hydrochloride, 10 mg	Part B Drug	
J1806	<i>esmolol in sterile water</i>	Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml crpjt suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, inner</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol hcl 20 mg/4 ml syrng suv, outer</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1920	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng inner, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J1921	<i>labetalol hcl 10 mg/2 ml syrng outer, suv, p/f</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1921	<i>labetalol intravenous solution</i>	Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg	Part B Drug	
J3490	RAPIBLYK	Unclassified drugs	Part B Drug	PA
Class Iv Antiarrhythmics				
J1163	<i>diltiazem hcl intravenous</i>	Injection, diltiazem hydrochloride, 0.5 mg	Part B Drug	
J1164	<i>diltiazem 100 mg/100 ml-nacl bag inner, suv, p/f</i>	Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg	Part B Drug	
J1164	<i>diltiazem 100 mg/100 ml-nacl bag outer, suv, p/f</i>	Injection, diltiazem hydrochloride in 0.72% sodium chloride, 0.5 mg	Part B Drug	
Dihydropyridines				
J0759	CLEVIPREX	Injection, clevidipine butyrate, 1 mg	Part B Drug	
Kallikrein Inhibitors (24:48:08)				
C9399	DAWNZERA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0593	TAKHZYRO	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0593	TAKHZYRO 300 MG/2 ML VIAL	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Part D Drug	
J1290	KALBITOR	Injection, ecallantide, 1 mg (For billing prior to 1/1/11 use J3590 or C9263)	Part D Drug	
Loop Diuretics (24:36)				
C9399	LASIX ONYU	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J1938	<i>furosemide injection</i>	Injection, furosemide, 1 mg	Part B Drug	
J1941	FUROSCIX	Injection, furosemide (furoscix), 20 mg	Part D Drug	
J1941	FUROSCIX READYFLOW	Injection, furosemide (furoscix), 20 mg	Part D Drug	
J3490	LASIX ONYU	Unclassified drugs	Part D Drug	
Nitrates And Nitrites				
J2305	<i>nitroglycerin in 5 % dextrose</i>	Injection, nitroglycerin, 5 mg	Part B Drug	
J2305	<i>nitroglycerin intravenous</i>	Injection, nitroglycerin, 5 mg	Part B Drug	
Osmotic Diuretics (24:36)				
J2151	<i>mannitol 20 %</i>	Injection, mannitol, 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2151	OSMITROL 10 %	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 20 %	Injection, mannitol, 250 mg	Part B Drug	
Vasodilating Agents, Miscellaneous				
J1325	<i>epoprostenol</i>	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	FLOLAN 0.5 MG VIAL	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	FLOLAN 1.5 MG VIAL	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	VELETRI	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1749	AURLUMYN	Injection, iloprost, 0.1 mcg	Not Covered	
J3285	REMODULIN 100 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMODULIN 20 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMODULIN 200 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMODULIN 50 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	<i>treprostinil sodium</i>	Injection, treprostinil, 1 mg	Part B Drug	PA
J3535	TYVASO DPI 16 MCG CARTRIDGE	Drug administered through a metered dose inhaler	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3535	TYVASO DPI 16 MCG CARTRIDGE INNER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 16 MCG CARTRIDGE OUTER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 16-32-48 MCG TITRAT	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 32 MCG CARTRIDGE	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 32 MCG CARTRIDGE INNER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 32 MCG CARTRIDGE OUTER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 32-64 MCG MAINT KIT	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 48 MCG CARTRIDGE	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 48 MCG CARTRIDGE INNER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 48 MCG CARTRIDGE OUTER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 64 MCG CARTRIDGE	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 64 MCG CARTRIDGE INNER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 64 MCG CARTRIDGE OUTER	Drug administered through a metered dose inhaler	Part D Drug	
J3535	TYVASO DPI 80 MCG CARTRIDGE INNER	Drug administered through a metered dose inhaler	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3535	TYVASO DPI 80 MCG CARTRIDGE OUTER	Drug administered through a metered dose inhaler	Part D Drug	
J7686	TYVASO	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO INSTITUTIONAL START KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO REFILL KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO STARTER KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Cellular And Gene Therapy				
<i>Cellular Therapy</i>				
C9399	AMTAGVI	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
C9399	LANTIDRA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
C9399	OMISIRGE	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3402	RYONCIL	Injection, remestemcel-I-rknd, per therapeutic dose	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products); ST applies
J3590	LANTIDRA	Unclassified biologics	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3590	OMISIRGE	Unclassified biologics	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3590	RETHYMIC	Unclassified biologics	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9999	AMTAGVI	Not otherwise classified, antineoplastic drugs	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2043	PROVENGE	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion (Code Price is per 250 mL)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Gene Therapy				
C9399	KEBILIDI	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J1411	HEMGENIX	Injection, etranacogene dezaparvovec-drlb, per therapeutic dose	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J1412	ROCTAVIAN	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2×10^{13} vector genomes (All NDCs inactive as of 6/10/2026)	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1413	ELEVIDYS	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3386	WASKYRA	Injection, etuvetidigene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products); Drug Name: Waskyra
J3387	SKYSONA	Injection, elivaldogene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3389	ZEVASKYN	Topical administration, prademagene zamikeracel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3391	LENMELDY	Injection, atidarsagene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3392	CASGEVY	Injection, exagamglogene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products); ST applies
J3393	ZYNTEGLO	Injection, betibeglogene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3394	LYFGENIA	Injection, lovotibeglogene autotemcel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products); ST applies
J3398	LUXTURNA	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3399	ZOLGENSMA	Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10 ¹⁵ vector genomes	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3401	VYJUVEK	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10 ⁹ pfu/ml vector genomes, per 0.1 ml	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3403	ENCELTO	Revakinagene taroretcel-lwey, per implant	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3404	PAPZIMEOS	Injection, zopapogene imadenovect-drba suspension, per therapeutic dose	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3405	ITVISM	Injection, onasemnogene abeparvovec-brve, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3590	KEBILIDI	Unclassified biologics	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9029	ADSTILADRIN	Intravesical instillation, nadofaragene firadenovect-vncg, per therapeutic dose	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J9325	IMLYGIC	Injection, talimogene laherparepvec, per 1 million plaque forming units (For billing prior to 1/1/17 use J9999 or C9472 for OPPS billing)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2041	YESCARTA	Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (For billing prior to 4/1/18 use J9999 or C9399 for OPPS billing) (Code Price is for drug ONLY) (Code re-used by CMS)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2042	KYMRIAH	Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code was reused by CMS 1/1/2019) (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2053	TECARTUS	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2054	BREYANZI	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2054	BREYANZI CD4 COMPONENT (2OF 2)	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2054	BREYANZI CD8 COMPONENT (1OF 2)	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2055	ABECMA	Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q2056	CARVYKTI	Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2057	TECELRA	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Q2058	AUCATZYL	Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion (Split dose infusion; complete therapy=2 separate infusions 10 days apart)	Medicare Chemo	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
Central Nervous System Agents				
<i>Amyotrophic Lateral Sclerosis(ALS) Agent</i>				
J1301	edaravone	Injection, edaravone, 1 mg	Part B Drug	PA
J1301	RADICAVA	Injection, edaravone, 1 mg	Part B Drug	PA
J1304	QALSODY	Injection, tofersen, 1 mg	Part B Drug	PA
<i>Analgesics And Antipyretics, Misc.</i>				
J8499	JOURNAVX	Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Anorexic Agents, Miscellaneous				
C9399	MOUNJARO	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	OZEMPIC SUBCUTANEOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	VICTOZA 2-PAK	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	VICTOZA 3-PAK	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	WEGOVY SUBCUTANEOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	MOUNJARO	Unclassified drugs	Part D Drug	
J3490	OZEMPIC SUBCUTANEOUS	Unclassified drugs	Part D Drug	
J3490	SAXENDA	Unclassified drugs	Part D Drug	
J3490	VICTOZA 2-PAK	Unclassified drugs	Part D Drug	
J3490	VICTOZA 3-PAK	Unclassified drugs	Part D Drug	
J3490	WEGOVY SUBCUTANEOUS	Unclassified drugs	Part D Drug	
J8499	WEGOVY 1.5 MG TABLET	Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified	Part D Drug	
Anticholinergic Agents (Cns)				
J0515	<i>benztropine injection</i>	Injection, benztropine mesylate, per 1mg	Part B Drug	
Antidepressants, Miscellaneous				
J3490	KETALAR	Unclassified drugs	Not Covered	
J3490	<i>ketamine injection</i>	Unclassified drugs	Not Covered	
Antimanic Agents				
J0401	ABILIFY MAINTENA	Injection, aripiprazole (abilify maintena), 1 mg	Part B Drug	
J0402	ABILIFY ASIMTUFII	Injection, aripiprazole (abilify asimtufii), 1 mg	Part B Drug	
J1943	ARISTADA INITIO	Injection, aripiprazole lauroxil, (aristada initio), 1 mg	Part B Drug	
J1944	ARISTADA	Injection, aripiprazole lauroxil, (aristada), 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2358	ZYPREXA RELPREVV	Injection, olanzapine, long-acting, 1 mg	Part B Drug	
J2359	<i>olanzapine intramuscular</i>	Injection, olanzapine, 0.5 mg	Part B Drug	
J2359	ZYPREXA INTRAMUSCULAR	Injection, olanzapine, 0.5 mg	Part B Drug	
J2794	RISPERDAL CONSTA	Injection, risperidone (risperdal consta), 0.5 mg	Part B Drug	
J2794	<i>risperidone microspheres</i>	Injection, risperidone (risperdal consta), 0.5 mg	Part B Drug	
J2798	PERSERIS	Injection, risperidone, (perseris), 0.5 mg	Part B Drug	
J2799	UZEDY	Injection, risperidone (uzedy), 1 mg	Part B Drug	
J2801	RYKINDO	Injection, risperidone (rykindo), 0.5 mg	Part B Drug	
J3486	GEODON INTRAMUSCULAR	Injection, ziprasidone mesylate, 10 mg	Part B Drug	
J3486	<i>ziprasidone mesylate</i>	Injection, ziprasidone mesylate, 10 mg	Part B Drug	
Antimigraine Agents, Miscellaneous				
J0131	<i>acetaminophen 1,000 mg/100 ml bag plf, single use</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml bag single-use, plf</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner, suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner, suv, plf</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner,suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer, suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer, suv, plf</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer,suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0134	<i>acetaminophen 1,000 mg/100 ml bag plf, suv, inner</i>	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0134	<i>acetaminophen 1,000 mg/100 ml bag plf, suv, outer</i>	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0136	<i>acetaminophen 1,000 mg/100 ml bag plf, suv</i>	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0136	<i>acetaminophen 500 mg/50 ml bag single use, plf</i>	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0137	<i>acetaminophen 1,000 mg/100 ml bag inner, single use</i>	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0137	<i>acetaminophen 1,000 mg/100 ml bag outer, single use</i>	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0138	COMBOGESIC IV	Injection, acetaminophen 10 mg and ibuprofen 3 mg	Part B Drug	
Anxiolytics, Sedatives, And Hypnotics, Misc				
J2550	PHENERGAN	Injection, promethazine HCl, up to 50 mg	Part B Drug	
J2550	<i>promethazine injection</i>	Injection, promethazine HCl, up to 50 mg	Part B Drug	
J3490	PRECEDEX 1,000 MCG/250 ML BAG SUV, P/F, OUTER	Unclassified drugs	Part B Drug	
J3490	PRECEDEX 200 MCG/50 ML BAG SUV, P/F, OUTER	Unclassified drugs	Part B Drug	
J3490	PRECEDEX 400 MCG/100 ML BAG SUV, P/F, OUTER	Unclassified drugs	Part B Drug	
Atypical Antipsychotics				
J0401	ABILIFY MAINTENA	Injection, aripiprazole (abilify maintena), 1 mg	Part B Drug	
J0402	ABILIFY ASIMTUFII	Injection, aripiprazole (abilify asimtufii), 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1943	ARISTADA INITIO	Injection, aripiprazole lauroxil, (aristada initio), 1 mg	Part B Drug	
J1944	ARISTADA	Injection, aripiprazole lauroxil, (aristada), 1 mg	Part B Drug	
J2358	ZYPREXA RELPREVV	Injection, olanzapine, long-acting, 1 mg	Part B Drug	
J2359	<i>olanzapine intramuscular</i>	Injection, olanzapine, 0.5 mg	Part B Drug	
J2359	ZYPREXA INTRAMUSCULAR	Injection, olanzapine, 0.5 mg	Part B Drug	
J2426	INVEGA SUSTENNA	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	Part B Drug	
J2427	INVEGA HAFYERA	Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg	Part B Drug	
J2427	INVEGA TRINZA	Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg	Part B Drug	
J2428	ERZOFRI	Injection, paliperidone palmitate extended release (erzofri), 1 mg	Part B Drug	PA; ST applies
J2794	RISPERDAL CONSTA	Injection, risperidone (risperdal consta), 0.5 mg	Part B Drug	
J2794	<i>risperidone microspheres</i>	Injection, risperidone (risperdal consta), 0.5 mg	Part B Drug	
J2798	PERSERIS	Injection, risperidone, (perseris), 0.5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2799	UZEDY	Injection, risperidone (uzedy), 1 mg	Part B Drug	
J2801	RYKINDO	Injection, risperidone (rykindo), 0.5 mg	Part B Drug	
J3486	GEODON INTRAMUSCULAR	Injection, ziprasidone mesylate, 10 mg	Part B Drug	
J3486	<i>ziprasidone mesylate</i>	Injection, ziprasidone mesylate, 10 mg	Part B Drug	
Barbiturates (Anticonvulsants)				
J2560	<i>phenobarbital sodium</i>	Injection, phenobarbital sodium, up to 120 mg	Part B Drug	
J2561	SEZABY	Injection, phenobarbital sodium (sezaby), 1 mg	Part B Drug	
Barbiturates (Anxiolytic, Sedative/Hyp)				
J2560	<i>phenobarbital sodium</i>	Injection, phenobarbital sodium, up to 120 mg	Part B Drug	
J2561	SEZABY	Injection, phenobarbital sodium (sezaby), 1 mg	Part B Drug	
Benzodiazepines (Anticonvulsants)				
J2060	ATIVAN INJECTION	Injection, lorazepam, 2 mg	Part B Drug	
J2060	<i>lorazepam injection</i>	Injection, lorazepam, 2 mg	Part B Drug	
J3360	<i>diazepam injection</i>	Injection, diazepam, up to 5 mg	Part B Drug	
J3490	<i>midazolam intramuscular</i>	Unclassified drugs	Part B Drug	
Benzodiazepines (Anxiolytic, Sedative/Hyp)				
J2060	ATIVAN INJECTION	Injection, lorazepam, 2 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2060	<i>lorazepam injection</i>	Injection, lorazepam, 2 mg	Part B Drug	
J2252	<i>midazolam in nacl,iso-osmo(pf) intravenous solution</i>	Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg	Part B Drug	
J3360	<i>diazepam injection</i>	Injection, diazepam, up to 5 mg	Part B Drug	
Butyrophenones				
J1630	<i>haloperidol lac 5 mg/ml syring plf, suv, inner</i>	Injection, haloperidol, up to 5 mg	Part B Drug	
J1630	<i>haloperidol lac 5 mg/ml syring plf, suv, outer</i>	Injection, haloperidol, up to 5 mg	Part B Drug	
J1630	<i>haloperidol lactate injection</i>	Injection, haloperidol, up to 5 mg	Part B Drug	
J1631	<i>haloperidol decanoate</i>	Injection, haloperidol decanoate, per 50 mg	Part B Drug	
Calcitonin Gene-Related Peptide Antag.				
J3031	AJOVY AUTOINJECTOR	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Part D Drug	
J3031	AJOVY SYRINGE	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3032	VYEPTI	Injection, eptinezumab-jjmr, 1 mg	Part B Drug	PA; ST applies
Central Nervous System Agents, Misc.				
J3490	VYLEESI	Unclassified drugs	Part D Drug	
Dibenzoxapines				
J2062	ADASUVE	Loxapine for inhalation, 1 mg	Not Covered	
Dopamine Precursors				
J7340	DUOPA	Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 mL	Part B Drug	
J7356	VYALEV	Injection, foscarnidopa 0.25 mg/foslevodopa 5 mg	Part B Drug	PA
Non-Barbiturates				
J3490	KETALAR	Unclassified drugs	Not Covered	
J3490	<i>ketamine injection</i>	Unclassified drugs	Not Covered	
Nonergot-Deriv.Dopamine Receptor Agonist				
C9399	ONAPGO	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0364	APOKYN	Injection, apomorphine hydrochloride, 1 mg	Part D Drug	
J0364	<i>apomorphine</i>	Injection, apomorphine hydrochloride, 1 mg	Part D Drug	
J3490	ONAPGO	Unclassified drugs	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Non-Opioid Analgesics				
J0131	<i>acetaminophen 1,000 mg/100 ml bag p/f, single use</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml bag single-use, p/f</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner, suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner, suv, p/f</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl inner,suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer, suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer, suv, p/f</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0131	<i>acetaminophen 1,000 mg/100 ml vl outer,suv</i>	Injection, acetaminophen, not otherwise specified, 10 mg	Part B Drug	
J0134	<i>acetaminophen 1,000 mg/100 ml bag p/f, suv, inner</i>	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0134	<i>acetaminophen 1,000 mg/100 ml bag p/f, suv, outer</i>	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0136	<i>acetaminophen 1,000 mg/100 ml bag p/f, sub</i>	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0136	<i>acetaminophen 500 mg/50 ml bag single use, p/f</i>	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0137	<i>acetaminophen 1,000 mg/100 ml bag inner, single use</i>	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0137	<i>acetaminophen 1,000 mg/100 ml bag outer, single use</i>	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	Part B Drug	
J0138	COMBOGESIC IV	Injection, acetaminophen 10 mg and ibuprofen 3 mg	Part B Drug	
J2278	PRIALT	Injection, ziconotide, 1 microgram	Part B Drug	
Opioid Agonists (28:08)				
J1171	DILAUDID 0.2 MG/ML SYRINGE SUV, P/F, INNER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 0.2 MG/ML SYRINGE SUV, P/F, OUTER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 0.5 MG/0.5 ML SYRINGE SUV, P/F, INNER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 0.5 MG/0.5 ML SYRINGE SUV, P/F, OUTER	Injection, hydromorphone, 0.1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1171	DILAUDID 1 MG/ML SYRINGE SUV, P/F, INNER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 1 MG/ML SYRINGE SUV, P/F, OUTER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 2 MG/ML SYRINGE SUV, P/F, INNER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	DILAUDID 2 MG/ML SYRINGE SUV, P/F, OUTER	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	<i>hydromorphone (pf)</i>	Injection, hydromorphone, 0.1 mg	Part B Drug	
J1171	<i>hydromorphone injection</i>	Injection, hydromorphone, 0.1 mg	Part B Drug	
J2175	DEMEROL	Injection, meperidine hydrochloride, per 100 mg	Part B Drug	
J2175	DEMEROL (PF)	Injection, meperidine hydrochloride, per 100 mg	Part B Drug	
J2175	<i>meperidine (pf)</i>	Injection, meperidine hydrochloride, per 100 mg	Part B Drug	
Opioid Antagonists (28:10)				
J2312	LIFEMS NALOXONE	Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg	Part B Drug	
J2312	<i>naloxone injection</i>	Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg	Part B Drug	
J2315	VIVITROL	Injection, naltrexone, depot form, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Opioid Partial Agonists				
J0577	BRIXADI	Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy	Part B Drug	
J0578	BRIXADI	Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy	Part B Drug	
J0592	<i>buprenorphine hcl injection</i>	Injection, buprenorphine hydrochloride, 0.1 mg	Part B Drug	
Q9991	SUBLOCADE	Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg (For billing prior to 7/1/18 use J3490 or C9399 for Hospital OPPS use) (Code Price is per 100 mg)	Part B Drug	
Q9992	SUBLOCADE	Injection, buprenorphine extended-release (Sublocade), greater than 100 mg (For billing prior to 7/1/18 use J3490 or C9399 for Hospital OPPS use) (Code Price is per 300 mg)	Part B Drug	
Phenothiazines				
J2679	<i>fluphenazine hcl injection</i>	Injection, fluphenazine hcl, 1.25 mg	Part B Drug	
J2680	<i>fluphenazine decanoate</i>	Injection, fluphenazine decanoate, up to 25 mg	Part B Drug	
J3230	<i>chlorpromazine injection</i>	Injection, chlorpromazine HCl, up to 50 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Reversible Cox-1/Cox-2 Inhibitors				
J0138	COMBOGESIC IV	Injection, acetaminophen 10 mg and ibuprofen 3 mg	Part B Drug	
J0668	ZYNRELEF	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg	Part B Drug	
J1737	XIFYRM	Injection, meloxicam (azurity), 1 mg	Part B Drug	
Devices				
Devices				
J7318	DUROLANE	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg	Part B Drug	
J7320	GENVISC 850	Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg (Code re-used by CMS effective 1/1/17) (GenVisc 850 dose is 25 mg/2.5 mL) (Note: Total dose regimen = 3 - 5 injections)	Part B Drug	PA
J7321	HYALGAN	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose (Hyalgan dose is 20 mg/2 mL, Supartz and Visco-3 dose is 25 mg/2.5 mL) (Note: Total dose regimen = 3 - 5 injections)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7321	SUPARTZ FX	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose (Hyalgan dose is 20 mg/2 mL, Supartz and Visco-3 dose is 25 mg/2.5 mL) (Note: Total dose regimen = 3 - 5 injections)	Part B Drug	
J7321	VISCO-3	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose (Hyalgan dose is 20 mg/2 mL, Supartz and Visco-3 dose is 25 mg/2.5 mL) (Note: Total dose regimen = 3 - 5 injections)	Part B Drug	PA
J7322	HYMOVIS	Hyaluronan or derivative, hymovis or hymovis one, for intra-articular injection, 1 mg	Part B Drug	PA
J7322	HYMOVIS ONE	Hyaluronan or derivative, hymovis or hymovis one, for intra-articular injection, 1 mg	Part B Drug	PA
J7323	EUFLEXXA	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose (20 mg/2 mL) (Note: Total dose regimen = 3 injections)	Part B Drug	
J7324	ORTHOVISC	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose (30 mg/2 mL) (Note: Total dose regimen = 3 - 4 injections)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7325	SYNVISC	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg (For billing prior to 1/1/10 see J7322 for Synvisc and J3490 for Synvisc-One)	Part B Drug	PA
J7325	SYNVISC-ONE	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg (For billing prior to 1/1/10 see J7322 for Synvisc and J3490 for Synvisc-One)	Part B Drug	PA
J7326	GEL-ONE	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose	Part B Drug	PA
J7327	MONOVISC	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose (For billing prior to 1/1/15 use C9399 or J3490) (Dose 88 mg/4 mL) (Note: Total dose regimen = 1 dose)	Part B Drug	PA
J7328	GELSYN-3	Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg	Part B Drug	
J7329	TRIVISC	Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg	Part B Drug	PA
J7331	SYNOJOYNT 1% 20 MG/2 ML SYRING	Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg	Part B Drug	PA
J7332	TRILURON	Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Diagnostic Agents				
<i>Adrenocortical Insufficiency</i>				
J0801	ACTHAR	Injection, corticotropin (acthar gel), up to 40 units	Part D Drug	
J0801	ACTHAR SELFJECT	Injection, corticotropin (acthar gel), up to 40 units	Part D Drug	
J0802	CORTROPHIN GEL	Injection, corticotropin (ani), up to 40 units	Part D Drug	
<i>Diagnostic Agents</i>				
A9596	ILLUCCIX	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie (NDC Unit Pricing is based on 7 mCi dose)	Part B Drug	
J1611	<i>glucagon 1 mg vial inner, suv</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon 1 mg vial outer, suv</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon 1 mg vial suv, inner</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon 1 mg vial suv, outer</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1611	<i>glucagon 1 mg vial sub,inner</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon 1 mg vial sub,outer</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
Gallbladder Function				
J2805	KINEVAC	Injection, sincalide, 5 micrograms	Part B Drug	
J2805	<i>sincalide</i>	Injection, sincalide, 5 micrograms	Part B Drug	
Kidney Function				
J2151	<i>mannitol 20 %</i>	Injection, mannitol, 250 mg	Part B Drug	
J2151	<i>mannitol 25 %</i>	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 10 %	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 20 %	Injection, mannitol, 250 mg	Part B Drug	
Myasthenia Gravis				
J2710	BLOXIVERZ	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine 3 mg/3 ml syringe inner, sub</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine 3 mg/3 ml syringe outer, sub</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	
J2710	<i>neostigmine methylsulfate intravenous solution</i>	Injection, neostigmine methylsulfate, up to 0.5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Thyroid Function				
J3240	THYROGEN	Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial (Code Price is per 1 vial)	Part B Drug	
Electrolytic, Caloric, And Water Balance				
Caloric Agents				
B4185	CLINOLIPID	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)
B4185	INTRALIPID	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)
B4185	KABIVEN	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
B4185	NUTRILIPID	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)
B4185	PERIKABIVEN	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)
B4185	SMOFLIPID	Parenteral nutrition solution, not otherwise specified, 10 grams lipids (Effective 2/1/07 Code Price is per 10 gm lipids and is based on median pricing methodology - previously Code Price was based on 1 mL and average pricing methodology)	Part B Drug	B vs D (PA applies)
J3490	AMINOSYN II 10 %	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	AMINOSYN II 15 %	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	AMINOSYN-PF 10 %	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	AMINOSYN-PF 7 % (SULFITE-FREE)	Unclassified drugs	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	CLINIMIX 5%/D15W SULFITE FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 4.25%/D10W SULF FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 4.25%-5% SOLUTION INNER, SUV	Unclassified drugs	Part B Drug	
J3490	CLINIMIX 4.25%-5% SOLUTION OUTER, SUV	Unclassified drugs	Part B Drug	
J3490	CLINIMIX 4.25%-5% SOLUTION SINGLE USE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 5%-20% SOLUTION INNER, SUV	Unclassified drugs	Part B Drug	
J3490	CLINIMIX 5%-20% SOLUTION OUTER, SUV	Unclassified drugs	Part B Drug	
J3490	CLINIMIX 5%-20% SOLUTION SINGLE USE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 6%-D5W (SULFITE-FREE)	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 8%- D10W(SULFITE-FREE)	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX 8%- D14W(SULFITE-FREE)	Unclassified drugs	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	CLINIMIX E 2.75%/D5W SULF FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 4.25%/D10W SULF FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 4.25%/D5W SULF FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 5%/D15W SULFIT FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 5%/D20W SULFIT FREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 8%-D10W SULFITEFREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	CLINIMIX E 8%-D14W SULFITEFREE	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	PREMASOL 10 %	Unclassified drugs	Part B Drug	B vs D (PA applies)
J3490	TROPHAMINE 10 %	Unclassified drugs	Part B Drug	B vs D (PA applies)
J7042	D5 % (D-GLUCOSE)-0.9 % SODCHLR	5% Dextrose/normal saline (500 mL = 1 unit)	Part B Drug	
Electrolytic, Caloric, Water Balance Misc,				
J0584	CRYSVITA	Injection, burosumab-twza 1 mg	Part B Drug	PA
Irrigating Solutions				
J2151	mannitol 20 %	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 10 %	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 20 %	Injection, mannitol, 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Loop Diuretics (40:28)				
C9399	LASIX ONYU	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J1807	<i>ethacrynate sodium</i>	Injection, ethacrynate sodium, 1 mg	Part B Drug	
J1938	<i>furosemide injection</i>	Injection, furosemide, 1 mg	Part B Drug	
J1941	FUROSCIX	Injection, furosemide (furoscix), 20 mg	Part D Drug	
J1941	FUROSCIX READYFLOW	Injection, furosemide (furoscix), 20 mg	Part D Drug	
J3490	LASIX ONYU	Unclassified drugs	Part D Drug	
Osmotic Diuretics (40:28)				
J2151	<i>mannitol 20 %</i>	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 10 %	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 20 %	Injection, mannitol, 250 mg	Part B Drug	
Phosphate-Removing Agents				
J0607	FOSRENOL	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)	Not Separately Payable	
J0607	<i>lanthanum</i>	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)	Not Separately Payable	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0608	FOSRENOL	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)	Not Separately Payable	
J0609	AURYXIA	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)	Not Separately Payable	
J0615	<i>calcium acetate</i>	Calcium acetate, oral, 23 mg (for esrd on dialysis)	Not Separately Payable	
J0615	<i>calcium acetate(phosphat bind)</i>	Calcium acetate, oral, 23 mg (for esrd on dialysis)	Not Separately Payable	
J0618	<i>calcium chloride</i>	Injection, calcium chloride, 2 mg	Part B Drug	
Replacement Preparations				
C9399	ZYCUBO	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0618	<i>calcium chloride</i>	Injection, calcium chloride, 2 mg	Part B Drug	
J3490	PLASMA-LYTE 148 PH 7.4	Unclassified drugs	Part B Drug	
J3490	PLASMA-LYTE A	Unclassified drugs	Part B Drug	
J3490	<i>potassium phos in 0.9 % nacl intravenous piggyback</i>	Unclassified drugs	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	ZYCUBO	Unclassified drugs	Part D Drug	
Enzymes				
Enzyme Inhibitors				
J1202	OPFOLDA	Miglustat, oral, 65 mg	Part D Drug	
Enzymes				
C9399	LOARGYS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
C9399	REVCovi	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA
J0180	FABRAZYME	Injection, agalsidase beta, 1 mg	Part B Drug	PA
J0217	LAMZEDE	Injection, velmanase alfa-tycv, 1 mg	Part B Drug	PA
J0218	XENPOZYME	Injection, olipudase alfa-rpcp, 1 mg	Part B Drug	PA
J0219	NEXVIAZYME	Injection, avalglucosidase alfa-ngpt, 4 mg	Part B Drug	PA
J0221	LUMIZYME	Injection, alglucosidase alfa, (Lumizyme), 10 mg (For billing prior to 1/1/12 use J3590 or C9277)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0567	BRINEURA INTRAVENTRICULAR KIT	Injection, cerliponase alfa, 1 mg	Part B Drug	PA
J0775	XIAFLEX	Injection, collagenase, clostridium histolyticum, 0.01 mg (For billing prior to 1/1/11 use J3590 or C9266)	Part B Drug	PA; No PA required for ICD-10 codes M72.0 or N48.6.
J1203	POMBILITI	Injection, cipaglucosidase alfa-atga, 5 mg	Part B Drug	PA
J1322	VIMIZIM	Injection, elosulfase alfa, 1 mg (For billing prior to 1/1/15 use C9022 or J3590)	Part B Drug	PA; No PA required for ICD-10 code: E76.210.
J1458	NAGLAZYME	Injection, galsulfase, 1 mg	Part B Drug	
J1743	ELAPRASE	Injection, idursulfase, 1 mg	Part B Drug	
J1786	CEREZYME	Injection, imiglucerase, 10 units	Part B Drug	
J1931	ALDURAZYME	Injection, laronidase, 0.1 mg	Part B Drug	
J2508	ELFABRIO	Injection, pegunigalsidase alfa-iwxj, 1 mg	Part B Drug	PA
J2783	ELITEK	Injection, rasburicase, 0.5 mg	Part B Drug	
J2840	KANUMA	Injection, sebelipase alfa, 1 mg (For billing prior to 1/1/17 use J3590 or C9478 for OPSS billing)	Part B Drug	PA
J3060	ELELYSO	Injection, taliglucerase alfa, 10 units	Part B Drug	
J3385	VPRIV	Injection, velaglucerase alfa, 100 units (For billing prior to 1/1/11 use J3490 or C9271)	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3397	MEPSEVII	Injection, vestronidase alfa-vjbk, 1 mg	Part B Drug	PA
J3590	LOARGYS	Unclassified biologics	Part B Drug	PA
J3590	REVCIVI	Unclassified biologics	Part B Drug	PA
J7171	ADZYNMA	Injection, adamts13, recombinant-krhn, 10 iu	Part B Drug	PA
J7639	PULMOZYME	Dornase alfa, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram	Part B Drug	B vs D (PA applies)
J9021	RYLAZE	Injection, asparaginase, recombinant, (rylaze), 0.1 mg	Medicare Chemo	PA
J9118	ASPARLAS	Injection, calaspargase pegol-mknl, 10 units	Medicare Chemo	PA; No PA required for ICD-10 codes C91.00 - C91.02, C83.50 - C83.59.
Eye, Ear, Nose And Throat (Eent) Preps.				
Antibacterials (52:04)				
J1271	DOXY-100	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1271	<i>doxycycline hyclate 100 mg vial plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, sub, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial plf, sub, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vial sub, plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J2280	<i>moxifloxacin-sodium chloride(iso)</i>	Injection, moxifloxacin, 100 mg	Part B Drug	
J2281	<i>moxifloxacin-sodium acetate, sul-water</i>	Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg	Part B Drug	
Antiglaucoma Agents, Miscellaneous				
J7315	MITOSOL	Mitomycin, ophthalmic, 0.2 mg (Code re-used by CMS effective 1/1/13) (For billing prior to 1/1/13 use J3490 or C9399)	Part B Drug	
Anti-Inflammatory Agents (Eent)				
J3241	TEPEZZA	Injection, teprotumumab-trbw, 10 mg	Part B Drug	PA; ST applies
J7502	<i>cyclosporine modified</i>	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	<i>cyclosporine oral</i>	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7502	GENGRAF	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	GENGRAF 100 MG/ML SOLUTION	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	NEORAL	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	SANDIMMUNE ORAL	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7515	<i>cyclosporine modified</i>	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	<i>cyclosporine oral</i>	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	GENGRAF	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	NEORAL	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	SANDIMMUNE ORAL	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7516	<i>cyclosporine 250 mg/5 ml ampul p/f, sub, inner</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	<i>cyclosporine 250 mg/5 ml ampul p/f, sub, outer</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	<i>cyclosporine 250 mg/5 ml ampul sub</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	SANDIMMUNE INTRAVENOUS	Injection, cyclosporine, 250 mg	Part B Drug	
Antivirals (Eent)				
J1570	<i>ganciclovir sodium</i>	Injection, ganciclovir sodium, 500 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Corticosteroids (Eent)				
J1095	DEXYCU (PF)	Injection, dexamethasone 9 percent, intraocular, 1 microgram (Code reused by CMS January 1, 2019) (Each single dose vial provides a 0.005 mL dose equivalent to 517 micrograms)	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial inner, suv, p/f</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial inner,suv,p/f</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial outer, suv, p/f</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial outer,suv,p/f</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial sdv, p/f, inner</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial sdv, p/f, outer</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial suv, p/f</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial suv, p/f, inner</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 10 mg/ml vial suv, p/f, outer</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone sodium phos (pf) injection syringe</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1100	<i>dexamethasone sodium phosphate injection</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	DOUBLEDEX (PF)	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	MAS CARE-PAK (PF)	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J3299	XIPERE (PF)	Injection, triamcinolone acetonide (xipere), 1 mg	Part B Drug	PA
J7311	RETISERT	Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg	Part B Drug	PA; ST applies
J7312	OZURDEX	Injection, dexamethasone, intravitreal implant, 0.1 mg (For billing prior to 1/1/11 use J3490 or C9256)	Part B Drug	PA
J7313	ILUVIEN	Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg	Part B Drug	PA
J7314	YUTIQ	Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg	Part B Drug	PA
J7402	SINUVA	Mometasone furoate sinus implant, (sinuva), 10 micrograms	Part B Drug	PA
Eent Drugs, Miscellaneous				
J2779	SUSVIMO 10 MG/0.1 ML KIT	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2787	PHOTREXA CROSS-LINKING KIT	Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml	Part B Drug	
Q5124	BYOOVIZ	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	Part B Drug	PA; No PA required for ICD-10 codes E08.311, E08.319, E08.3211-E08.3213, E08.3291 - E08.3293, E08.3311-E08.3313, E08.3391 - E08.3393, E08.3411- E08.3413, E08.3491 - E08.3493, E08.3511- E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211-E09.3213, E09.3291 - E09.3291, E09.3311-E09.3313, E09.3391 - E09.3393, E09.3411- E09.3413, E09.3491 - E09.3493, E09.3511- E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211- E10.3213, E10.3291 - E10.3293, E10.3311- E10.3313, E10.3391 - E10.3393, E10.3411- E10.3413, E10.3491 - E10.3493, E10.3511- E10.3513, E10.3591-E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.3210 - H35.3233, H35.351 - H35.353, H44.21 - H44.2E9.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Eent Nonsteroidal Anti-Inflam. Agents				
J1097	OMIDRIA	phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml	Part B Drug	
Local Anesthetics (Eent)				
J2403	IHEEZO (PF)	Chloroprocaine hcl ophthalmic, 3% gel, 1 mg	Part B Drug	PA; ST applies
Macular Degeneration Agents				
J2781	SYFOVRE (PF)	Injection, pegcetacoplan, intravitreal, 1 mg	Part B Drug	PA
J2782	IZERVAY (PF)	Injection, avacincapted pegol, 0.1 mg	Part B Drug	PA
J3396	VISUDYNE	Injection, verteporfin, 0.1 mg	Part B Drug	PA; No PA required for ICD-10 codes B39.4,B39.5, H32,H35.3210-H35.3233, H35.711 - H35.713, H44.20-H44.2E9.
Mydriatics				
J1097	OMIDRIA	phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml	Part B Drug	
J2371	<i>phenylephrine hcl injection</i>	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
J2371	VAZCULEP	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
Osmotic Agents				
J2151	<i>mannitol 20 %</i>	Injection, mannitol, 250 mg	Part B Drug	
J2151	OSMITROL 10 %	Injection, mannitol, 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2151	OSMITROL 20 %	Injection, mannitol, 250 mg	Part B Drug	
<i>Prostaglandin Analogs</i>				
J7351	DURYSTA	Injection, bimatoprost, intracameral implant, 1 microgram	Part B Drug	PA; ST applies
J7355	IDOSE TR	Injection, travoprost, intracameral implant, 1 microgram	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Vascular Endothelial Growth Factor Antag				
J0177	EYLEA HD	Injection, aflibercept hd, 1 mg	Part B Drug	PA; No PA required when billed with the following ICD-10 codes: A18.53, E08.311, E08.319, E08.3211 - E08.3213, E08.3291 - E08.3293, E08.3311 - E08.3313, E08.3391 - E08.3393, E08.3411 - E08.3413, E08.3491 - E08.3493, E08.3511 - E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211 - E09.3213, E09.3291 - E09.3291, E09.3311 - E09.3313, E09.3391 - E09.3393, E09.3411 - E09.3413, E09.3491 - E09.3493, E09.3511 - E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211 - E10.3213, E10.3291 - E10.3293, E10.3311 - E10.3313, E10.3391 - E10.3393, E10.3411 - E10.3413, E10.3491 - E10.3493, E10.3511 - E10.3513, E10.3591 - E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411- E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8190, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.101 - H35.169, H35.3210 - H35.3233, H35.351 - H35.353

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0178	EYLEA	Injection, aflibercept, 1 mg	Part B Drug	PA; No PA required when billed with the following ICD-10 codes: A18.53, E08.311, E08.319, E08.3211 - E08.3213, E08.3291 - E08.3293, E08.3311 - E08.3313, E08.3391 - E08.3393, E08.3411 - E08.3413, E08.3491 - E08.3493, E08.3511 - E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211 - E09.3213, E09.3291 - E09.3293, E09.3311 - E09.3313, E09.3391 - E09.3393, E09.3411 - E09.3413, E09.3491 - E09.3493, E09.3511 - E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211 - E10.3213, E10.3291 - E10.3293, E10.3311 - E10.3313, E10.3391 - E10.3393, E10.3411 - E10.3413, E10.3491 - E10.3493, E10.3511 - E10.3513, E10.3591 - E10.3593, E11.3211-E11.3213, E11.3291-E11.3293, E11.3311-E11.3313, E11.3391 - E11.3393, E11.3411-E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411- E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8190, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.101 - H35.169, H35.3210 - H35.3233, H35.351 - H35.353
J0179	BEOVU	Injection, brolucizumab-dbl, 1 mg	Part B Drug	PA; No PA required for ICD-10 codes H35.3210-H35.3213, H35.3220-H35.3223, H35.3230-H35.3233, H35.3290-H35.3293.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2777	VABYSMO	Injection, faricimab-svoa, 0.1 mg	Part B Drug	PA; No PA required for ICD-10 codes A18.53, E08.311, E08.319, E08.3211 - E08.3213, E08.3291 - E08.3293, E08.3311 - E08.3313, E08.3391 - E08.3393, E08.3411 - E08.3413, E08.3491 - E08.3493, E08.3511 - E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211 - E09.3213, E09.3291 - E09.3291, E09.3311 - E09.3313, E09.3391 - E09.3393, E09.3411 - E09.3413, E09.3491 - E09.3493, E09.3511 - E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211 - E10.3213, E10.3291 - E10.3293, E10.3311 - E10.3313, E10.3391 - E10.3393, E10.3411 - E10.3413, E10.3491 - E10.3493, E10.3511 - E10.3513, E10.3591 - E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8190, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.101 - H35.169, H35.3210 - H35.3233, H35.351 - H35.353

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2778	LUCENTIS INTRAVITREAL SYRINGE	Injection, ranibizumab, 0.1 mg	Part B Drug	PA; No PA required for ICD-10 codes E08.311, E08.319, E08.3211-E08.3213, E08.3291 - E08.3293, E08.3311-E08.3313, E08.3391 - E08.3393, E08.3411- E08.3413, E08.3491 - E08.3493, E08.3511- E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211-E09.3213, E09.3291 - E09.3291, E09.3311-E09.3313, E09.3391 - E09.3393, E09.3411- E09.3413, E09.3491 - E09.3493, E09.3511- E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211- E10.3213, E10.3291 - E10.3293, E10.3311- E10.3313, E10.3391 - E10.3393, E10.3411- E10.3413, E10.3491 - E10.3493, E10.3511- E10.3513, E10.3591-E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.3210 - H35.3233, H35.351 - H35.353, H44.21 - H44.2E9.
J2779	SUSVIMO	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5128	CIMERLI	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	Part B Drug	PA; No PA required for ICD-10 codes E08.311, E08.319, E08.3211-E08.3213, E08.3291 - E08.3293, E08.3311-E08.3313, E08.3391 - E08.3393, E08.3411- E08.3413, E08.3491 - E08.3493, E08.3511- E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211-E09.3213, E09.3291 - E09.3291, E09.3311-E09.3313, E09.3391 - E09.3393, E09.3411- E09.3413, E09.3491 - E09.3493, E09.3511- E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211- E10.3213, E10.3291 - E10.3293, E10.3311- E10.3313, E10.3391 - E10.3393, E10.3411- E10.3413, E10.3491 - E10.3493, E10.3511- E10.3513, E10.3591-E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.3210 - H35.3233, H35.351 - H35.353, H44.21 - H44.2E9.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5147	PAVBLU	Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg	Part B Drug	PA; No PA required for ICD-10 codes A18.53, E08.311, E08.319, E08.3211 - E08.3213, E08.3291 - E08.3293, E08.3311 - E08.3313, E08.3391 - E08.3393, E08.3411 - E08.3413, E08.3491 - E08.3493, E08.3511 - E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211 - E09.3213, E09.3291 - E09.3291, E09.3311 - E09.3313, E09.3391 - E09.3393, E09.3411 - E09.3413, E09.3491 - E09.3493, E09.3511 - E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211 - E10.3213, E10.3291 - E10.3293, E10.3311 - E10.3313, E10.3391 - E10.3393, E10.3411 - E10.3413, E10.3491 - E10.3493, E10.3511 - E10.3513, E10.3591 - E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8190, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.101 - H35.169, H35.3210 - H35.3233, H35.351 - H35.353.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5155	YESAFILI	Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg	Part B Drug	PA; No PA required when billed with the following ICD-10 codes: A18.53, E08.311, E08.319, E08.3211 - E08.3213, E08.3291 - E08.3293, E08.3311 - E08.3313, E08.3391 - E08.3393, E08.3411 - E08.3413, E08.3491 - E08.3493, E08.3511 - E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211 - E09.3213, E09.3291 - E09.3293, E09.3311 - E09.3313, E09.3391 - E09.3393, E09.3411 - E09.3413, E09.3491 - E09.3493, E09.3511 - E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211 - E10.3213, E10.3291 - E10.3293, E10.3311 - E10.3313, E10.3391 - E10.3393, E10.3411 - E10.3413, E10.3491 - E10.3493, E10.3511 - E10.3513, E10.3591 - E10.3593, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311 - E11.3313, E11.3391 - E11.3393, E11.3411 - E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211 - E13.3213, E13.3291 - E13.3293, E13.3311 - E13.3313, E13.3391 - E13.3393, E13.3411 - E13.3413, E13.3491 - E13.3493, E13.3511 - E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8190, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.101 - H35.169, H35.3210 - H35.3233, H35.351 - H35.353

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5168	NUFYMCO	Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg	Part B Drug	PA; No PA Required for ICD-10 codes E08.311, E08.319, E08.3211-E08.3213, E08.3291 - E08.3293, E08.3311-E08.3313, E08.3391 - E08.3393, E08.3411- E08.3413, E08.3491 - E08.3493, E08.3511- E08.3513, E08.3521 - E08.3523, E08.3531 - E08.3533, E08.3541 - E08.3543, E08.3551 - E08.3553, E08.3591 - E08.3593, E09.311, E09.319, E09.3211-E09.3213, E09.3291 - E09.3291, E09.3311-E09.3313, E09.3391 - E09.3393, E09.3411-E09.3413, E09.3491 - E09.3493, E09.3511- E09.3513, E09.3521 - E09.3523, E09.3531 - E09.3533, E09.3541 - E09.3543, E09.3551 - E09.3553, E09.3591 - E09.3593, E10.311, E10.319, E10.3211- E10.3213, E10.3291 - E10.3293, E10.3311- E10.3313, E10.3391 - E10.3393, E10.3411- E10.3413, E10.3491 - E10.3493, E10.3511- E10.3513, E10.3591-E10.3599, E11.3211-E11.3219, E11.3291-E11.3299, E11.3311- E11.3313, E11.3391 - E11.3393, E11.3411- E11.3413, E11.3491 - E11.3493, E11.3511 - E11.3513, E11.3521 - E11.3523, E11.3531 - E11.3533, E11.3541 - E11.3543, E11.3551 - E11.3553, E11.3591 - E11.3593, E13.311, E13.319, E13.3211- E13.3213, E13.3291 - E13.3293, E13.3311- E13.3313, E13.3391 - E13.3393, E13.3411-E13.3413, E13.3491 - E13.3493, E13.3511- E13.3513, E13.3521 - E13.3523, E13.3531 - E13.3533, E13.3541 - E13.3543, E13.3551 - E13.3553, E13.3591 - E13.3593, H34.8110, H34.8120, H34.8130, H34.8310, H34.8320, H34.8330, H34.8390, H35.051 - H35.053, H35.3210 - H35.3233, H35.351 - H35.353, H44.21 - H44.2E9; Drug Name: Nufymco
Vasoconstrictors				
J1097	OMIDRIA	phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2371	<i>phenylephrine hcl injection</i>	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
J2371	VAZCULEP	Injection, phenylephrine hydrochloride, 20 micrograms	Part B Drug	
Gastrointestinal Drugs				
5-Ht₃ Receptor Antagonists				
J1454	AKYNZEO (FOSNETUPITANT)	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Part B Drug	
J1626	<i>granisetron (pf)</i>	Injection, granisetron hydrochloride, 100 mcg	Part B Drug	
J1626	<i>granisetron hcl intravenous</i>	Injection, granisetron hydrochloride, 100 mcg	Part B Drug	
J1627	SUSTOL	Injection, granisetron, extended-release, 0.1 mg (For billing prior to 1/1/18 use J3490 or C9486 for OPPS billing)	Part B Drug	PA
J2405	<i>ondansetron hcl (pf)</i>	Injection, ondansetron hydrochloride, per 1 mg	Part B Drug	
J2405	<i>ondansetron hcl intravenous</i>	Injection, ondansetron hydrochloride, per 1 mg	Part B Drug	
J2468	POSFREA	Injection, palonosetron hydrochloride (posfrea), 25 micrograms	Part B Drug	
J2469	<i>palonosetron</i>	Injection, palonosetron HCl, 25 mcg	Part B Drug	
J8597	<i>ondansetron hcl oral</i>	Antiemetic drug, oral, not otherwise specified	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q0162	<i>ondansetron</i>	Ondansetron 1 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen - see also S0119	Part B Drug	B vs D (PA applies)
Q0162	<i>ondansetron hcl oral</i>	Ondansetron 1 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen - see also S0119	Part B Drug	B vs D (PA applies)
Q0166	<i>granisetron hcl oral</i>	Granisetron hydrochloride, 1 mg oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen - see also S0091	Part B Drug	B vs D (PA applies)
Antiemetics, Miscellaneous				
J2358	ZYPREXA RELPREVV	Injection, olanzapine, long-acting, 1 mg	Part B Drug	
J2359	<i>olanzapine intramuscular</i>	Injection, olanzapine, 0.5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2359	ZYPREXA INTRAMUSCULAR	Injection, olanzapine, 0.5 mg	Part B Drug	
Antiulcer Agents And Acid Suppressants				
J1836	METRO I.V.	Injection, metronidazole, 10 mg	Part B Drug	
J1836	<i>metronidazole in nacl (iso-os)</i>	Injection, metronidazole, 10 mg	Part B Drug	
Digestants				
J3490	GATTEX 30-VIAL	Unclassified drugs	Part D Drug	
J3490	GATTEX ONE-VIAL	Unclassified drugs	Part D Drug	
Dopamine Receptor Antagonists				
J0184	BARHEMSYS	Injection, amisulpride, 1 mg	Part B Drug	PA
J2550	PHENERGAN	Injection, promethazine HCl, up to 50 mg	Part B Drug	
J2550	<i>promethazine injection</i>	Injection, promethazine HCl, up to 50 mg	Part B Drug	
Gi Drugs, Miscellaneous				
J1440	REBYOTA	Fecal microbiota, live - jsml, 1 ml (Code reused effective 7/1/2023)	Part B Drug	PA; ST applies
Q0155	SYNDROS	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q0167	<i>dronabinol oral capsule</i>	Dronabinol, 2.5 mg oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at time of chemotherapy treatment, not to exceed a 48-hour dosage regimen (Code price is per 2.5 mg effective 5/31/01)	Part B Drug	B vs D (PA applies)
Q0167	MARINOL 2.5 MG CAPSULE	Dronabinol, 2.5 mg oral, FDA-approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at time of chemotherapy treatment, not to exceed a 48-hour dosage regimen (Code price is per 2.5 mg effective 5/31/01)	Part B Drug	B vs D (PA applies)
Histamine H2-Antagonists				
J1308	<i>famotidine (pf)-nacl (iso-os)</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial 25's, sdv, p/f, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial inner, p/f, suv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial inner, suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial outer, p/f, suv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial outer, suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1308	<i>famotidine 20 mg/2 ml vial p/f, inner, sdv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, outer, sdv</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, suv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial p/f, suv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial sdv,p/f,inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 20 mg/2 ml vial suv, p/f</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial 10's,mdv,outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial mdv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial mdv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial muv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 200 mg/20 ml vial muv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial mdv,inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial mdv,outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	

PA-Prior Authorization; **ST** applies-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1308	<i>famotidine 40 mg/4 ml vial muv, inner</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial muv, outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
J1308	<i>famotidine 40 mg/4 ml vial outer</i>	Injection, famotidine, 0.25 mg	Part B Drug	
Immunomodulatory Agents (56:44)				
J2267	OMVOH 100 MG/ML PEN	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	
J2267	OMVOH 100 MG/ML SYRINGE	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	
J2267	OMVOH 200 MG DOSE (100 MG/ML X 2 SYRINGES)	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	
J2267	OMVOH 200 MG DOSE (100 MG/ML X 2 PENS)	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	
J2267	OMVOH 300 MG DOSE (100 MG/ML-200 MG/2 ML)	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	
J2267	OMVOH INTRAVENOUS	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part B Drug	PA; ST applies
J2267	OMVOH PEN 300 MG DOSE (100 MG/ML-200 MG/2 ML)	Injection, mirikizumab-mrkz, 1 mg (Code Price is based on Median Pricing Methodology)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Neurokinin-1 Receptor Antagonists				
J0185	CINVANTI	Injection, aprepitant, 1 mg	Part B Drug	
J1434	FOCINVEZ	Injection, fosaprepitant (focinvez), 1 mg	Part B Drug	
J1453	EMEND (FOSAPREPITANT)	Injection, fosaprepitant, 1 mg	Part B Drug	
J1453	<i>fosaprepitant</i>	Injection, fosaprepitant, 1 mg	Part B Drug	
J1454	AKYNZEO (FOSNETUPITANT)	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Part B Drug	
J1456	<i>fosaprepitant</i>	Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg	Part B Drug	
J8501	<i>aprepitant</i>	Aprepitant, oral, 5 mg	Part B Drug	B vs D (PA applies)
J8501	EMEND	Aprepitant, oral, 5 mg	Part B Drug	B vs D (PA applies)
J8502	APONVIE	Injection, aprepitant (aponvie), 1 mg	Part B Drug	
Opioid Antagonists (56:18)				
J2212	RELISTOR SUBCUTANEOUS	Injection, methylnaltrexone, 0.1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part B Drug	
Proton-Pump Inhibitors				
J1370	<i>esomeprazole sodium</i>	Injection, esomeprazole sodium, 1 mg	Part B Drug	
J1370	NEXIUM I.V. 40 MG VIAL	Injection, esomeprazole sodium, 1 mg	Part B Drug	
J2470	<i>pantoprazole intravenous</i>	Injection, pantoprazole sodium, 40 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2470	PROTONIX INTRAVENOUS	Injection, pantoprazole sodium, 40 mg	Part B Drug	
J2471	<i>pantoprazole intravenous</i>	Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg	Part B Drug	
J2472	<i>pantoprazole in 0.9% sod chlor</i>	Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg	Part B Drug	
Heavy Metal Antagonists				
<i>Heavy Metal Antagonists</i>				
J0600	<i>edetate calcium disodium</i>	Injection, edetate calcium disodium, up to 1000 mg	Part B Drug	PA; No PA required for ICD 10 codes R78.79, T56.0x1A, T56.2xA-T56.2xD, T56.2x2A-T56.2x2D, T56.2x3A-T56.2x3D, T56.2x4A-T56.2x4D, T56.5x1A-T56.5x1D, T56.5x2A-T56.5x2D, T56.5x3A-T56.5x3D, T56.5x4A-T56.5x4D, T56.891A-T56.891D, T57.2x1A-T57.2x1D, T57.2x2A-T57.2x2D, T57.2x3A-T57.2x3D, T57.2x4A-T57.2x4D, Z77.012.
J0895	<i>deferoxamine</i>	Injection, deferoxamine mesylate, 500 mg	Part B Drug	PA; No PA required for ICD 10 codes D56.0-D56.9, D57.00-D57.819, E83.10-E83.119, T56.0x1A-T56.0x4S, T80.92xA-T80.92xS.
J0895	DESFERAL	Injection, deferoxamine mesylate, 500 mg	Part B Drug	PA; No PA required for ICD 10 codes D56.0-D56.9, D57.00-D57.819, E83.10-E83.119, T56.0x1A-T56.0x4S, T80.92xA-T80.92xS.
Hormones And Synthetic Substitutes				
<i>Adrenals</i>				
J1010	DEPO-MEDROL	Injection, methylprednisolone acetate, 1 mg	Part B Drug	
J1010	<i>methylprednisolone acetate</i>	Injection, methylprednisolone acetate, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1100	<i>dexamethasone 4 mg/ml vial sub, inner</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J1100	<i>dexamethasone 4 mg/ml vial sub, outer</i>	Injection, dexamethasone sodium phosphate, 1 mg	Part B Drug	
J2919	<i>methylprednisolone sodium succ</i>	Injection, methylprednisolone sodium succinate, 5 mg	Part B Drug	
J2919	SOLU-MEDROL	Injection, methylprednisolone sodium succinate, 5 mg	Part B Drug	
J2919	SOLU-MEDROL (PF)	Injection, methylprednisolone sodium succinate, 5 mg	Part B Drug	
J3304	ZILRETTA	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Part B Drug	
J7312	OZURDEX	Injection, dexamethasone, intravitreal implant, 0.1 mg (For billing prior to 1/1/11 use J3490 or C9256)	Part B Drug	PA
J7402	SINUVA	Mometasone furoate sinus implant, (sinuva), 10 micrograms	Part B Drug	PA
J7626	<i>budesonide inhalation</i>	Budesonide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 0.5 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7626	PULMICORT	Budesonide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 0.5 mg	Part B Drug	B vs D (PA applies)
Androgens				
J1072	AZMIRO	Injection, testosterone cypionate (azmiro), 1 mg	Part B Drug	PA; ST applies
J1073	TESTOPEL	Testosterone pellet, implant, 75 mg	Part B Drug	PA; ST applies
J3145	AVEED	Injection, testosterone undecanoate, 1 mg (For billing prior to 1/1/15 use C9023 or J3490)	Part B Drug	PA; ST applies
Antidiabetic Agents, Miscellaneous				
J9381	TZIELD	Injection, teplizumab-mzwv, 5 mcg	Part B Drug	PA
Antigonadotropins				
J1072	AZMIRO	Injection, testosterone cypionate (azmiro), 1 mg	Part B Drug	PA; ST applies
J1073	TESTOPEL	Testosterone pellet, implant, 75 mg	Part B Drug	ST applies
J3145	AVEED	Injection, testosterone undecanoate, 1 mg (For billing prior to 1/1/15 use C9023 or J3490)	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7295	ELURYNG	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	ENILLORING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	<i>etonogestrel-ethinyl estradiol</i>	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	HALOETTE	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	NUVARING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7296	KYLEENA	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg (For billing prior to 1/1/18 use Q9984)	Refer to Contraceptive Coverage	
J7301	SKYLA	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	Refer to Contraceptive Coverage	
J7307	NEXPLANON	Etonogestrel (contraceptive) implant system, including implant and supplies (Code Price is per 1 implant system)	Refer to Contraceptive Coverage	
J9155	FIRMAGON	Injection, degarelix, 1 mg (For billing prior to 1/1/10 use J9999 or C9399)	Medicare Chemo	PA; No PA required for ICD-10 codes C61, C79.82 and D07.5.

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9155	FIRMAGON KIT W DILUENT SYRINGE	Injection, degarelix, 1 mg (For billing prior to 1/1/10 use J9999 or C9399)	Medicare Chemo	PA; No PA required for ICD-10 codes C61, C79.82 and D07.5.
Antiparathyroid Agents				
J0604	<i>cinacalcet</i>	Cinacalcet, oral, 1 mg, (for ESRD on dialysis) (For billing prior to 1/1/18 use J8499)	Part B Drug	B vs D (PA applies)
J0604	SENSIPAR	Cinacalcet, oral, 1 mg, (for ESRD on dialysis) (For billing prior to 1/1/18 use J8499)	Part B Drug	B vs D (PA applies)
J0606	PARSABIV	Injection, etelcalcetide, 0.1 mg (For billing prior to 1/1/18 use J3490 or C9399 for OPPS billing)	Part B Drug	B vs D (PA applies)
Contraceptives				
J7294	ANNOVERA	Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each	Part D Drug	
J7295	ELURYNG	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	ENILLORING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	<i>etonogestrel-ethinyl estradiol</i>	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7295	HALOETTE	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	NUVARING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7296	KYLEENA	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg (For billing prior to 1/1/18 use Q9984)	Refer to Contraceptive Coverage	
J7301	SKYLA	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	Refer to Contraceptive Coverage	
J7307	NEXPLANON	Etonogestrel (contraceptive) implant system, including implant and supplies (Code Price is per 1 implant system)	Refer to Contraceptive Coverage	
Estrogens				
J1000	DEPO-ESTRADIOL	Injection, depo-estradiol cypionate, up to 5 mg	Part B Drug	
J7295	ELURYNG	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	ENILLORING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	<i>etonogestrel-ethinyl estradiol</i>	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7295	HALOETTE	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	NUVARING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
Glycogenolytic Agents				
J1610	GLUCAGON EMERGENCY KIT (HUMAN)	Injection, glucagon hydrochloride, per 1 mg	Part B Drug	
J1611	GLUCAGON (HCL) EMERGENCY KIT	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
J1611	<i>glucagon hcl</i>	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	Part B Drug	
Gonadotropins				
J1950	LUPRON DEPOT 11.25 MG 3MO KIT 3 MONTH, SUV	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT 3.75 MG KIT P/F, SUV	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT-PED	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	
J1950	LUPRON DEPOT-PED (3 MONTH)	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
J1951	FENSOLVI	Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg	Part B Drug	PA
J1952	CAMCEVI (6 MONTH)	Leuprolide injectable, camcevi, 1 mg	Medicare Chemo	
J1954	LUTRATE DEPOT (3 MONTH)	Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg	Medicare Chemo	
J3315	TRELSTAR	Injection, triptorelin pamoate, 3.75 mg	Part B Drug	B vs D (PA applies)
J3316	TRIPTODUR	Injection, triptorelin, extended-release, 3.75 mg	Part B Drug	
J9202	ZOLADEX	Goserelin acetate implant, per 3.6 mg	Not Covered	
J9217	ELIGARD	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (3 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	ELIGARD (6 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT (6 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT 22.5 MG 3MO KIT SUV, P/F	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9217	LUPRON DEPOT 7.5 MG 1 MONTH KT SINGLE DOSE	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	LUPRON DEPOT 7.5 MG 1 MONTH KT SUV, P/F	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	VABRINTY (1 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9217	VABRINTY (4 MONTH)	Leuprolide acetate (for depot suspension), 7.5 mg	Medicare Chemo	
J9218	<i>leuprolide</i>	Leuprolide acetate, per 1 mg	Part D Drug	
J9226	SUPPRELIN LA	Histrelin implant (Supprelin LA), 50 mg	Part B Drug	PA; ST applies
Incretin Mimetics				
C9399	BYDUREON BCISE	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	<i>liraglutide</i>	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	<i>liraglutide (weight loss)</i>	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	MOUNJARO	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	OZEMPIC SUBCUTANEOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	TRULICITY	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	VICTOZA 2-PAK	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	VICTOZA 3-PAK	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	WEGOVY SUBCUTANEOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	ZEPBOUND	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J3490	MOUNJARO	Unclassified drugs	Part D Drug	
J3490	OZEMPIC SUBCUTANEOUS	Unclassified drugs	Part D Drug	
J3490	SAXENDA	Unclassified drugs	Part D Drug	
J3490	TRULICITY	Unclassified drugs	Part D Drug	
J3490	VICTOZA 2-PAK	Unclassified drugs	Part D Drug	
J3490	VICTOZA 3-PAK	Unclassified drugs	Part D Drug	
J3490	WEGOVY SUBCUTANEOUS	Unclassified drugs	Part D Drug	
J3490	ZEPBOUND	Unclassified drugs	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J8499	WEGOVY 1.5 MG TABLET	Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified	Part D Drug	
Melanocortin Receptor Agonists				
J7352	SCENESSE	Afamelanotide implant, 1 mg	Part B Drug	PA
Parathyroid Agents				
C9399	YORVIPATH	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J3110	FORTEO	Injection, teriparatide, 10 mcg	Part D Drug	
J3110	teriparatide	Injection, teriparatide, 10 mcg	Part D Drug	
J3490	YORVIPATH	Unclassified drugs	Part D Drug	
Pituitary				
C9399	NGENLA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0801	ACTHAR	Injection, corticotropin (acthar gel), up to 40 units	Part D Drug	
J0801	ACTHAR SELFJECT	Injection, corticotropin (acthar gel), up to 40 units	Part D Drug	
J0802	CORTROPHIN GEL	Injection, corticotropin (ani), up to 40 units	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2596	<i>vasopressin in 0.9 % sod chlor intravenous solution</i>	Injection, vasopressin (long grove), not therapeutically equivalent to j2598, 1 unit	Part B Drug	
J2597	DDAVP INJECTION	Injection, desmopressin acetate, per 1 mcg	Part B Drug	
J2597	<i>desmopressin injection</i>	Injection, desmopressin acetate, per 1 mcg	Part B Drug	
J2598	<i>vasopressin</i>	Injection, vasopressin, 1 unit	Part B Drug	
J2598	VASOSTRICT	Injection, vasopressin, 1 unit	Part B Drug	
J2599	<i>vasopressin</i>	Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit	Part B Drug	
J2601	<i>vasopressin in 0.9 % sod chlor intravenous solution</i>	Injection, vasopressin (baxter), 1 unit	Part B Drug	
J2941	GENOTROPIN	Injection, somatropin, 1 mg	Part D Drug	
J2941	GENOTROPIN MINIQUICK	Injection, somatropin, 1 mg	Part D Drug	
J2941	HUMATROPE	Injection, somatropin, 1 mg	Part D Drug	
J2941	NORDITROPIN FLEXPRO	Injection, somatropin, 1 mg	Part D Drug	
J2941	NUTROPIN AQ NUSPIN 10 INJECTOR	Injection, somatropin, 1 mg	Part D Drug	
J2941	NUTROPIN AQ NUSPIN 20 INJECTOR	Injection, somatropin, 1 mg	Part D Drug	
J2941	NUTROPIN AQ NUSPIN 5 INJECTOR	Injection, somatropin, 1 mg	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2941	OMNITROPE	Injection, somatropin, 1 mg	Part D Drug	
J2941	SAIZEN SAIZENPREP	Injection, somatropin, 1 mg	Part D Drug	
J2941	SEROSTIM	Injection, somatropin, 1 mg	Part D Drug	
J2941	ZOMACTON	Injection, somatropin, 1 mg	Part D Drug	
J3590	NGENLA	Unclassified biologics	Part D Drug	
Progestins				
J7295	ELURYNG	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	ENILLORING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	<i>etonogestrel-ethinyl estradiol</i>	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	HALOETTE	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7295	NUVARING	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each	Part D Drug	
J7296	KYLEENA	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg (For billing prior to 1/1/18 use Q9984)	Refer to Contraceptive Coverage	
J7301	SKYLA	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	Refer to Contraceptive Coverage	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7307	NEXPLANON	Etonogestrel (contraceptive) implant system, including implant and supplies (Code Price is per 1 implant system)	Refer to Contraceptive Coverage	
Somatostatin Agonists				
J1930	<i>lanreotide</i>	Injection, lanreotide, 1 mg (Code re-used by CMS effective 1/1/2009)	Part B Drug	
J1930	SOMATULINE DEPOT	Injection, lanreotide, 1 mg (Code re-used by CMS effective 1/1/2009)	Part B Drug	
J1932	<i>lanreotide</i>	Injection, lanreotide, (cipla), 1 mg	Part B Drug	
J2353	<i>octreotide,microspheres</i>	Injection, octreotide, depot form for intramuscular injection, 1 mg	Part B Drug	
J2353	SANDOSTATIN LAR DEPOT	Injection, octreotide, depot form for intramuscular injection, 1 mg	Part B Drug	
J2502	SIGNIFOR LAR	Injection, pasireotide long acting, 1 mg (Code Price is based on Median pricing methodology due to flat pricing) (For billing prior to 1/1/16 use C9454 or J3490)	Part B Drug	PA; ST applies
Somatotropin Agonists				
C9399	EGRIFTA SV	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	EGRIFTA WR	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J2170	INCRELEX	Injection, mecaseimerin, 1 mg	Part D Drug	
Thyroid Agents				
J0650	<i>levothyroxine intravenous</i>	Injection, levothyroxine sodium, not otherwise specified, 10 mcg	Part B Drug	
J0651	<i>levothyroxine intravenous</i>	Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg	Part B Drug	
J0652	<i>levothyroxine intravenous</i>	Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg	Part B Drug	
Immunomodulatory Agents (90:00)				
Antimetabolites, Immunosupp Therapy Misc				
J7500	AZASAN	Azathioprine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J7500	<i>azathioprine</i>	Azathioprine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J7500	IMURAN	Azathioprine, oral, 50 mg	Part B Drug	B vs D (PA applies)
J7514	MYHIBBIN	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg	Part B Drug	B vs D (PA applies)
J7517	CELLCEPT ORAL CAPSULE	Mycophenolate mofetil, oral, 250 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7517	CELLCEPT ORAL TABLET	Mycophenolate mofetil, oral, 250 mg	Part B Drug	B vs D (PA applies)
J7517	<i>mycophenolate mofetil oral capsule</i>	Mycophenolate mofetil, oral, 250 mg	Part B Drug	B vs D (PA applies)
J7517	<i>mycophenolate mofetil oral tablet</i>	Mycophenolate mofetil, oral, 250 mg	Part B Drug	B vs D (PA applies)
J7518	<i>mycophenolate sodium</i>	Mycophenolic acid, oral, 180 mg	Part B Drug	B vs D (PA applies)
J7518	MYFORTIC	Mycophenolic acid, oral, 180 mg	Part B Drug	B vs D (PA applies)
Antimetabolites				
J9065	<i>cladribine</i>	Injection, cladribine, per 1 mg	Part B Drug	
April Or Baff Inhibitor Agents				
C9399	VOYXACT	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J3590	VOYXACT	Unclassified biologics	Part D Drug	
Bone-Modifying Agents				
J0897	PROLIA	Injection, denosumab, 1 mg (Code price uses median pricing methodology)	Part B Drug	PA; ST applies
J0897	XGEVA	Injection, denosumab, 1 mg (Code price uses median pricing methodology)	Part B Drug	PA; ST applies
J3111	EVENITY	Injection, romosozumab-aqqg, 1 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5136	JUBBONTI	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg	Part B Drug	Preferred
Q5136	WYOST	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg	Part B Drug	Preferred
Q5157	OSENVELT	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg (Code Price is based on median pricing methodology)	Part B Drug	PA; ST applies
Q5157	STOBOCLO	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg (Code Price is based on median pricing methodology)	Part B Drug	PA; ST applies
Q5158	BOMYNTRA	Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg (Code Price is based on median pricing methodology)	Part B Drug	PA; ST applies
Q5158	CONEXXENCE	Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg (Code Price is based on median pricing methodology)	Part B Drug	PA; ST applies
Q5159	OSPOMYV	Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5161	AUKELSO	Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5161	BOSAYA	Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg	Part B Drug	PA
Q5162	BILDYOS	Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg	Part B Drug	Preferred
Q5162	BILPREVDA	Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg	Part B Drug	Preferred
Q5166	JUBEREQ	Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg	Part B Drug	PA
Q5167	ENOB	Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg (Code price based on median pricing methodology)	Part B Drug	Preferred
Q5167	XTRENBO	Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg (Code price based on median pricing methodology)	Part B Drug	Preferred
Calcineurin Inhibitors, Misc (90:28)				
J7502	<i>cyclosporine modified</i>	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	<i>cyclosporine oral</i>	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	GENGRAF	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	GENGRAF 100 MG/ML SOLUTION	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	NEORAL	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)
J7502	SANDIMMUNE ORAL	Cyclosporine, oral, 100 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
J7503	ENVARUSUS XR	Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg (Code re-used by CMS effective 1/1/16)	Part B Drug	B vs D (PA applies)
J7507	PROGRAF ORAL	Tacrolimus, immediate release, oral, per 1 mg	Part B Drug	B vs D (PA applies)
J7507	<i>tacrolimus oral</i>	Tacrolimus, immediate release, oral, per 1 mg	Part B Drug	B vs D (PA applies)
J7508	ASTAGRAF XL	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Part B Drug	B vs D (PA applies)
J7508	<i>tacrolimus oral</i>	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Part B Drug	B vs D (PA applies)
J7515	<i>cyclosporine modified</i>	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	<i>cyclosporine oral</i>	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	GENGRAF	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	NEORAL	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7515	SANDIMMUNE ORAL	Cyclosporine, oral, 25 mg	Part B Drug	B vs D (PA applies)
J7516	<i>cyclosporine 250 mg/5 ml ampul p/f, suv, inner</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	<i>cyclosporine 250 mg/5 ml ampul p/f, suv, outer</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	<i>cyclosporine 250 mg/5 ml ampul suv</i>	Injection, cyclosporine, 250 mg	Part B Drug	
J7516	SANDIMMUNE INTRAVENOUS	Injection, cyclosporine, 250 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7521	PROGRAF ORAL	Tacrolimus, granules, oral suspension, 0.1 mg (Code price based on median pricing methodology)	Part B Drug	B vs D (PA applies)
J7525	PROGRAF INTRAVENOUS	Tacrolimus, parenteral, 5 mg	Part B Drug	
Complement Inhibitor Agents (90:20)				
J1289	YARTEMLEA	Injection, narsoplimab-wuug, 1 mg	Part B Drug	PA
J1299	SOLIRIS	Injection, eculizumab, 2 mg	Part B Drug	PA; ST applies
J1302	ENJAYMO	Injection, sutimlimab-jome, 10 mg	Part B Drug	PA; ST applies
J1303	ULTOMIRIS	Injection, ravulizumab-cwvz, 10 mg	Part B Drug	PA; ST applies
J1307	PIASKY	Injection, crovalimab-akkz, 10 mg	Part B Drug	PA
J2781	SYFOVRE (PF)	Injection, pegcetacoplan, intravitreal, 1 mg	Part B Drug	PA
J2782	IZERVAY (PF)	Injection, avacincapted pegol, 0.1 mg	Part B Drug	PA
J3490	EMPAVELI	Unclassified drugs	Part B Drug	B vs D (PA applies)
Q5152	BKEMV	Injection, eculizumab-aeab (bkemv), biosimilar, 2 mg	Part B Drug	PA; ST applies
Complement Inhibitors (90:08)				
C9399	ZILBRYSQ	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	ZILBRYSQ	Unclassified drugs	Part B Drug	PA; ST applies
<i>Disease-Modifying Antirheumat Drugs Misc</i>				
C9399	ENTYVIO PEN	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0129	ORENCIA (WITH MALTOSE)	Injection, abatacept, 10 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug self administered)	Part B Drug	PA; ST applies
J0129	ORENCIA CLICKJECT	Injection, abatacept, 10 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug self administered)	Part D Drug	
J3380	ENTYVIO	Injection, vedolizumab, intravenous, 1 mg	Part B Drug	PA; ST applies
<i>Disease-Modifying Antirheumatic Drugs</i>				
J1628	TREMFYA INTRAVENOUS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part B Drug	PA; ST applies
J1628	TREMFYA ONE-PRESS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1628	TREMFYA PEN	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1628	TREMFYA PEN INDUCTION PK(2PEN)	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1628	TREMFYA SUBCUTANEOUS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J8610	<i>methotrexate sodium oral</i>	Methotrexate, oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8610	TREXALL	Methotrexate, oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8611	JYLAMVO	Methotrexate (jylamvo), oral, 2.5 mg	Medicare Chemo	B vs D (PA applies)
J8612	XATMEP	Methotrexate (xatmep), oral, 2.5 mg	Part B Drug	B vs D (PA applies)
J9311	RITUXAN HYCELA	Injection, rituximab 10 mg and hyaluronidase	Medicare Chemo	PA; ST applies
J9312	RITUXAN	Injection, rituximab, 10 mg	Medicare Chemo	PA; ST applies
Q5115	TRUXIMA	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Medicare Chemo	
Q5119	RUXIENCE	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	Medicare Chemo	
Q5123	RIABNI	Injection, rituximab-arrr, biosimilar, (riabni), 10 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Igg1 Monoclonal Antibodies				
C9399	BENLYSTA SUBCUTANEOUS	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0490	BENLYSTA INTRAVENOUS	Injection, belimumab, 10 mg	Part B Drug	PA; ST applies
J0491	SAPHNELO INTRAVENOUS	Injection, anifrolumab-fnia, 1 mg	Part B Drug	PA; ST applies
J0491	SAPHNELO PEN	Injection, anifrolumab-fnia, 1 mg	Part D Drug	
Immunomodulatory Agents (90:00)				
J7527	everolimus 0.25 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 0.25 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.25 mg tablet inner	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.25 mg tablet outer	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.5 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 0.5 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.5 mg tablet inner	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.5 mg tablet outer	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7527	everolimus 0.75 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 0.75 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.75 mg tablet inner	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 0.75 mg tablet outer	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 1 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 1 mg tablet	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 1 mg tablet inner	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 1 mg tablet inner	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	everolimus 1 mg tablet outer	Everolimus, oral, 0.25 mg	Part B Drug	
J7527	everolimus 1 mg tablet outer	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J7527	ZORTRESS	Everolimus, oral, 0.25 mg	Part B Drug	B vs D (PA applies)
J8530	cyclophosphamide oral	Cyclophosphamide, oral, 25 mg	Part B Drug	B vs D (PA applies)
J9071	cyclophosphamide 1 gm/5 ml vl muv, p/f	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	cyclophosphamide 1 gm/5 ml vl suv	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	cyclophosphamide 2 gm/10 ml vl muv, p/f	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9071	<i>cyclophosphamide 500 mg/2.5 ml mov, p/f</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9071	<i>cyclophosphamide 500 mg/2.5 ml suv</i>	Injection, cyclophosphamide, (auromedics), 5 mg	Medicare Chemo	
J9072	<i>cyclophosphamide 1 gm/2 ml vl</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	<i>cyclophosphamide 2 gm/4 ml vl</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	<i>cyclophosphamide 500 mg/ml vl</i>	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9072	FRINDOVYX	Injection, cyclophosphamide (frindovyx), 5 mg	Medicare Chemo	PA; ST applies
J9073	<i>cyclophosphamide 1 gm/5 ml vl inner, mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 1 gm/5 ml vl mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 1 gm/5 ml vl outer, mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 2 gm/10 ml vl mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 500 mg/2.5 ml inner, mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9073	<i>cyclophosphamide 500 mg/2.5 ml mov, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9073	<i>cyclophosphamide 500 mg/2.5 ml outer, muv, p/f</i>	Injection, cyclophosphamide (dr. reddy's), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 1 gm/10 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 1 gm/10 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 2 gm/20 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 2 gm/20 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 500 mg/5 ml vial inner, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9074	<i>cyclophosphamide 500 mg/5 ml vial outer, muv, p/f</i>	Injection, cyclophosphamide (sandoz), 5 mg	Medicare Chemo	
J9075	<i>cyclophosphamide intravenous recon soln</i>	Injection, cyclophosphamide, not otherwise specified, 5mg	Medicare Chemo	
J9076	<i>cyclophosphamide 1 gm/5 ml vial muv, p/f</i>	Injection, cyclophosphamide (baxter), 5 mg	Medicare Chemo	
J9076	<i>cyclophosphamide 500 mg/2.5 ml muv, p/f</i>	Injection, cyclophosphamide (baxter), 5 mg	Medicare Chemo	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Interferon Gamma Inhibitor Agents, Misc				
J9210	GAMIFANT	Injection, emapalumab-lzsg, 1 mg	Part B Drug	PA; ST applies
Interferons				
J1830	BETASERON SUBCUTANEOUS KIT	Injection, interferon beta-1B, 0.25 mg (code may be used for Medicare when drug administered under direct supervision of a physician; not for use if self-administered)	Part D Drug	
J9215	ALFERON N	Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 IU (All NDCs inactive as of 5/8/2024)	Medicare Chemo	
Interleukin Inhibitor Agents, Misc				
J0480	SIMULECT	Injection, basiliximab, 20 mg	Part B Drug	
J2357	XOLAIR	Injection, omalizumab, 5 mg	Part B Drug	PA; ST applies
Interleukin-Mediated Agents, Misc				
C9399	KEVZARA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J3247	COSENTYX INTRAVENOUS	Injection, secukinumab, intravenous, 1 mg	Part B Drug	PA; ST applies
J3262	ACTEMRA 200 MG/10 ML VIAL	Injection, tocilizumab, 1 mg (For billing prior to 1/1/11 use J3590 or C9264)	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3262	ACTEMRA 400 MG/20 ML VIAL	Injection, tocilizumab, 1 mg (For billing prior to 1/1/11 use J3590 or C9264)	Part B Drug	PA; ST applies
J3262	ACTEMRA 80 MG/4 ML VIAL	Injection, tocilizumab, 1 mg (For billing prior to 1/1/11 use J3590 or C9264)	Part B Drug	PA; ST applies
J3357	STELARA SUBCUTANEOUS	Ustekinumab, for subcutaneous injection, 1 mg (Code price based on median pricing methodology)	Part D Drug	
J3357	<i>ustekinumab subcutaneous</i>	Ustekinumab, for subcutaneous injection, 1 mg (Code price based on median pricing methodology)	Part D Drug	
J3358	STELARA INTRAVENOUS	Ustekinumab, for intravenous injection, 1 mg (For billing prior to 1/1/18 use Q9989)	Part B Drug	PA; ST applies
J3358	<i>ustekinumab intravenous</i>	Ustekinumab, for intravenous injection, 1 mg (For billing prior to 1/1/18 use Q9989)	Part B Drug	PA; ST applies
J3590	ACTEMRA ACTPEN	Unclassified biologics	Part D Drug	
J3590	ACTEMRA SUBCUTANEOUS	Unclassified biologics	Part D Drug	
J3590	COSENTYX (2 SYRINGES)	Unclassified biologics	Part D Drug	
J3590	COSENTYX PEN	Unclassified biologics	Part D Drug	
J3590	COSENTYX PEN (2 PENS)	Unclassified biologics	Part D Drug	
J3590	COSENTYX SUBCUTANEOUS	Unclassified biologics	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3590	COSENTYX UNOREADY PEN	Unclassified biologics	Part D Drug	
J3590	KEVZARA	Unclassified biologics	Part D Drug	
J3590	KINERET	Unclassified biologics	Part D Drug	
Q0234	TOFIDENCE 200 MG/10 ML VIAL	Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg	Part B Drug	PA
Q0234	TOFIDENCE 400 MG/20 ML VIAL	Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg	Part B Drug	PA
Q0234	TOFIDENCE 80 MG/4 ML VIAL	Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q0234	TOFIDENCE 80 MG/4 ML VIAL	Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg	Part B Drug	PA; ST applies
Q0238	TYENNE 200 MG/10 ML VIAL	Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Not Covered	
Q0238	TYENNE 400 MG/20 ML VIAL	Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Not Covered	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q0238	TYENNE 80 MG/4 ML VIAL	Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Not Covered	
Q0249	ACTEMRA 200 MG/10 ML VIAL	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Not Covered	
Q0249	ACTEMRA 400 MG/20 ML VIAL	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Not Covered	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q0249	ACTEMRA 80 MG/4 ML VIAL	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Not Covered	
Q5098	IMULDOSA INTRAVENOUS	Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5098	IMULDOSA SUBCUTANEOUS	Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg	Part D Drug	
Q5099	STEQEYMA INTRAVENOUS	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5099	STEQEYMA SUBCUTANEOUS	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	Part D Drug	
Q5100	YESINTEK INTRAVENOUS	Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg	Part B Drug	
Q5100	YESINTEK SUBCUTANEOUS	Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg	Part D Drug	
Q5133	TOFIDENCE 200 MG/10 ML VIAL	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5133	TOFIDENCE 400 MG/20 ML VIAL	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5133	TOFIDENCE 80 MG/4 ML VIAL	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5135	TYENNE 200 MG/10 ML VIAL	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5135	TYENNE 400 MG/20 ML VIAL	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5135	TYENNE 80 MG/4 ML VIAL	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5135	TYENNE AUTOINJECTOR	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	Part D Drug	
Q5135	TYENNE SUBCUTANEOUS	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	Part D Drug	
Q5137	WEZLANA SUBCUTANEOUS	Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg	Part D Drug	
Q5138	WEZLANA INTRAVENOUS	Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg	Part B Drug	PA; ST applies
Q5156	AVTOZMA AUTOINJECTOR	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg	Part D Drug	
Q5156	AVTOZMA INTRAVENOUS	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q5164	STARJEMZA INTRAVENOUS	Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg	Part B Drug	PA
Q5164	STARJEMZA SUBCUTANEOUS	Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg	Part D Drug	
Q9996	PYZCHIVA AUTOINJECTOR	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg	Part D Drug	
Q9996	PYZCHIVA SUBCUTANEOUS	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q9996	<i>ustekinumab-ttwe subcutaneous</i>	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg	Part D Drug	
Q9997	PYZCHIVA INTRAVENOUS	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg	Part B Drug	PA; ST applies
Q9997	<i>ustekinumab-ttwe intravenous</i>	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg	Part B Drug	PA; ST applies
Q9998	SELARSDI INTRAVENOUS	Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg	Part B Drug	
Q9998	SELARSDI SUBCUTANEOUS	Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg	Part D Drug	
Q9998	<i>ustekinumab-aekn</i>	Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg	Part D Drug	
Q9999	OTULFI INTRAVENOUS	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	Part B Drug	PA; ST applies
Q9999	OTULFI SUBCUTANEOUS	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	Part D Drug	
Monoclonal Antibodies (90:04)				
C9399	KESIMPTA PEN	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0202	LEMTRADA	Injection, alemtuzumab, 1 mg	Part B Drug	PA
J2323	TYSABRI	Injection, natalizumab, 1 mg	Part B Drug	PA
J2329	BRIUMVI	Injection, ublituximab-xiiy, 1mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2350	OCREVUS	Injection, ocrelizumab, 1 mg (For billing prior to 1/1/18 use J3590 or C9494 for OPPS billing) (Code re-used by CMS 1/1/18)	Part B Drug	
J3590	KESIMPTA PEN	Unclassified biologics	Part D Drug	
Q5134	TYRUKO	Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg	Part B Drug	PA
Monoclonal Antibodies (90:10)				
C9399	LEQEMBI IQLIK 360 MG/1.8 ML AUTOINJECTOR	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0174	LEQEMBI	Lecanemab-irmb, for intravenous injection, 1 mg	Part B Drug	PA
J0175	KISUNLA	Injection, donanemab-azbt, 2 mg	Part B Drug	PA
J3490	LEQEMBI IQLIK 360 MG/1.8 ML AUTOINJECTOR	Unclassified drugs	Part D Drug	
Monoclonal Antibodies (90:12)				
J1823	UPLIZNA	Injection, inebilizumab-cdon, 1 mg	Part B Drug	PA
Mtor Inhibitors, Miscellaneous				
J7520	sirolimus	Sirolimus, oral, 1 mg	Part B Drug	B vs D (PA applies)
Neonatal Fc Receptor Blockers				
J9256	IMAAVY	Injection, nipocalimab-aahu, 3 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J9332	VYVGART	Injection, efgartigimod alfa-fcab, 2mg	Part B Drug	PA; ST applies
J9333	RYSTIGGO	Injection, rozanolixizumab-noli, 1 mg	Part B Drug	PA
J9334	VYVGART HYTRULO SUBCUTANEOUS SOLUTION	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	Part B Drug	PA; ST applies
J9334	VYVGART HYTRULO SUBCUTANEOUS SYRINGE	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	Part D Drug	
Polyclonal Antibodies, Miscellaneous				
J7504	ATGAM	Lymphocyte immune globulin, anti-thymocyte globulin, equine, parenteral, 250 mg	Part B Drug	
T-Cell Costimulatory Blockers, Misc				
J0485	NULOJIX	Injection, belatacept, 1 mg (For billing prior to 1/1/13 use C9286 or J3590)	Part B Drug	PA; ST applies
Tumor Necrosis Factor Inhibitors, Misc				
C9399	adalimumab-adaz	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPSC/ CPT Code	Drug Name	HCPSC/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	AMJEVITA(CF)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	AMJEVITA(CF) AUTOINJECTOR	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HADLIMA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HADLIMA PUSHTOUCH	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HADLIMA(CF)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	HADLIMA(CF) PUSHTOUCH	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HYRIMOZ PEN CROHN'S-UC STARTER	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HYRIMOZ PEN PSORIASIS STARTER	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HYRIMOZ(CF)	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	HYRIMOZ(CF) PEDI CROHN STARTER	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	HYRIMOZ(CF) PEN	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	YUSIMRY(CF) PEN	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0139	HUMIRA	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	
J0139	HUMIRA PEN	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	
J0139	HUMIRA(CF)	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	
J0139	HUMIRA(CF) PEN	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0139	HUMIRA(CF) PEN CROHNS-UC-HS	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	
J0139	HUMIRA(CF) PEN PSOR-UV-ADOL HS	Injection, adalimumab, 1 mg (Use NDC level pricing for appropriate reimbursement based on NDC submitted)	Part D Drug	
J0717	CIMZIA 2X200 MG/ML SYRINGE KIT 2X200MG SYR/BOX, SUV	Injection, certolizumab pegol, 1 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	Part B Drug	PA; ST applies
J0717	CIMZIA POWDER FOR RECONST	Injection, certolizumab pegol, 1 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	Part B Drug	PA; ST applies
J0717	CIMZIA STARTER KIT	Injection, certolizumab pegol, 1 mg (Code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1438	ENBREL	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician; not for use when drug is self-administered)	Part D Drug	
J1438	ENBREL MINI	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician; not for use when drug is self-administered)	Part D Drug	
J1438	ENBREL SURECLICK	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician; not for use when drug is self-administered)	Part D Drug	
J1602	SIMPONI ARIA	Injection, golimumab, 1 mg, for intravenous use (For billing prior to 1/1/14 use C9399 or J3590)	Part B Drug	PA; ST applies
J1745	<i>infliximab</i>	Injection, infliximab, excludes biosimilar, 10 mg (Code is to be used for Remicade or Infliximab)	Part B Drug	PA; ST applies
J1745	REMICADE	Injection, infliximab, excludes biosimilar, 10 mg (Code is to be used for Remicade or Infliximab)	Part B Drug	PA; ST applies
J1748	ZYMFENTRA	Injection, infliximab-dyyb (zymfentra), 10 mg	Part B Drug	PA; ST applies
J3590	SIMPONI	Unclassified biologics	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5103	INFLECTRA	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg	Part B Drug	PA; ST applies
Q5104	RENFLEXIS	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg	Part B Drug	
Q5121	AVSOLA	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	Part B Drug	
Q5140	<i>adalimumab-fkjp</i>	Injection, adalimumab-fkjp, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5140	HULIO(CF)	Injection, adalimumab-fkjp, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5140	HULIO(CF) PEN	Injection, adalimumab-fkjp, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5141	<i>adalimumab-aaty</i>	Injection, adalimumab-aaty, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5141	ADALIMUMAB-AATY(CF) AI CROHNS	Injection, adalimumab-aaty, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5141	YUFLYMA(CF)	Injection, adalimumab-aaty, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5141	YUFLYMA(CF) AI CROHN'S-UC-HS	Injection, adalimumab-aaty, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5141	YUFLYMA(CF) AUTOINJECTOR	Injection, adalimumab-aaty, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5142	<i>adalimumab-ryvk</i>	Injection, adalimumab-ryvk biosimilar, 1 mg	Part D Drug	
Q5142	SIMLANDI(CF)	Injection, adalimumab-ryvk biosimilar, 1 mg	Part D Drug	
Q5142	SIMLANDI(CF) AUTOINJECTOR	Injection, adalimumab-ryvk biosimilar, 1 mg	Part D Drug	
Q5143	<i>adalimumab-adbm</i>	Injection, adalimumab-adbm, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5143	CYLTEZO(CF)	Injection, adalimumab-adbm, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5143	CYLTEZO(CF) PEN	Injection, adalimumab-adbm, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5143	CYLTEZO(CF) PEN CROHN'S-UC-HS STARTER 40 MG/0.8 ML	Injection, adalimumab-adbm, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5143	CYLTEZO(CF) PEN PSORIASIS-UVEITIS STARTER 40 MG/0.8 ML	Injection, adalimumab-adbm, biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5144	<i>adalimumab-aacf</i>	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Q5144	ADALIMUMAB-AACF(CF) PEN CROHNS	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg	Part D Drug	
Q5144	ADALIMUMAB-AACF(CF) PEN PS-UV	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg	Part D Drug	
Q5145	ABRILADA(CF)	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Q5145	ABRILADA(CF) PEN	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg (Recommend NDC Level Pricing)	Part D Drug	
Local Anesthetics				
Local Anesthetics				
C9144	POSIMIR	Injection, bupivacaine (posimir), 1 mg	Part B Drug	
C9399	XARACOLL	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	
J0665	<i>bupivacaine (pf)</i>	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	<i>bupivacaine hcl</i>	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	<i>bupivacaine-dextrose-water(pf)</i>	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0665	MARCAINE	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	MARCAINE (PF)	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	MARCAINE SPINAL (PF)	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	SENSORCAINE	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	SENSORCAINE-MPF	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0665	SENSORCAINE-MPF SPINAL	Injection, bupivacaine, not otherwise specified, 0.5 mg	Part B Drug	
J0666	<i>bupivacaine liposome (pf)</i>	Injection, bupivacaine liposome, 1 mg	Part B Drug	
J0666	EXPAREL (PF)	Injection, bupivacaine liposome, 1 mg	Part B Drug	
J0668	ZYNRELEF	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg	Part B Drug	
J2403	IHEEZO (PF)	Chloroprocaine hcl ophthalmic, 3% gel, 1 mg	Part B Drug	PA; ST applies
J2795	NAROPIN (PF)	Injection, ropivacaine hydrochloride, 1 mg	Part B Drug	
J2795	<i>ropivacaine (pf) injection solution</i>	Injection, ropivacaine hydrochloride, 1 mg	Part B Drug	
J2795	<i>ropivacaine (pf)-nacl, iso-osm injection</i>	Injection, ropivacaine hydrochloride, 1 mg	Part B Drug	
J3490	POSIMIR	Unclassified drugs	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	XARACOLL	Unclassified drugs	Part B Drug	
Miscellaneous Therapeutic Agents				
<i>Antigout Agents</i>				
J0206	<i>allopurinol sodium</i>	Injection, allopurinol sodium, 1 mg	Part B Drug	
J0206	ALOPRIM	Injection, allopurinol sodium, 1 mg	Part B Drug	
J2507	KRYSTEXXA	Injection, pegloticase, 1 mg (For billing prior to 1/1/12 use J3590 or C9281)	Part B Drug	PA; ST applies
<i>Antisense Oligonucleotides</i>				
J1426	AMONDYS-45	Injection, casimersen, 10 mg	Part B Drug	PA
J1427	VILTEPSO	Injection, viltolarsen, 10 mg	Part B Drug	PA
J1428	EXONDYS-51	Injection, eteplirsan, 10 mg (For billing prior to 1/1/18 use J3490 or C9484 for OPPS billing)	Part B Drug	PA
J1429	VYONDYS-53	Injection, golodirsan, 10 mg	Part B Drug	PA
J2326	SPINRAZA (PF)	Injection, nusinersen, 0.1 mg (Effective 5/1/2026: Recommend NDC Level Pricing for appropriate reimbursement based on NDC submitted)	Part B Drug	PA; ST applies
<i>Bone Anabolic Agents</i>				
J3110	FORTEO	Injection, teriparatide, 10 mcg	Part D Drug	
J3110	<i>teriparatide</i>	Injection, teriparatide, 10 mcg	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Bone Resorption Inhibitors				
J1000	DEPO-ESTRADIOL	Injection, depo-estradiol cypionate, up to 5 mg	Part B Drug	
J1740	<i>ibandronate intravenous syringe</i>	Injection, ibandronate sodium, 1 mg	Part B Drug	
J2430	<i>pamidronate intravenous solution</i>	Injection, pamidronate disodium, per 30 mg	Part B Drug	
J3489	RECLAST	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml inner, suv, p/f</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml sdv</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml single use</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml single use bottle</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml single use, p/f</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml single-use</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid 5 mg/100 ml suv, p/f</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic acid intravenous solution</i>	Injection, zoledronic acid, 1 mg	Part B Drug	
J3489	<i>zoledronic ac-mannitol-0.9nacl</i>	Injection, zoledronic acid, 1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Bradykinin Receptor Antagonists				
J1744	FIRAZYR	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
J1744	<i>icatibant</i>	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
J1744	SAJAZIR	Injection, icatibant, 1 mg (For billing prior to 1/1/13 use J3490 or C9399)	Part D Drug	
Complement Inhibitors (92:32)				
J0596	RUCONEST	Injection, c-1 esterase inhibitor (recombinant), Ruconest, 10 units (For billing prior to 1/1/16 use C9445 or J3590)	Part D Drug	
J0597	BERINERT	Injection, C-1 esterase inhibitor (human), Berinert, 10 units (For billing prior to 1/1/11 use J3590 or C9269)	Part D Drug	
J0598	CINRYZE	Injection, C1 esterase inhibitor (human), Cinryze, 10 units	Part B Drug	PA; ST applies
J0599	HAEGARDA	Injection, c-1 esterase inhibitor (human), (haegarda), 10 units	Part D Drug	
J9376	VEOPOZ	Injection, pozelimab-bbfg, 1 mg	Part B Drug	PA
Complement Inhibitors				
Q5151	EPYSQLI	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Immunomodulatory Agents				
J2351	OCREVUS ZUNOVO	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	Part B Drug	
J9015	PROLEUKIN	Injection, aldesleukin, per single-use vial	Part B Drug	
Other Miscellaneous Therapeutic Agents				
C9399	FORZINITY	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
C9399	YUWIWEL	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J0222	ONPATTRO	Injection, Patisiran, 0.1 mg	Part B Drug	PA
J0223	GIVLAARI	Injection, givosiran, 0.5 mg	Part B Drug	PA
J0224	OXLUMO	Injection, lumasiran, 0.5 mg	Part B Drug	PA
J0225	AMVUTTRA	Injection, vutrisiran, 1 mg	Part B Drug	PA
J0591	KYBELLA	Injection, deoxycholic acid, 1 mg	Not Covered	
J1809	NULIBRY	Injection, fosdenopterin, 0.1 mg	Part B Drug	PA
J1955	CARNITOR INTRAVENOUS	Injection, levocarnitine, per 1 g	Part B Drug	
J1955	<i>levocarnitine intravenous</i>	Injection, levocarnitine, per 1 g	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3490	FORZINITY	Unclassified drugs	Part D Drug	
J3490	RIVFLOZA	Unclassified drugs	Part B Drug	PA
J3490	YUWIWEL	Unclassified drugs	Part D Drug	
J9038	NIKTIMVO	Injection, axatilimab-csfr, 0.1 mg	Part B Drug	PA; ST applies
Protective Agents				
J7352	SCENESSE	Afamelanotide implant, 1 mg	Part B Drug	PA
Oxytocics				
Oxytocics				
J0675	<i>carboprost tromethamine</i>	Injection, carboprost tromethamine, 0.1 mg	Part B Drug	
J0675	HEMABATE	Injection, carboprost tromethamine, 0.1 mg	Part B Drug	
J2210	<i>methylergonovine injection</i>	Injection, methylergonovine maleate, up to 0.2 mg	Part B Drug	
Radioactive Agents				
Radioactive Agents				
A9513	LUTATHERA	Lutetium lu 177, dotatate, therapeutic, 1 millicurie	Medicare Chemo	PA
A9601	TAUVID	Flortaucipir f 18 injection, diagnostic, 1 millicurie	Part B Drug	
A9606	XOFIGO	Radium Ra-223 dichloride, therapeutic, per microcurie (For billing prior to 1/1/15 use C9399 or A9699)	Medicare Chemo	
A9607	PLUVICTO	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	Medicare Chemo	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Respiratory Tract Agents				
<i>Alpha And Beta Adrenergic Agonist(Respr)</i>				
J0164	<i>epineph 16 mg/250 ml-0.9% nacl</i>	Injection, epinephrine in sodium chloride (baxter), 0.1 mg	Part B Drug	
J0165	ADRENALIN	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	ADYPHREN AMP	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	ADYPHREN II	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	<i>epinephrine hcl (pf)</i>	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	<i>epinephrine injection solution</i>	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	EPINEPHRINE PROFESSIONAL	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	EPINEPHRINESNAP	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	EPINEPHRINESNAP-EMS	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0165	EPINEPHRINESNAP-V	Injection, epinephrine, not otherwise specified, 0.1 mg	Part B Drug	
J0166	<i>epinephrine hcl (pf)</i>	Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0166	<i>epinephrine injection solution</i>	Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0167	<i>epinephrine 1 mg/10 ml abbojct outer, sub</i>	Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg (All NDCs inactive as of 11/4/2025)	Part B Drug	
J0167	<i>epinephrine 1 mg/10 ml abbojct sub, inner</i>	Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg (All NDCs inactive as of 11/4/2025)	Part B Drug	
J0167	<i>epinephrine 1 mg/10 ml abbojct sub, outer</i>	Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg (All NDCs inactive as of 11/4/2025)	Part B Drug	
J0168	<i>epinephrine 0.1 mg/ml syringe sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0168	<i>epinephrine 1 mg/10 ml luerjet inner, sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0168	<i>epinephrine 1 mg/10 ml luerjet outer, sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J0168	<i>epinephrine 1 mg/10 ml luerjet sub</i>	Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0169	ADRENALIN	Injection, epinephrine (adrenalin), not therapeutically equivalent to j0165, 0.1 mg	Part B Drug	
J3490	AUVI-Q	Unclassified drugs	Part D Drug	
J3490	<i>epinephrine injection auto-injector</i>	Unclassified drugs	Part D Drug	
J3490	EPIPEN	Unclassified drugs	Part D Drug	
J3490	EPIPEN 2-PAK	Unclassified drugs	Part D Drug	
J3490	EPIPEN JR 2-PAK	Unclassified drugs	Part D Drug	
J3490	NEFFY	Unclassified drugs	Part D Drug	
J3490	REZIPRES	Unclassified drugs	Part B Drug	
Anticholinergic Agents (Respir. Tract)				
J7620	<i>ipratropium-albuterol</i>	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME	Part B Drug	B vs D (PA applies)
J7644	<i>ipratropium bromide inhalation solution</i>	Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram	Part B Drug	B vs D (PA applies)
J7677	YUPELRI	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through DME, 1 microgram	Part B Drug	PA; ST applies

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Dual Phosphodiesterase Inhibitor (48:34)				
J7601	OHTUVAYRE	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg	Part B Drug	PA; B vs D (PA applies); ST applies
First Generation Antihist.(Respir Tract)				
J1200	<i>diphenhydramine hcl injection</i>	Injection, diphenhydramine HCl, up to 50 mg	Part B Drug	
J2550	PHENERGAN	Injection, promethazine HCl, up to 50 mg	Part B Drug	
J2550	<i>promethazine injection</i>	Injection, promethazine HCl, up to 50 mg	Part B Drug	
Interleukin Antagonists				
J0517	FASENRA	Injection, benralizumab, 1 mg	Part B Drug	PA; ST applies
J0517	FASENRA PEN	Injection, benralizumab, 1 mg	Part D Drug	
J0638	ILARIS (PF)	Injection, canakinumab, 1 mg (For billing prior to 1/1/11 use J3590 or C9399)	Part B Drug	PA; ST applies
J2182	NUCALA SUBCUTANEOUS AUTO-INJECTOR	Injection, mepolizumab, 1 mg (For billing prior to 1/1/17 use J3590 or C9473 for OPPS billing)	Part D Drug	
J2182	NUCALA SUBCUTANEOUS RECON SOLN	Injection, mepolizumab, 1 mg (For billing prior to 1/1/17 use J3590 or C9473 for OPPS billing)	Part B Drug	PA; ST applies
J2182	NUCALA SUBCUTANEOUS SYRINGE	Injection, mepolizumab, 1 mg (For billing prior to 1/1/17 use J3590 or C9473 for OPPS billing)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J2356	TEZSPIRE	Injection, tezepelumab-ekko, 1 mg	Part B Drug	PA
J2361	EXDENSUR	Injection, depemokimab-ulaa, 1 mg	Part B Drug	PA
J2786	CINQAIR	Injection, reslizumab, 1 mg (For billing prior to 1/1/17 use J3590 or C9481 for OPBS billing)	Part B Drug	PA; ST applies
Mast-Cell Stabilizers				
J7631	<i>cromolyn inhalation</i>	Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit-dose form, per 10 milligrams	Part B Drug	B vs D (PA applies)
J7631	<i>cromolyn oral</i>	Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit-dose form, per 10 milligrams	Part B Drug	B vs D (PA applies)
Mucolytic Agents				
J7608	<i>acetylcysteine</i>	Acetylcysteine, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per gram	Part B Drug	B vs D (PA applies)
J7639	PULMOZYME	Dornase alfa, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per milligram	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Prostacyclin & Prostacyclin Derivatives				
J3285	REMODULIN 8 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
Q4074	VENTAVIS 10 MCG/1 ML SOLUTION SINGLE-USE,P/F	Iloprost, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 20 micrograms (All NDCs Inactive as of 10/15/2025)	Part B Drug	PA; B vs D (PA applies); ST applies
Respiratory Tract Agents, Miscellaneous				
C9399	WINREVAIR	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	PA; ST applies
J3590	WINREVAIR	Unclassified biologics	Part B Drug	PA; ST applies
Second Generation Antihist(Respir Tract)				
J1201	QUZYTIR	Injection, cetirizine hydrochloride, 0.5 mg	Part B Drug	PA; ST applies
Select.Beta-2-Adrenergic Agonist(Respir)				
J3105	terbutaline subcutaneous	Injection, terbutaline sulfate, up to 1 mg	Part B Drug	
J3535	XOPENEX HFA	Drug administered through a metered dose inhaler	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7605	<i>arformoterol</i>	Arformoterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 15 micrograms	Part B Drug	B vs D (PA applies)
J7605	BROVANA	Arformoterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 15 micrograms	Part B Drug	B vs D (PA applies)
J7606	<i>formoterol fumarate</i>	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms	Part B Drug	B vs D (PA applies)
J7606	PERFOROMIST	Formoterol fumarate, inhalation solution, FDA approved final product, non-compounded, administered through DME, unit dose form, 20 micrograms	Part B Drug	B vs D (PA applies)
J7611	<i>albuterol sulfate inhalation solution for nebulization</i>	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCPCS/ CPT Code	Drug Name	HCPCS/CPT Code Description	Coverage Level	Notes & Restrictions
J7612	<i>levalbuterol hcl</i>	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7613	<i>albuterol sulfate inhalation solution for nebulization</i>	Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7614	<i>levalbuterol hcl</i>	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	B vs D (PA applies)
J7614	XOPENEX 1.25 MG/3 ML SOLUTION P/F, 24'S	Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg (Code reinstated effective 4/1/2008)	Part B Drug	
J7620	<i>ipratropium-albuterol</i>	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
Vasodilating Agents (Respiratory Tract)				
J1325	<i>epoprostenol</i>	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	FLOLAN 0.5 MG VIAL	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	FLOLAN 1.5 MG VIAL	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1325	VELETRI	Injection, epoprostenol, 0.5 mg (see J3490 or S0155 for billing epoprostenol diluent)	Part B Drug	
J1749	AURLUMYN	Injection, iloprost, 0.1 mcg	Not Covered	
J3285	REMOTULIN 100 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMOTULIN 20 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMOTULIN 200 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	REMOTULIN 50 MG/20 ML VIAL	Injection, treprostinil, 1 mg	Part B Drug	PA
J3285	<i>treprostinil sodium</i>	Injection, treprostinil, 1 mg	Part B Drug	PA

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans

Last updated August 24, 2026

HCP/CS/ CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7686	TYVASO	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO INSTITUTIONAL START KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO REFILL KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
J7686	TYVASO STARTER KIT	Treprostinil, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, 1.74 mg (For billing prior to 1/1/11 use J7699)	Part B Drug	PA; B vs D (PA applies); ST applies
Skin And Mucous Membrane Agents				
Antibacterials (84:04)				
J0736	CLEOCIN INJECTION	Injection, clindamycin phosphate, 300 mg	Part B Drug	
J0736	<i>clindamycin in 5 % dextrose</i>	Injection, clindamycin phosphate, 300 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0736	<i>clindamycin phosphate injection</i>	Injection, clindamycin phosphate, 300 mg	Part B Drug	
J0737	<i>clindamycin in 0.9 % sod chlor</i>	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg	Part B Drug	
J1271	DOXY-100	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl inner, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	
J1271	<i>doxycycline hyclate 100 mg vl outer, suv, plf</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl plf, suv, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl plf, suv, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl suv, plf, inner</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1271	<i>doxycycline hyclate 100 mg vl suv, plf, outer</i>	Injection, doxycycline hyclate, 1 mg	Part B Drug	B vs D (PA applies)
J1836	METRO I.V.	Injection, metronidazole, 10 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J1836	<i>metronidazole in nacl (iso-os)</i>	Injection, metronidazole, 10 mg	Part B Drug	
Antiproliferants				
C9399	FAVLYXA	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part B Drug	
J7308	LEVULAN	Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg)	Part B Drug	
J9190	ADRUCIL	Injection, fluorouracil, 500 mg	Medicare Chemo	
J9190	<i>fluorouracil intravenous</i>	Injection, fluorouracil, 500 mg	Medicare Chemo	
J9999	FAVLYXA	Not otherwise classified, antineoplastic drugs	Part B Drug	
Antipruritics And Local Anesthetics				
J0879	KORSUVA	Injection, difelikefalin, 0.1 microgram, (for esrd on dialysis)	Not Separately Payable	
Antivirals (Skin And Mucous Membrane)				
J0133	<i>acyclovir 1,000 mg/20 ml vial inner, suv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 1,000 mg/20 ml vial outer, suv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J0133	<i>acyclovir 1,000 mg/20 ml vial sdv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 1,000 mg/20 ml vial suv, inner</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 1,000 mg/20 ml vial suv, outer</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 1,000 mg/20 ml vial suv, p/f, inner</i>	Injection, acyclovir, 5 mg	Part B Drug	
J0133	<i>acyclovir 1,000 mg/20 ml vial suv, p/f, outer</i>	Injection, acyclovir, 5 mg	Part B Drug	
J0133	<i>acyclovir 500 mg/10 ml vial inner, suv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 500 mg/10 ml vial inner, suv, p/f</i>	Injection, acyclovir, 5 mg	Part B Drug	
J0133	<i>acyclovir 500 mg/10 ml vial outer, suv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 500 mg/10 ml vial outer, suv, p/f</i>	Injection, acyclovir, 5 mg	Part B Drug	
J0133	<i>acyclovir 500 mg/10 ml vial sdv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 500 mg/10 ml vial suv</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 500 mg/10 ml vial suv, inner</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)
J0133	<i>acyclovir 500 mg/10 ml vial suv, outer</i>	Injection, acyclovir, 5 mg	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J7354	YCANTH	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)	Part B Drug	
Cell Stimulants And Proliferants				
J2425	KEPIVANCE	Injection, palifermin, 50 micrograms	Part B Drug	
Corticosteroids (Skin, Mucous Membrane)				
J7311	RETISERT	Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg	Part B Drug	PA; ST applies
J7313	ILUVIEN	Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg	Part B Drug	PA
J7314	YUTIQ	Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg	Part B Drug	PA
J7402	SINUVA	Mometasone furoate sinus implant, (sinuva), 10 micrograms	Part B Drug	PA
Immunomodulatory Agents (84:06)				
C9399	BIMZELX	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
C9399	BIMZELX AUTOINJECTOR	Unclassified drugs or biologicals (This code should only be used for drugs and biologicals that are approved by the FDA on or after January 1, 2004) (Hospital Outpatient Use ONLY)	Part D Drug	
J1628	TREMFYA INTRAVENOUS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part B Drug	PA; ST applies
J1628	TREMFYA ONE-PRESS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1628	TREMFYA PEN	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1628	TREMFYA PEN INDUCTION PK(2PEN)	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1628	TREMFYA SUBCUTANEOUS	Injection, guselkumab, 1 mg (Effective 1/1/2025 Code Level Pricing has been reinstated)	Part D Drug	
J1747	SPEVIGO	Injection, spesolimab-sbzo, 1 mg	Part B Drug	PA; ST applies
J2327	SKYRIZI INTRAVENOUS	Injection, risankizumab-rzaa, intravenous, 1 mg	Part B Drug	PA; ST applies
J3245	ILUMYA	Injection, tildrakizumab, 1 mg (Code reused by CMS 1/1/2019)	Part B Drug	PA; ST applies
J3590	SILIQ	Unclassified biologics	Part D Drug	
J3590	SKYRIZI 150 MG/ML SYRINGE	Unclassified biologics	Part D Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
J3590	SKYRIZI SUBCUTANEOUS PEN INJECTOR	Unclassified biologics	Part D Drug	
J3590	SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR	Unclassified biologics	Part D Drug	
J7503	ENVARUSUS XR	Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg (Code re-used by CMS effective 1/1/16)	Part B Drug	B vs D (PA applies)
J7507	PROGRAF ORAL	Tacrolimus, immediate release, oral, per 1 mg	Part B Drug	B vs D (PA applies)
J7507	<i>tacrolimus oral</i>	Tacrolimus, immediate release, oral, per 1 mg	Part B Drug	B vs D (PA applies)
J7508	ASTAGRAF XL	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Part B Drug	B vs D (PA applies)
J7508	<i>tacrolimus oral</i>	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Part B Drug	B vs D (PA applies)
J7520	<i>sirolimus</i>	Sirolimus, oral, 1 mg	Part B Drug	B vs D (PA applies)
J7521	PROGRAF ORAL	Tacrolimus, granules, oral suspension, 0.1 mg (Code price based on median pricing methodology)	Part B Drug	B vs D (PA applies)
J7525	PROGRAF INTRAVENOUS	Tacrolimus, parenteral, 5 mg	Part B Drug	
J7525	<i>tacrolimus intravenous</i>	Tacrolimus, parenteral, 5 mg	Part B Drug	

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

HCP/CS/CPT Code	Drug Name	HCP/CS/CPT Code Description	Coverage Level	Notes & Restrictions
<i>Skin And Mucous Membrane Agents, Misc.</i>				
J3389	ZEVASKYN	Topical administration, prademagene zamikeracel, per treatment	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J3401	VYJUVEK	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10 ⁹ pfu/ml vector genomes, per 0.1 ml	Part B Drug	PA; Cellular/Gene Therapy (For more information, see the website FDA's Approved Cellular and Gene Therapy Products)
J7336	QUTENZA	Capsaicin 8% patch, per square centimeter	Part B Drug	PA; ST applies
<i>Sunscreen Agents</i>				
J7352	SCENESSE	Afamelanotide implant, 1 mg	Part B Drug	PA
Vitamins				
<i>Vitamin D</i>				
J0636	<i>calcitriol intravenous</i>	Injection, calcitriol, 0.1 mcg	Part B Drug	
J8499	<i>doxercalciferol oral</i>	Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified	Part B Drug	B vs D (PA applies)

PA-Prior Authorization; **ST applies**-Step Therapy applies;
B vs D (PA applies)-Part B vs Part D

Priority Health Medicare Plans
Last updated August 24, 2026

Index

ABECMA.....	58, 124	AKYNZEO (FOSNETUPITANT).....	168, 174	ARANESP (IN POLYSORBATE)	
ABELCET.....	30	<i>albuterol sulfate</i>	82, 232, 233		85, 86, 87, 88, 89, 90, 91
ABILIFY ASIMTUFII.....	127, 130	ALDURAZYME.....	151	<i>arformoterol</i>	81, 232
ABILIFY MAINTENA.....	127, 130	ALFERON N.....	25, 47, 202	ARISTADA.....	127, 131
ABRAXANE.....	49	ALHEMO PEN.....	102	ARISTADA INITIO.....	127, 131
ABRILADA(CF).....	219	ALIMTA.....	51	ARZERRA.....	51
ABRILADA(CF) PEN.....	219	ALIQOPA.....	41	ASCENIV.....	64
<i>acetaminophen</i>	128, 129, 130, 135, 136	<i>allopurinol sodium</i>	221	ASPARLAS.....	43, 152
<i>acetylcysteine</i>	4, 230	ALOPRIM.....	221	ASTAGRAF XL.....	194, 241
ACTEMRA.....	202, 203, 206, 207	ALPHANATE.....	103	ATGAM.....	211
ACTEMRA ACTPEN.....	203	ALPHANINE SD.....	106	ATIVAN.....	132
ACTHAR.....	142, 186	ALPROLIX.....	107	<i>atropine</i>	73
ACTHAR SELFJECT.....	142, 186	ALTUVIIIIO.....	108	AUCATZYL.....	59, 125
<i>acyclovir sodium</i>	28, 237, 238	ALYGLO.....	64	AUKELSO.....	192
ADAKVEO.....	90	ALYMSYS.....	60	AURLUMYN.....	116, 234
<i>adalimumab-aacf</i>	218	<i>amikacin</i>	16	AURYXIA.....	149
ADALIMUMAB-AACF(CF) PEN CROHNS..	219	AMINOSYN II 10 %.....	145	AUVI-Q.....	72, 228
ADALIMUMAB-AACF(CF) PEN PS-UV.....	219	AMINOSYN II 15 %.....	145	AVASTIN.....	32, 33, 39
<i>adalimumab-aaty</i>	217	AMINOSYN-PF 10 %.....	145	AVEED.....	177
ADALIMUMAB-AATY(CF) AI CROHNS.....	217	AMINOSYN-PF 7 % (SULFITE-FREE).....	145	AVGEMSI.....	45
<i>adalimumab-adaz</i>	211	AMJEVITA(CF).....	212	AVOPEF.....	33, 56
<i>adalimumab-adbm</i>	218	AMJEVITA(CF) AUTOINJECTOR.....	212	AVSOLA.....	217
<i>adalimumab-fkjp</i>	217	AMONDYS-45.....	221	AVTOZMA.....	208
<i>adalimumab-ryvk</i>	218	<i>amphotericin b</i>	30	AVTOZMA AUTOINJECTOR.....	208
ADASUVE.....	134	<i>amphotericin b liposome</i>	30	AVYCAZ.....	15
ADCETRIS.....	40	AMTAGVI.....	33, 56, 119, 120	AXTLE.....	50
ADRENALIN.....	71, 72, 226, 228	AMVUTTRA.....	224	<i>azacitidine</i>	38
ADRENALIN IN 0.9 % SOD CHLOR.....	71	ANASCORP.....	4, 64	AZACTAM.....	26
ADRIAMYCIN.....	37	ANAVIP.....	4, 64	AZASAN.....	190
ADRUCIL.....	45, 237	ANKTIVA.....	38	<i>azathioprine</i>	190
ADSTILADRIN.....	38, 122	ANNOVERA.....	179	AZEDRA DOSIMETRIC.....	32
ADVATE.....	104	APHEXDA.....	93	AZEDRA THERAPEUTIC.....	32
ADYNOVATE.....	107	APOKYN.....	134	AZMIRO.....	177
ADYPHREN.....	71	<i>apomorphine</i>	134	<i>aztreonam</i>	26
ADYPHREN AMP.....	226	APONVIE.....	174	<i>baclofen</i>	78
ADYPHREN II.....	226	<i>aprepitant</i>	174	BALFAXAR.....	102
ADZYNMA.....	152	APRETUDE.....	24	BARHEMSYS.....	170
AFSTYLA.....	108	ARALAST NP.....	84	BAVENCIO.....	38
AJOVY AUTOINJECTOR.....	133			BAXDELA.....	30
AJOVY SYRINGE.....	133			BEIZRAY.....	44

BEIZRAY-ALBUMIN.....	45	BREYANZI CD8 COMPONENT (1OF 2)		<i>chlorpromazine</i>	138
BELEODAQ.....	39		58, 124	CIMERLI.....	164
BELRAPZO.....	39	BRINEURA.....	151	CIMZIA.....	215
<i>bendamustine</i>	39	BRIUMVI.....	209	CIMZIA POWDER FOR RECONST.....	215
BENDEKA.....	39	BRIXADI.....	138	CIMZIA STARTER KIT.....	215
BENEFIX.....	106	BROVANA.....	81, 232	<i>cinacalcet</i>	179
BENLYSTA.....	198	<i>budesonide</i>	176	CINQAIR.....	230
<i>benztropine</i>	74, 127	<i>bupivacaine (pf)</i>	219	CINRYZE.....	223
BEOVU.....	161	<i>bupivacaine hcl</i>	219	CINVANTI.....	174
BERINERT.....	223	<i>bupivacaine liposome (pf)</i>	220	<i>cisplatin</i>	41
BESPONSA.....	48	<i>bupivacaine-dextrose-water(pf)</i>	219	<i>cladribine</i>	41, 191
BESREMI.....	34, 56	<i>buprenorphine hcl</i>	138	CLEOCIN.....	25, 235
BETASERON.....	202	BYDUREON BCISE.....	183	CLEVIPREX.....	114
BETHKIS.....	16	BYOOVIZ.....	157	<i>clindamycin in 0.9 % sod chlor</i>	26, 236
BEYFORTUS.....	26, 27	CABENUVA.....	24	<i>clindamycin in 5 % dextrose</i>	25, 235
BILDYOS.....	193	CABLIVI.....	109	<i>clindamycin phosphate</i>	26, 236
BILPREVDA.....	193	<i>calcitriol</i>	242	CLINIMIX 5%/D15W SULFITE FREE.....	146
BIMZELX.....	239	<i>calcium acetate</i>	149	CLINIMIX 4.25%/D10W SULF FREE.....	146
BIMZELX AUTOINJECTOR.....	240	<i>calcium acetate(phosphat bind)</i>	149	CLINIMIX 4.25%/D5W SULFIT FREE.....	146
BIORPHEN.....	73	<i>calcium chloride</i>	4, 149	CLINIMIX 5%-D20W(SULFITE-FREE).....	146
<i>bivalirudin</i>	90	CAMCEVI (6 MONTH).....	35, 182	CLINIMIX 6%-D5W (SULFITE-FREE).....	146
BIVIGAM.....	65	CAMPTOSAR.....	46	CLINIMIX 8%-D10W(SULFITE-FREE).....	146
BIZENGRI.....	55	<i>capecitabine</i>	37	CLINIMIX 8%-D14W(SULFITE-FREE).....	146
BKEMV.....	195	<i>carboplatin</i>	40	CLINIMIX E 2.75%/D5W SULF FREE.....	147
BLNREP.....	40	<i>carboprost tromethamine</i>	225	CLINIMIX E 4.25%/D10W SUL FREE.....	147
<i>bleomycin</i>	39	<i>carmustine</i>	40	CLINIMIX E 4.25%/D5W SULF FREE.....	147
BLINCYTO.....	39	CARNITOR.....	224	CLINIMIX E 5%/D15W SULFIT FREE.....	147
BLOXIVERZ.....	80, 143	CARVYKTI.....	58, 125	CLINIMIX E 5%/D20W SULFIT FREE.....	147
BOMYNTRA.....	192	CASGEVY.....	121	CLINIMIX E 8%-D10W SULFITEFREE.....	147
<i>bortezomib</i>	39, 40	<i>caspofungin</i>	20	CLINIMIX E 8%-D14W SULFITEFREE.....	147
BORUZU.....	41	<i>cefazolin</i>	8, 9, 10	CLINOLIPID.....	144
BOSAYA.....	193	<i>cefazolin in dextrose (iso-os)</i>	9, 10	COAGADEX.....	102
BOTOX.....	75	<i>cefazolin in dextrose 5 %</i>	10	COLUMVI.....	50
BOTOX COSMETIC.....	77	<i>cefepime</i>	15	COMBOGESIC IV.....	130, 136, 139
BREVIBLOC.....	83, 111, 113	CEFOTAN.....	10	COMIRNATY 2025-2026(5-11Y)(PF).....	70
BREVIBLOC IN NACL (ISO-OSM) 83, 111, 113		<i>cefotetan</i>	10	COMIRNATY 2025-26 (12Y UP)(PF).....	70
BREYANZI.....	57, 124	<i>ceftaroline fosamil</i>	15	CONEXXENCE.....	192
BREYANZI CD4 COMPONENT (2OF 2)		<i>ceftriaxone</i>	11, 12, 13, 14, 15	CONTEPO.....	31
.....	58, 124	<i>ceftriaxone in dextrose,iso-os</i>	15	CORIFACT.....	103
		CELLCEPT.....	190, 191	CORTROPHIN GEL.....	142, 186
		CEREZYME.....	151	COSELA.....	6

COSENTYX.....	202, 203	DEPO-MEDROL.....	175	ELLENCE.....	45
COSENTYX (2 SYRINGES).....	203	DESCOVY.....	25, 29	ELOCTATE.....	107
COSENTYX PEN.....	203	DESFERAL.....	4, 175	ELREXFIO.....	34
COSENTYX PEN (2 PENS).....	203	<i>desmopressin</i>	101, 187	ELURYNG.....	178, 179, 180, 188
COSENTYX UNOREADY PEN.....	204	<i>dexamethasone sodium phos (pf)</i>	155	ELZONRIS.....	49
COSMEGEN.....	44	<i>dexamethasone sodium phosphate</i>	156, 176	EMBLAVEO.....	26
CRESEMBA.....	19	<i>dexrazoxane hcl</i>	6	EMEND.....	174
<i>cromolyn</i>	230	DEXYCU (PF).....	155	EMEND (FOSAPREPITANT).....	174
CRYSVITA.....	147	<i>diazepam</i>	132, 133	EMPAVELI.....	195
CUTAQUIG.....	64	<i>digoxin</i>	112	EMPLICITI.....	45
CUVITRU.....	65	DILAUDID (PF).....	136, 137	EMRELIS.....	53
<i>cyclophosphamide</i>	37, 41, 42, 43, 199, 200, 201	<i>diltiazem hcl</i>	114	<i>emtricitabine-tenofovir (tdf)</i>	24, 28
<i>cyclosporine</i>	153, 154, 193, 194	<i>diltiazem hcl in nacl,iso-osm</i>	112, 114	ENBREL.....	216
<i>cyclosporine modified</i>	153, 154, 193, 194	<i>diphenhydramine hcl</i>	6, 229	ENBREL MINI.....	216
CYKLOKAPRON.....	101	<i>docetaxel</i>	44, 48	ENBREL SURECLICK.....	216
CYLTEZO(CF).....	218	DOCIVYX.....	44	ENCELTO.....	122
CYLTEZO(CF) PEN.....	218	DOUBLEDEX (PF).....	156	ENFLONSIA.....	27
CYLTEZO(CF) PEN CROHN'S-UC-HS.....	218	<i>doxercalciferol</i>	242	ENERGIX-B (PF).....	69
CYLTEZO(CF) PEN PSORIASIS-UV.....	218	<i>doxorubicin</i>	37	ENERGIX-B PEDIATRIC (PF).....	69
CYRAMZA.....	52	DOXY-100.....	17, 30, 152, 236	ENHERTU.....	55
D5 % (D-GLUCOSE)-0.9 % SODCHLR.....	147	<i>doxycycline hyclate</i>	17, 18, 30, 31, 152, 153, 236	ENILLORING.....	178, 179, 180, 188
<i>dacarbazine</i>	44	<i>dronabinol</i>	171	ENJAYMO.....	195
<i>dactinomycin</i>	44	DUOPA.....	134	ENOBY.....	193
<i>dalbavancin</i>	22	DUROLANE.....	139	ENTYVIO.....	196
DALVANCE.....	22	DURYSTA.....	159	ENTYVIO PEN.....	196
DANYELZA.....	54	DYSPORT.....	77	ENVARUS XR.....	194, 241
<i>daptomycin</i>	20	<i>edaravone</i>	125	<i>epineph bitart in 0.9% sod chl</i>	71, 226
<i>daptomycin in 0.9 % sod chlor</i>	20	<i>edetate calcium disodium</i>	4, 175	<i>epinephrine</i>	71, 72, 226, 227, 228
DARZALEX.....	44	EGRIFTA SV.....	189	<i>epinephrine hcl (pf)</i>	71, 226
DARZALEX FASPRO.....	44	EGRIFTA WR.....	190	EPINEPHRINE PROFESSIONAL.....	226
DATROWAY.....	38	ELAHERE.....	41	EPINEPHRINESNAP.....	226
DAWNZERA.....	114	ELAPRASE.....	151	EPINEPHRINESNAP-EMS.....	226
DAXXIFY.....	78	ELELYSO.....	151	EPINEPHRINESNAP-V.....	226
DDAVP.....	101, 187	ELEVIDYS.....	121	EPIPEN.....	72, 228
<i>decitabine</i>	34	ELFABRIO.....	151	EPIPEN 2-PAK.....	72, 228
DEFENCATH.....	29, 90	ELIGARD.....	47, 182	EPIPEN JR 2-PAK.....	72, 228
<i>deferoxamine</i>	4, 175	ELIGARD (3 MONTH).....	47, 182	<i>epirubicin</i>	45
DEMEROL.....	137	ELIGARD (4 MONTH).....	47, 182	EPKINLY.....	53
DEMEROL (PF).....	137	ELIGARD (6 MONTH).....	47, 182	EPOGEN.....	91, 93
DEPO-ESTRADIOL.....	180, 222	ELITEK.....	151	<i>epoprostenol</i>	116, 234
				EPYSQLI.....	223

ERBITUX.....	41	FETROJA.....	30	GELSYN-3.....	141
<i>eribulin</i>	45	FIBRYGA.....	102	<i>gemcitabine</i>	46
<i>ertapenem</i>	19	FILKRI.....	90, 93	GENGRAF.....	154, 193, 194
ERZOFRI.....	131	FIRAZYR.....	112, 223	GENOTROPIN.....	187
<i>esmolol</i>	83, 111, 113	FIRMAGON.....	44, 178	GENOTROPIN MINIQUEL.....	187
<i>esmolol in nacl (iso-osm)</i>	83, 111, 113	FIRMAGON KIT W DILUENT SYRINGE.....	44, 179	GENVISC 850.....	139
<i>esmolol in sterile water</i>	84, 111, 113	FLEBOGAMMA DIF.....	66, 67	GEODON.....	128, 132
<i>esomeprazole sodium</i>	174	FLOLAN.....	116, 234	GIVLAARI.....	224
ESPEROCT.....	107	<i>floxuridine</i>	46	GLASSIA.....	84
<i>ethacrynate sodium</i>	148	<i>fluorouracil</i>	45, 237	GLUCAGON (HCL) EMERGENCY KIT... 5, 181	
ETHYOL.....	5	<i>fluphenazine decanoate</i>	138	GLUCAGON EMERGENCY KIT (HUMAN).....	5, 181
<i>etonogestrel-ethinyl estradiol</i>	178, 179, 180, 188	<i>fluphenazine hcl</i>	138	<i>glucagon hcl</i>	5, 142, 143, 181
ETOPOPHOS.....	45	FOCINVEZ.....	174	GRAFAPEX.....	34
<i>etoposide</i>	45	FOLOTYN.....	52	<i>granisetron (pf)</i>	168
EUFLEXXA.....	140	<i>formoterol fumarate</i>	82, 232	<i>granisetron hcl</i>	168, 169
EVENITY.....	191	FORTEO.....	186, 221	GRANIX.....	93
<i>everolimus (immunosuppressive)</i>	36, 37, 198, 199	FORZINITY.....	224, 225	HADLIMA.....	212
EVKEEZA.....	110	<i>fosaprepitant</i>	174	HADLIMA PUSHTOUCH.....	212
EVOMELA.....	48	FOSRENOL.....	148, 149	HADLIMA(CF).....	212
EXDENSUR.....	230	FRINDOVYX.....	42, 200	HADLIMA(CF) PUSHTOUCH.....	213
EXONDYS-51.....	221	FULPHILA.....	100	HAEGARDA.....	223
EXPAREL (PF).....	220	<i>fulvestrant</i>	55	HALAVEN.....	45
EYLEA.....	161	FUROSCIX.....	115, 148	HALOETTE.....	178, 180, 181, 188
EYLEA HD.....	160	FUROSCIX READYFLOW.....	115, 148	<i>haloperidol decanoate</i>	133
FABRAZYME.....	150	<i>furosemide</i>	115, 148	<i>haloperidol lactate</i>	133
<i>famotidine</i>	7, 8, 172, 173	FYARRO.....	53	HEMABATE.....	225
<i>famotidine (pf)</i>	6, 7, 171, 172	FYLNETRA.....	101	HEMGENIX.....	101, 120
<i>famotidine (pf)-nacl (iso-os)</i>	6, 171	GABLOFEN.....	78, 79	HEMLIBRA.....	102
FASENRA.....	229	GAMIFANT.....	202	HEMOFIL M HIGH.....	104
FASENRA PEN.....	229	GAMMAGARD LIQUID.....	66	HEMOFIL M LOW.....	104
FASLODEX.....	55	GAMMAGARD LIQUID ERC.....	66	HEMOFIL M MID.....	104
FAVLYXA.....	34, 56, 237	GAMMAGARD S-D (IGA < 1 MCG/ML).....	66	HEMOFIL M SUPER HIGH.....	104
FEIBA NF.....	106	GAMMAPLEX.....	65	HEPAGAM B.....	67
FENSOLVI.....	35, 182	GAMMAPLEX (WITH SORBITOL).....	65	HEPZATO.....	48
FERAHEME.....	109	GAMUNEX-C.....	65	HEPZATO (50 MM CATHETER).....	48
<i>ferric carboxymaltose</i>	108	<i>ganciclovir sodium</i>	29, 154	HEPZATO (62 MM CATHETER).....	48
FERRLECIT.....	109	GATTEX 30-VIAL.....	170	HERCEPTIN.....	54
<i>ferumoxytol</i>	109	GATTEX ONE-VIAL.....	170	HERCEPTIN HYLECTA.....	54
FESILTY.....	102	GAZYVA.....	51	HERCESSI.....	60
		GEL-ONE.....	141	HERZUMA.....	59

HIZENTRA.....	65	IMLYGIC.....	53, 122	KEPIVANCE.....	239
HULIO(CF).....	217	IMMPHENTIV.....	73	KESIMPTA PEN.....	209, 210
HULIO(CF) PEN.....	217	IMULDOSA.....	207	KETALAR.....	127, 134
HUMATE-P.....	103	IMURAN.....	190	<i>ketamine</i>	127, 134
HUMATROPE.....	187	INCRELEX.....	190	KEVZARA.....	202, 204
HUMIRA.....	214	INFED.....	108	KEYTRUDA.....	49
HUMIRA PEN.....	214	INFLECTRA.....	217	KEYTRUDA QLEX.....	50
HUMIRA(CF).....	214	<i>infliximab</i>	216	KHAPZORY.....	5
HUMIRA(CF) PEN.....	214	INJECTAFER.....	108	KIMMTRAK.....	49
HUMIRA(CF) PEN CROHNS-UC-HS.....	215	INLEXZO.....	45	KIMYRSA.....	22
HUMIRA(CF) PEN PSOR-UV-ADOL HS.....	215	INTRALIPID.....	144	KINERET.....	204
HYALGAN.....	139	INVEGA HAFYERA.....	131	KINEVAC.....	143
<i>hydromorphone</i>	137	INVEGA SUSTENNA.....	131	KISUNLA.....	210
<i>hydromorphone (pf)</i>	137	INVEGA TRINZA.....	131	KITABIS PAK.....	16
HYMOVIS.....	140	<i>ipratropium bromide</i>	74, 228	KOATE.....	104
HYMOVIS ONE.....	140	<i>ipratropium-albuterol</i>	73, 83, 228, 233	KOGENATE FS.....	104, 105, 106
HYMPAVZI PEN.....	102	<i>irinotecan</i>	46	KORSUVA.....	237
HYPERRHO.....	68	<i>iron sucrose</i>	108	KOVALTRY.....	108
HYQVIA.....	67	<i>isoniazid</i>	18	KRYSTEXXA.....	221
HYRIMOZ PEN CROHN'S-UC STARTER..	213	ISTODAX.....	53	KYBELLA.....	224
HYRIMOZ PEN PSORIASIS STARTER.....	213	ITVISMA.....	122	KYLEENA.....	178, 180, 188
HYRIMOZ(CF).....	213	IVRA.....	48	KYMRIAH.....	57, 123
HYRIMOZ(CF) PEDI CROHN STARTER....	213	IXEMPRA.....	46	KYPROLIS.....	40
HYRIMOZ(CF) PEN.....	214	IXINITY.....	108	KYXATA.....	50
<i>ibandronate</i>	222	IZERVAY (PF).....	158, 195	<i>labetalol</i>	79, 80, 81, 109, 110, 111, 112, 113, 114
<i>icatibant</i>	112, 223	JELMYTO.....	50	LAMZEDE.....	150
IDAMYCIN PFS.....	46	JEMPERLI.....	49	LANOXIN.....	112
<i>idarubicin</i>	46	JEUVEAU.....	78	LANOXIN PEDIATRIC.....	112
IDELVION.....	107	JEVTANA.....	40	<i>lanreotide</i>	189
IDOSE TR.....	159	JIVI.....	107	<i>lanthanum</i>	148
IFEX.....	46	JOBEVNE.....	60	LANTIDRA.....	119
<i>ifosfamide</i>	46	JOURNAVX.....	125	LASIX ONYU.....	115, 148
IHEEZO (PF).....	158, 220	JUBBONTI.....	192	LEMTRADA.....	209
ILARIS (PF).....	27, 229	JUBEREQ.....	193	LENMELDY.....	121
ILLUCCIX.....	142	JYLAMVO.....	37, 197	LEQEMBI.....	210
ILUMYA.....	240	KABIVEN.....	144	LEQEMBI IQLIK.....	210
ILUVIEN.....	156, 239	KADCYLA.....	54	LEQVIO.....	110
IMAAVY.....	210	KALBITOR.....	115	<i>leucovorin calcium</i>	5
IMDELLTRA.....	38	KANJINTI.....	59	LEUKINE.....	93
IMFINZI.....	44	KANUMA.....	151	<i>leuprolide</i>	48, 183
IMJUDO.....	54	KEBILIDI.....	120, 122		

<i>levalbuterol hcl</i>	82, 83, 233	MEPSEVII.....	152	NEBUPENT.....	18
<i>levocarnitine</i>	224	<i>meropenem</i>	19	NEFFY.....	73, 228
<i>levoleucovorin calcium</i>	5	<i>meropenem-0.9% sodium chloride</i>	19	NEORAL.....	154, 193, 194
<i>levothyroxine</i>	190	<i>mesna</i>	6	<i>neostigmine methylsulfate</i>	80, 143
LEVULAN.....	237	MESNEX.....	6	NEULASTA.....	93
LIBTAYO.....	43	<i>methotrexate sodium</i>	37, 197	NEULASTA ONPRO.....	93
LIFEMS NALOXONE.....	5, 137	<i>methylergonovine</i>	225	NEUPOGEN.....	92
<i>linezolid in dextrose 5%</i>	29	<i>methylprednisolone acetate</i>	175	NEXIUM IV.....	174
<i>linezolid-0.9% sodium chloride</i>	29	<i>methylprednisolone sodium succ</i>	176	NEXPLANON.....	178, 180, 189
LIORESAL.....	78, 79	<i>metoprolol tartrate</i>	83, 110, 112	NEXVIAZYME.....	150
<i>liraglutide</i>	183	METRO I.V.....	16, 27, 170, 236	NGENLA.....	186, 188
<i>liraglutide (weight loss)</i>	184	<i>metronidazole in nacl (iso-os)</i> ..	16, 27, 170, 237	NIKTIMVO.....	225
LOARGYS.....	150, 152	<i>micafungin</i>	21	NIPENT.....	49
LOQTORZI.....	35	<i>micafungin in 0.9 % sodium chl</i>	21	<i>nitroglycerin</i>	115
<i>lorazepam</i>	132, 133	<i>midazolam</i>	132	<i>nitroglycerin in 5 % dextrose</i>	115
LUCENTIS.....	163	<i>midazolam in nacl,iso-osmo(pf)</i>	133	NIVESTYM.....	100
LUMIZYME.....	150	MIRCERA.....	89, 92	NORDITROPIN FLEXPOR.....	187
LUNSUMIO.....	54	<i>mitomycin</i>	50	NOVOEIGHT.....	103
LUNSUMIO VELO.....	54	MITOSOL.....	153	NOVOSEVEN RT.....	104
LUPRON DEPOT.....	35, 47, 181, 183	<i>mitoxantrone</i>	50	NPLATE.....	93
LUPRON DEPOT (3 MONTH).....	35, 47, 181, 182	MNEXSPIKE 2025-2026 (PF).....	71	NUCALA.....	229
LUPRON DEPOT (4 MONTH).....	47, 182	MONJUVI.....	54	NUFYMCO.....	167
LUPRON DEPOT (6 MONTH).....	47, 182	MONOFERRIC.....	108	NULIBRY.....	224
LUPRON DEPOT-PED.....	35, 181	MONOVISC.....	141	NULOJIX.....	211
LUPRON DEPOT-PED (3 MONTH).....	35, 181	MOUNJARO.....	126, 127, 184, 185	NUTRILIPID.....	145
LUTATHERA.....	31, 225	<i>moxifloxacin-sod.ace,sul-water</i>	153	NUTROPIN AQ NUSPIN.....	187
LUTRATE DEPOT (3 MONTH).....	35, 182	<i>moxifloxacin-sod.chloride(iso)</i>	30, 153	NUVARING.....	178, 180, 181, 188
LUXTURNA.....	121	MOZOBIL.....	93	NUVAXOVID 2025-2026 (PF).....	70
LYFGENIA.....	121	MUTAMYCIN.....	50	NUWIQ.....	107
LYMPHIR.....	44	MVASI.....	59	NUZYRA.....	17
LYNOZYFIC.....	56	<i>mycophenolate mofetil</i>	191	NYPOZI.....	101
<i>mannitol 20 %</i>	115, 143, 147, 148, 158	<i>mycophenolate sodium</i>	191	NYVEPRIA.....	101
<i>mannitol 25 %</i>	143	MYFORTIC.....	191	OBIZUR.....	104
MARCAINE.....	220	MYHIBBIN.....	190	OCREVUS.....	210
MARCAINE (PF).....	220	MYLOTARG.....	46	OCREVUS ZUNOVO.....	224
MARCAINE SPINAL (PF).....	220	MYOBLOC.....	77	OCTAGAM.....	66
MARGENZA.....	54	N/A.....	2, 3	<i>octreotide,microspheres</i>	189
MARINOL.....	171	<i>nafcillin in dextrose iso-osm</i>	30	OGIVRI.....	59
MAS CARE-PAK (PF).....	156	NAGLAZYME.....	151	OHTUVAYRE.....	229
<i>melphalan hcl</i>	48	<i>naloxone</i>	5, 137	<i>olanzapine</i>	128, 131, 169
<i>meperidine (pf)</i>	137	NAROPIN (PF).....	220	OMIDRIA.....	158, 167

OMISIRGE.....	119	PALFORZIA (LEVEL 9).....	62, 63	POSIMIR.....	219, 220
OMNITROPE.....	188	PALFORZIA (LEVEL 10).....	62, 63	<i>potassium phos in 0.9 % nacl</i>	149
OMVOH.....	173	PALFORZIA (LEVEL 11 UP-DOSE).....	62, 63	POTELIGEO.....	46
OMVOH PEN.....	173	PALFORZIA INITIAL (1-3 YRS).....	62, 64	<i>pralatrexate</i>	52
ONAPGO.....	134	PALFORZIA INITIAL (4-17 YRS).....	63, 64	PRECEDEX IN 0.9 % SODIUM CHLOR.....	130
ONCASPAR.....	49	PALFORZIA LEVEL 11 MAINTENANCE.....	63, 64	PREMASOL 10 %.....	147
<i>ondansetron</i>	169	<i>palonosetron</i>	168	PREVDUO.....	80
<i>ondansetron hcl</i>	168, 169	<i>pamidronate</i>	222	PREVYMIS.....	20
<i>ondansetron hcl (pf)</i>	168	<i>pantoprazole</i>	174, 175	PRIALT.....	136
ONIVYDE.....	46	<i>pantoprazole in 0.9% sod chlor</i>	175	PRIVIGEN.....	64
ONPATTRO.....	224	PANZYGA.....	68	PROCRT.....	91, 92, 93, 94
ONTRUZANT.....	59	PAPZIMEOS.....	122	PROFILNINE.....	106
OPDIVO.....	51	PARAPLATIN.....	40	PROGRAF.....	194, 195, 241
OPDIVO QVANTIG.....	50	PARSABIV.....	179	PROLASTIN-C.....	84
OPDUALAG.....	51	PAVBLU.....	165	PROLEUKIN.....	38, 224
OPFOLDA.....	150	<i>pemetrexed</i>	52	PROLIA.....	191
ORBACTIV.....	22	<i>pemetrexed disodium</i>	50, 51, 53	<i>promethazine</i>	8, 130, 170, 229
ORENCIA (WITH MALTOSE).....	196	PEMFEXY.....	51	PROTONIX.....	175
ORENCIA CLICKJECT.....	196	PEMGARDA (EUA).....	27	PROVENGE.....	57, 120
ORTHOVISC.....	140	PEMRYDI RTU.....	53	PULMICORT.....	177
OSENVELT.....	192	<i>pentamidine</i>	18	PULMOZYME.....	152, 230
OSMITROL 10 %.....	116, 143, 147, 148, 158	PERFOROMIST.....	82, 232	PYZCHIVA.....	208, 209
OSMITROL 20 %.....	116, 143, 147, 148, 159	PERIKABIVEN.....	145	PYZCHIVA AUTOINJECTOR.....	208
OSPOMYV.....	192	PERJETA.....	52	QALSODY.....	125
OTULFI.....	209	PERSERIS.....	128, 131	QFITLIA.....	102
<i>oxaliplatin</i>	49	PHENERGAN.....	8, 130, 170, 229	QFITLIA PEN.....	102
OXLUMO.....	224	<i>phenobarbital sodium</i>	132	QIVIGY.....	68
OZEMPIC.....	126, 127, 184, 185	<i>phenylephrine hcl</i>	73, 158, 168	QUTENZA.....	242
OZURDEX.....	156, 176	PHESGO.....	52	QUZYTIR.....	8, 231
<i>paclitaxel</i>	49	PHOTOFIN.....	55	RADICAVA.....	125
<i>paclitaxel protein-bound</i>	49	PHOTREXA CROSS-LINKING KIT.....	157	RAPIBLYK.....	114
PADCEV.....	45	PIASKY.....	195	REBINYN.....	107
PALFORZIA (LEVEL 0).....	62, 63	<i>piperacillin-tazobactam</i>	21, 22	REBLOZYL.....	89, 92
PALFORZIA (LEVEL 1).....	60, 63	PLASMA-LYTE 148 PH 7.4.....	149	REBYOTA.....	170
PALFORZIA (LEVEL 2).....	60, 63	PLASMA-LYTE A.....	149	RECARBRIO.....	19
PALFORZIA (LEVEL 3).....	60, 63	<i>plerixafor</i>	93	RECLAST.....	222
PALFORZIA (LEVEL 4).....	61, 63	PLUVICTO.....	32, 225	RECOMBIMATE.....	106
PALFORZIA (LEVEL 5).....	61, 63	POLIVY.....	52	RECOMBIVAX HB (PF).....	68, 69
PALFORZIA (LEVEL 6).....	61, 63	POMBILITI.....	151	REDEMPLO.....	110
PALFORZIA (LEVEL 7).....	61, 63	PORTRAZZA.....	50	RELEUKO.....	101
PALFORZIA (LEVEL 8).....	61, 63	POSFREA.....	168	RELISTOR.....	174

REMICADE.....	216	SAXENDA.....	127, 185	<i>succinylcholine-sod cl,iso(pf)</i>	79
REMODULIN.....	116, 231, 234	SCENESSE.....	186, 225, 242	SUNLENCA.....	23
RENFLEXIS.....	217	SELARSDI.....	209	SUPARTZ FX.....	140
RETACRIT.....	94, 95, 96, 97, 98, 99, 100	SENSIPAR.....	179	SUPPRELIN LA.....	48, 183
RETHYMIC.....	120	SENSORCAINE.....	220	SUSTOL.....	168
RETISERT.....	156, 239	SENSORCAINE-MPF.....	220	SUSVIMO.....	163
REVCIVI.....	150, 152	SENSORCAINE-MPF SPINAL.....	220	SUSVIMO (INITIAL FILL).....	156
REZIPRES.....	73, 228	SEROSTIM.....	188	SYFOVRE (PF).....	158, 195
REZZAYO.....	20	SEVENFACT.....	108	SYLVANT.....	35
RHOGAM ULTRA-FILTERED PLUS.....	68	SEZABY.....	132	SYNAGIS.....	26
RHOPHYLAC.....	68	SIGNIFOR LAR.....	189	SYNDROS.....	170
RIABNI.....	59, 197	SILIQ.....	240	SYNOJOYNT.....	141
RISPERDAL CONSTA.....	128, 131	SIMLANDI(CF).....	218	SYNVISC.....	141
<i>risperidone microspheres</i>	128, 131	SIMLANDI(CF) AUTOINJECTOR.....	218	SYNVISC-ONE.....	141
RITUXAN.....	52, 197	SIMPONI.....	216	<i>tacrolimus</i>	194, 241
RITUXAN HYCELA.....	52, 197	SIMPONI ARIA.....	216	TAKHZYRO.....	114, 115
RIVFLOZA.....	225	SIMULECT.....	202	TALVEY.....	35
RIXUBIS.....	106	<i>sincalide</i>	143	TAUVID.....	225
ROCTAVIAN.....	101, 120	SINUVA.....	156, 176, 239	TECARTUS.....	57, 123
ROLVEDON.....	93	<i>sirolimus</i>	210, 241	TECELRA.....	125
<i>romidepsin</i>	52, 53	SIVEXTRO.....	29	TECENTRIQ.....	38
<i>ropivacaine (pf)</i>	220	SKYLA.....	178, 180, 188	TECENTRIQ HYBREZA.....	38
<i>ropivacaine (pf)-nacl,iso-osm</i>	220	SKYRIZI.....	240, 241	TECVAYLI.....	55
RUCONEST.....	223	SKYSONA.....	121	TEFLARO.....	16
RUXIENCE.....	59, 197	SMOFLIPID.....	145	TEPADINA.....	53
RYBREVANT.....	41	<i>sodium ferric gluconat-sucrose</i>	109	TEPEZZA.....	153
RYBREVANT FASPRO.....	41	SOLIRIS.....	195	TEPYLUTE.....	53
RYKINDO.....	128, 132	SOLU-MEDROL.....	176	<i>terbutaline</i>	81, 231
RYLAZE.....	38, 152	SOLU-MEDROL (PF).....	176	<i>teriparatide</i>	186, 221
RYONCIL.....	119	SOMATULINE DEPOT.....	189	TESTOPEL.....	177
RYPLAZIM.....	84	SPEVIGO.....	240	TEVIMBRA.....	53
RYSTIGGO.....	211	SPIKEVAX 2025-2026(12Y UP)(PF).....	71	TEZSPIRE.....	230
RYTELO.....	34	SPIKEVAX 2025-26 (6M-11Y) (PF).....	70	THYROGEN.....	144
RYZNEUTA.....	93	SPINRAZA (PF).....	221	TICE BCG.....	38
SAIZEN SAIZENPREP.....	188	STARJEMZA.....	208	TIVDAK.....	49
SAJAZIR.....	112, 223	STELARA.....	203	TOBI.....	16
SANDIMMUNE.....	154, 193, 194	STEQEYMA.....	207	TOBI PODHALER.....	16
SANDOSTATIN LAR DEPOT.....	189	STIMUFEND.....	101	<i>tobramycin</i>	17
SAPHNELO.....	198	STOBOCLO.....	192	<i>tobramycin in 0.225 % nacl</i>	17
SAPHNELO PEN.....	198	SUBLOCADE.....	138	<i>tobramycin with nebulizer</i>	17
SARCLISA.....	48	<i>succinylcholine chloride</i>	79	TOFIDENCE.....	204, 205, 207

<i>topotecan</i>	54	<i>ustekinumab</i>	203	VONVENDI.....	102
<i>tranexamic acid</i>	101	<i>ustekinumab-aekn</i>	209	<i>voriconazole</i>	19
TRAZIMERA.....	59	<i>ustekinumab-ttwe</i>	209	<i>voriconazole-hpbcd</i>	19
TREANDA.....	39	UZEDY.....	128, 132	VOYXACT.....	191
TRELSTAR.....	36, 182	VABOMERE.....	19	VPRIV.....	151
TREMFYA.....	196, 197, 240	VABRINTY (1 MONTH).....	47, 183	VYALEV.....	134
TREMFYA ONE-PRESS.....	196, 240	VABRINTY (4 MONTH).....	47, 183	VYEPTI.....	134
TREMFYA PEN.....	197, 240	VABYSMO.....	162	VYJUVEK.....	122, 242
TREMFYA PEN INDUCTION PK(2PEN)		VAFSEO.....	89, 92	VYKOURA.....	5
.....	197, 240	<i>valrubicin</i>	55	VYLEESI.....	134
<i>treprostinil sodium</i>	116, 234	VALSTAR.....	55	VYLOY.....	35
TRETEN.....	103	<i>vancomycin</i>	22, 23	VYONDYS-53.....	221
TREXALL.....	37, 197	<i>vancomycin in 0.9 % sodium chl</i>	22	VYVGART.....	211
TRILURON.....	141	<i>vancomycin in dextrose 5 %</i>	22	VYVGART HYTRULO.....	211
TRIPTODUR.....	36, 182	<i>vancomycin-diluent combo no.1</i>	23	VYXEOS.....	44
TRIVISC.....	141	<i>vasopressin</i>	187	WASKYRA.....	121
TRODELVY.....	52	<i>vasopressin in 0.9 % sod chlor</i>	187	WEGOVY.....	126, 127, 185, 186
TROGARZO.....	24	VASOSTRICT.....	187	WEZLANA.....	208
TROPHAMINE 10 %.....	147	VAZCULEP.....	73, 158, 168	WILATE.....	103
TRULICITY.....	184, 185	VECTIBIX.....	51	WINREVAIR.....	231
TRUVADA.....	25, 28, 29	VEGZELMA.....	60	WYOST.....	192
TRUXIMA.....	59, 197	VEKLURY.....	28	XARACOLL.....	219, 221
TYENNE.....	205, 206, 208	VELCADE.....	39	XATMEP.....	37, 197
TYENNE AUTOINJECTOR.....	208	VELETRI.....	116, 234	XELODA.....	37
TYRUKO.....	210	VENOFER.....	109	XEMBIFY.....	65
TYSABRI.....	209	VENTAVIS.....	231	XENPOZYME.....	150
TYVASO.....	118, 235	VEOPOZ.....	223	XEOMIN.....	78
TYVASO DPI.....	116, 117, 118	VFEND IV.....	19	XERAVA.....	22
TYVASO INSTITUTIONAL START KIT		VIBATIV.....	22	XGEVA.....	191
.....	118, 235	VICTOZA 2-PAK.....	126, 127, 184, 185	XIAFLEX.....	151
TYVASO REFILL KIT.....	118, 235	VICTOZA 3-PAK.....	126, 127, 185	XIFYRM.....	139
TYVASO STARTER KIT.....	118, 235	VIDAZA.....	38	XIPERE (PF).....	156
TYZAVAN.....	23	VILTEPSO.....	221	XOFIGO.....	225
TZIELD.....	177	VIMIZIM.....	151	XOLAIR.....	202
UDENYCA.....	100	<i>vinblastine</i>	55	XOPENEX.....	83, 233
UDENYCA AUTOINJECTOR.....	100	<i>vincristine</i>	55	XOPENEX HFA.....	81, 231
UDENYCA ONBODY.....	100	<i>vinorelbine</i>	55	XTRENBO.....	193
ULTOMIRIS.....	195	VISCO-3.....	140	XYNTHA.....	103
UNITUXIN.....	34, 56	VISUDYNE.....	158	XYNTHA SOLOFUSE.....	103
UNLOXCYT.....	49	VIVIMUSTA.....	41	YARTEMLEA.....	195
UPLIZNA.....	210	VIVITROL.....	84, 137	YCANTH.....	239

YERVOY.....	48	ZOSYN IN DEXTROSE (ISO-OSM).....	21
YESAFILI.....	166	ZUSDURI.....	50
YESCARTA.....	56, 123	ZYCUBO.....	149, 150
YESINTEK.....	207	ZYMFENTRA.....	216
YEZTUGO.....	23	ZYNLONTA.....	55
YIMMUGO.....	64	ZYNRELEF.....	139, 220
YONDELIS.....	54	ZYNTGLO.....	121
YORVIPATH.....	186	ZYNYZ.....	54
YUFLYMA(CF).....	217	ZYPREXA.....	128, 131, 170
YUFLYMA(CF) AI CROHN'S-UC-HS.....	217	ZYPREXA RELPREVV.....	128, 131, 169
YUFLYMA(CF) AUTOINJECTOR.....	218	ZYVOX.....	29
YUPELRI.....	74, 228		
YUSIMRY(CF) PEN.....	214		
YUTIQ.....	156, 239		
YUVIWEL.....	224, 225		
ZALTRAP.....	55		
ZANOSAR.....	53		
ZARXIO.....	94		
ZEMAIRA.....	84		
ZEMDRI.....	16		
ZEPBOUND.....	185		
ZEPZELCA.....	48		
ZERBAXA.....	15		
ZEVALIN (Y-90).....	31		
ZEVASKYN.....	121, 242		
ZEVTERA.....	15		
ZIEXTENZO.....	100		
ZIIHERA.....	49		
ZILBRYSQ.....	195, 196		
ZILRETTA.....	176		
ZIMHI.....	5		
ZINPLAVA.....	64		
<i>ziprasidone mesylate</i>	128, 132		
ZIRABEV.....	59		
ZOLADEX.....	46, 182		
<i>zoledronic acid</i>	222		
<i>zoledronic acid-mannitol-water</i>	222		
<i>zoledronic ac-mannitol-0.9nacl</i>	222		
ZOLGENSMA.....	122		
ZOMACTON.....	188		
ZORTRESS.....	37, 199		

